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Abstract	  
Marfan syndrome (MFS) is an autosomal dominant inherited connective tissue disorder 
with an incidence of approximately 1 in 5,000 worldwide. It can vary in severity from 
mild to severe and may finally cause the death of affected individuals as a result of 
dissection of the thoracic aortic aneurysm (TAA). The possible pathogenesis remains 
uncertain, but essentially all patients have a mutation in the fibrillin-1 gene, either 
inherited or as a sporadic mutation.  
Diagnosis of people at risk is critical but difficult, as there may be no clinical signs or 
obvious aortic enlargement in young patients. All too often, however, diagnosis is not 
straightforward. Therefore, there is a need for improved diagnostic accuracy, better 
risk-stratification and more effective therapeutic intervention for individuals and their 
families. The TGF-β1 signalling pathways play a vital role in the progression of aortic 
aneurysm formation, and can be perturbed in MFS due to reduced capacity of mutant 
fibrillin to sequestering TGF-β1 within the extra cellular matrix. Altered TGF-β1 
signalling can result in upregulation of matrix metalloproteinases, which contribute to 
aneurysm formation. Animal studies suggest the potential utility as biomarkers of 
thoracic aortic disease  
MMP-3 
MMP-3 has been implicated in thoracic aortic aneurysm formation. It is a stromelysin 
that can degrade intact collagen and is secreted from vascular smooth muscle cells. A 
moderate elevation in MMP-3 within the circulation has been observed in patients 
suffering from atherosclerotic aneurysms, and MMP-3 is believed to decrease within the 
aortic tissue of patients suffering from thoracic aneurysm associated with a bicuspid 
aortic valve. 
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Our data have shown that the levels of circulating MMP-3 are significantly higher in 
males compared to females. Paradoxically, the levels of circulating MMP-3 fall in MFS 
patients, presumably as a compensatory mechanism to limit pathological extra-cellular 
matrix remodelling. These data are new and novel findings, and may explain, in part, 
the more severe disease that is seen in males compared to females in MFS. Serial 
determinations of MMP-3 levels in individuals may be of use for monitoring response 
to therapy, for example, pharmacological interventions. 
TGF-β1 
Our data show that there is no difference in the level of circulating TGF-β1 in MFS 
patients compared to controls. However, a consistent, small, non-significant trend 
towards higher levels was observed across all MFS patient groups, compared to 
controls, but this trend was small, and, even if real, may be of limited clinical 
significance. It is possible that this trend may become significant if a larger number of 
patients had been recruited.  
MMP-2 and MMP-9 
Although no significant differences were seen in MFS patients compared to controls for 
the biomarkers MMP-2, MMP-9, TIMP-1 and TIMP-2, a consistent trend was observed 
for several biomarkers towards higher levels in MFS patients compared to controls. 
Specifically, data for MMP-2 (overall trend, plus weakly significant difference in 
female surgical MFS patients compared to controls) and TIMP-2 (weakly significant 
difference) support the possibility that these two biomarkers may be slightly elevated in 
MFS compared to controls.  
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TIMP-1 and TIMP-2 
All the TIMPs are able to inhibit all the MMPs to some extent, but TIMP-2 most 
effectively inhibits MMP-2 and TIMP-1 most effectively inhibits MMP-9. Thus, the 
ratios MMP 2:TIMP 2 and MMP 9:TIMP 1 may be indices of the balance of the 
proteolytic activity. 
Our data show that circulating levels of TIMP-1 and TIMP-2 also do not change 
significantly in MFS compared to controls. However, circulating levels of TIMP-1 
correlated strongly with TIMP-2 levels in all groups (controls and MFS). This result is 
consistent with the hypothesis that TIMP-1 and TIMP-2 are unregulated at least partly 
by the same signalling processes. 
ACE polymorphism 
This study aimed to determine whether the ACE I/D polymorphism genotype correlated 
with the disease phenotype in patients with MFS, with the expectation that the DD 
phenotype could result in a more severe phenotype. Our study was hampered by the 
small numbers of controls and patients, but our data are consistent with the hypothesis 
that, if there is any effect on phenotype by the ACE I/D polymorphism, then it is a very 
small one.  
We found no difference in the allelic or genotypic frequency of the ACE 
insertion/deletion polymorphism in MFS patients compared to control subjects. 
Additionally, there is no difference in these frequencies when MFS patients are 
stratified by severity (surgical versus non-surgical patients).  
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Chapter	  1	  
Introduction	  
 
1.1	   Genetic	  thoracic	  aortic	  aneurysm	  disease	  –	  clinical	  
Genetic aneurysmal aortopathy often occurs within the ascending aorta and may be 
either familial (inherited) or may be a complication of certain syndromes. Marfan 
syndrome (MFS), familial thoracic aortic aneurysm disease (FTAD) and bicuspid aortic 
valve (BAV) are the three most common forms of genetic aortopathy that cause 
ascending aortic aneurysms and also pose the severest threat to the survival of patients. 
Marfan syndrome (MFS) is the commonest form of genetic aneurysmal aortopathy and 
is an inherited connective tissue disease. Its manifestations are syndromic and are 
associated with pathology within various systems, such as ocular, skeletal, pulmonary, 
cutaneous, neurological and cardiovascular abnormalities (DePaepe et al., 1996). MFS 
has been attributed predominantly to heterozygous mutations in the fibrillin-1 gene 
(FBN1) that encodes the fibrillin-1 protein (Keane et al., 2008). The incidence of MFS 
is between 1 in 5,000 to 10,000 neonates; and occurs across all ethnicities (Faivre et al., 
2007) (Pearson et al., 2008). Since MFS is one of the most common potentially lethal 
diseases in young adults and it is associated with premature death in untreated patients, 
there is a strong imperative to diagnose correctly and as early as possible. However, the 
risk of both false positive and negative diagnosis is relatively high in many clinical 
cases, leading to the death of patients because of misdiagnosis (Elefteriades et al., 
2010).  
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The mechanism by which FBN1 mutations result in thoracic aortic aneurysm remains 
ambiguous. Fibrillin-1 has been accepted as a structural scaffold for extra-cellular 
microfibril formation and subsequent elastic fibre formation. This functional finding 
suggests that fibrillin-1 mutations might cause a mechanical weakness in the aortic wall. 
However, fibrillin-1 has also been shown to be involved in the sequestration of 
transforming growth factor-β (TGF-β), which is a key signalling molecule associated 
with fibrous tissue formation. Therefore, mutations in fibrillin-1 may also lead to an 
abnormal TGF-β signalling pathway within the aortic wall (El-Hamamsy et al., 2009). 
These two potential mechanisms of fibrillin-1 mutation pathogenesis are not mutually 
exclusive. 
 
1.1.1	   Normal	  thoracic	  aortic	  function	  
The thoracic aorta primarily serves as a blood conduit originating from the left ventricle. 
The unique shape and mechanical properties of the aortic root and ascending aorta have 
a direct influence on left ventricular workload and coronary blood flow (Bellhouse et 
al., 1968). Active regulation of the size and shape of the aorta has a direct effect on 
systemic blood volume and pressure as well. Sufficient and normal function of the 
thoracic aorta results in a dynamic, tightly regulated and highly preserved micro-
structural organization of the aortic wall (El-Hamamsy et al., 2009).  
All arterial walls have the same basic triple layer anatomy; they are intima, media and 
adventitia. These layers are separated from each other by two layers of thick elastic 
fibres; the internal and external elastic laminae. The basic structural and functional unit 
in the aortic wall is the lamellar unit (Wolinsky et al., 1967). Each lamellar unit is 
composed of a vascular smooth muscle cell (VSMC) between two layers of elastin 
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fibres. These fibres contain microfibrils and proteoglycans, forming the extracellular 
matrix (ECM) (see Figure 1.1). 
The lamellar unit has both tensile strength and elastic recoil properties, allowing the 
aorta to withstand high pressures during systole and to return to its initial diameter 
during diastole. Medial thickness in the ascending aorta is regulated by changes in the 
number of lamellae (Wolinsky et al., 1967). Interaction between the cellular and 
extracellular components in the wall matrix mediates these various functions of the 
aorta. Dysregulation of one or more of these components can result in thoracic aortic 
aneurysm formation, as observed in MFS.  
 
Figure	  1.1	   The	  lamellar	  unit	  of	  the	  aortic	  wall.	   	  
Figure	  1.1	  is	  an	  electron	  micrograph	  of	  a	  single	  lamellar	  unit	  in	  the	  medial	  layer	  of	  the	  
aortic	  wall.	   In	   the	  picture,	   vascular	   smooth	  muscle	   cells	   (VSMC)	   locate	  between	   two	  
layers	   of	   elastin	   fibres	   and	   surrounded	   by	   ECM	   proteins	   containing	  microfibrils	   and	  
proteoglycans.	  The	  lamellar	  unit	   is	   intercalated	  by	  collagen	  bundles.	   It	  represents	  the	  
basic	  structural	  and	  functional	  unit	  of	  the	  aortic	  wall.	  (El-­‐Hamamsy	  et	  al.,	  2009)	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1.1.2	   Diseases	  of	  the	  thoracic	  aorta	  
1.1.2.1	   Atherosclerotic	  aortic	  disease	   	  
Atherosclerosis (also known as arteriosclerotic vascular disease or ASVD) is a 
condition in which the arterial wall thickens asymmetrically as a consequence of the 
accumulation of fatty materials such as cholesterol and triglyceride. It is a disease 
affecting arterial blood vessels, a chronic inflammatory response in the walls of arteries, 
caused mainly by the accumulation of macrophages and promoted by the accumulation 
of low-density lipoproteins (LDL, plasma proteins that carry cholesterol and 
triglycerides). Additionally, there is a failure to adequately remove fats and cholesterol 
from the macrophages by functional high-density lipoproteins (HDL). It is often 
referred to as a hardening of the arteries. It results in the formation of multiple plaques 
within the artery wall Atherosclerosis within the arch of the aorta can lead to aneurysm 
within the arch and is the commonest cause of thoracic aortic aneurysm (Glagov et al., 
1987). 
 
1.1.2.2	   Inflammatory	  aortic	  diseases	   	  
Inflammatory aortic disorders may cause a weakening of the aortic walls. Bacterial and 
fungal aortitis are uncommon; however, focal disruption of the vessel wall can lead to 
aneurysm formation, dissection or rupture (Erbel et al., 2001). Inflammation occurs in 
the infectious disease luetic (syphilitic) aortitis, which results in a thickening of the 
aortic wall. Aortitis is the main cardiovascular manifestation of syphilis and is observed 
in both the proximal and distal parts of the aorta (Turck et al., 1985). Autoimmune 
diseases of the aorta include vasculitis in large and medium size vessels, such as 
Behçet’s disease, Cogan’s disease, giant cell arteritis, rheumatoid disease, Takayasu 
aortitis and Ormond’s disease (aortitis with retroperitoneal fibrosis) (Sterio et al., 1988).  
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1.1.2.3	   Genetic	  aortic	  diseases	   	  
Genetic factors have been shown to play a role in the aetiology of thoracic aortic 
aneurysm and dissection (TAAD) and abdominal aortic aneurysm (AAA) even when 
they are not associated with syndromic forms of aortic disease, such as Marfan 
syndrome, Ehlers-Danlos syndrome, Loeys-Dietz syndrome, or other rare aortic 
syndromes (Kuivaniemi et al., 2008). 
 
Table	  1.1	   Chromosomal	   Loci	   Harbouring	   Genes	   for	   Syndromic	   and	  
Non-­‐syndromic	  Aortic	  Aneurysms.	  
OMIM	   indicates	   Online	   Mendelian	   Inheritance	   in	   Man;	   ID,	   identification;	   AD,	  
autosomal	   dominant;	   COL3A1,	   gene	   symbol	   for	   type	   III	   procollagen;	   TGFΒR1	   and	   2,	  
gene	  symbols	   for	   transforming	  growth	   factor-­‐β	   receptors	  1	  and	  2;	  and	  MYH11,	  gene	  
symbol	  for	  smooth	  muscle	  myosin	  heavy	  chain.	  All	  loci	  except	  the	  EDS4	  and	  AAT5	  were	  
identified	  by	  DNA	   linkage	   studies	  with	  either	   family-­‐based	  or	   “affected	   relative	  pair”	  
approaches.	  No	  genes	  harbouring	  mutations	  in	  aneurysm	  patients	  in	  the	  AAA1,	  AAA2,	  
AAT1,	  AAT2,	  or	  AAT6	  loci	  have	  yet	  been	  identified	  (Kuivaniemi	  et	  al.,	  2008).	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Ehlers–Danlos syndrome (EDS) (also known as Cutis hyperelastica) is a group of 
inherited connective tissue disorders, caused by a defect in the synthesis of collagen 
(Type I or III). The collagen defect renders key structures more elastic, for example, 
skin, joints, muscles, ligaments, blood vessels and visceral organs. The severity of the 
mutation can vary from mild to life threatening. There is no cure, and treatment is 
supportive.  
Loeys–Dietz syndrome is a recently-discovered autosomal dominant genetic syndrome 
which has many features similar to Marfan syndrome, but which is caused by mutations 
encoding transforming growth factor-β receptor 1 (TGFBR1) or 2 (TGFBR2) genes 
(Loeys et al., 2006) (LeMaire et al., 2007) (Loeys et al., 2005).  
 
1.1.3	   Marfan	  Syndrome	  
Marfan syndrome (MFS) is an autosomal dominant inherited connective disorder with 
an incidence of approximately 1 in 5,000 worldwide. This syndrome can vary in 
severity from mild to severe and may ultimately cause the patients’ death as a 
consequence of dissection of the thoracic aortic aneurysm (TAA). Antoine Marfan, a 
French paediatrician, first named it. He diagnosed and recorded clinical statistics after 
recording notable symptoms in a 5-year-old girl in 1896. However, after nearly one 
century, the responsible mutant gene, the fibrillin-1 gene (FBN1) was ultimately 
identified by Francesco Ramirez at the Mount Sinai Medical Centre in New York City 
in 1991 (Nijbroek et al., 1995). FBN1 is located on chromosome 15. 
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Fibrillin is a 350 kD calcium-binding glycoprotein found in the extracellular matrix and 
is essential for the formation of elastic and non-elastic fibres found in connective tissue. 
Fibrillin-1 was isolated by Engvall in 1986 (Sakai et al., 1986), and is a major 
component of the microfibrils. It serves as a structural component of 10-12 nm 
calcium-binding microfibrils that form a sheath surrounding amorphous elastin.  
The clinical diagnosis of MFS is made in accordance with the Ghent criteria (section 
2.1.3). MFS patients should be diagnosed by actual multi-organ dysfunctions, such as 
skeletal, ocular, pulmonary and cardiovascular abnormalities. Skeletal complications 
mainly include scoliosis, pectus excavatum/carinatum and arachnodactyly. Ectopia 
lentis is the cardinal ophthalmic sign. Sudden pneumothorax, early emphysema and 
sleep apnoea can also occur. The most significant cardiovascular symptom is thoracic 
aortic aneurysm (TAA), which has the highest association with the mortality and 
morbidity of MFS patients.  
 
1.1.3.1	   Family	  history	  
A positive family history, when available, plays an important part in the diagnosis of 
MFS. MFS is an autosomal dominant inherited condition, and about 75% of patients 
have a positive family history. In the remaining 25% of cases, the genetic mutation 
associated with Marfan syndrome occurs spontaneously. Although people with Marfan 
syndrome often share similar physical features, the disease doesn't affect everyone in 
the same way; even in the same family, referred to as "variable expression". Some have 
mild symptoms and stable aortic disease, while others demonstrate severe dysfunction. 
Consequently, it can be hard to predict how the disease will progress in affected 
individuals. 
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1.1.3.2	   Ocular	  features	  
Ectopia lentis (EL) and myopia are considered to be the most significant ocular 
symptoms during MFS progression. Ectopia lentis reﬂects failure of ciliary zonules, 
which are the supporting structures for the lens. A dislocated lens is more likely to 
occur temporarily upwards, however, there is no strong evidence showing the deviation 
occurs in a specific direction (Loeys et al., 2010). EL can occur in the absence of 
cardiovascular manifestations of MFS, and certain mutations in FBN1 have an increased 
association with EL.  
 
Figure	  1.2	   Ectopia	  lentis	  in	  MFS	  patients.	  
http://www.virtualmedicalcentre.com/diseases/marfan's-­‐syndrome/625	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1.1.3.3	   Skeletal	  features	  
MFS patients are tall and slim, with arachnodactyly, abnormal chest shape as well as 
scoliosis. Characteristically, there is disproportionate overgrowth of the long bones.  
The overgrowth of arms and legs can lead to an arm span greater than 1.05 times the 
height or a reduced upper to lower segment ratio (lengths above and below the pubic 
symphysis) (in the absence of severe scoliosis). Moreover, arachnodactyly (overgrowth 
of the fingers) is generally a subjective finding of overgrowth of bones. The 
combination of long fingers and loose joints leads to the “Golden” Walker-Murdoch or 
wrist criteria: full overlap of the distal phalanges of the thumb and fifth finger when 
wrapped around the contralateral wrist. Also, the Steinberg or thumb sign is present 
when the distal phalanx of the thumb fully extends beyond the ulnar border of the hand 
when folded across the palm (Kliegman: Nelson Textbook of Pediatrics, 19th ed.). In 
the foot, pes planus (flat feet) are frequently present, and vary from mild and 
asymptomatic to severe deformity, where medial displacement of the medial malleolus 
results in collapse of the arch and often reactive hip and knee disturbances. However, 
some other affected individuals have an exaggerated arch, pes cavus (Kliegman: Nelson 
Textbook of Pediatrics, 19th ed.). 
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Figure	  1.3	   Finger	  features	  of	  MFS.	   	  
a)	  the	  Steinberg	  or	  thumb	  sign;	  b)	  Walker-­‐Murdoch	  or	  wrist	  criteria.	  
http://palmreadingperspectives.files.wordpress.com/2011/05/marfan-­‐syndrome-­‐hand
-­‐diagnosis.jpg	  
 
Moreover, anterior chest deformity, such as pectus carinatum and pectus excavatum, is 
caused by overgrowth of the ribs, pushing the sternum anteriorly or posteriorly, 
respectively. Although commonly present, thoracolumbar scoliosis must be sufficiently 
severe (> 20˚) to contribute to the skeletal criteria for the syndrome. Protrusio acetabuli 
may also be present. Although joint laxity or hypermobility is frequently identified, 
joints can be normal or even develop contractures. Reduced extension of the elbows is 
common and can contribute to the designation of major involvement of the skeleton. 
Contracture of the fingers (camptodactyly) is also commonly observed, especially in 
children with severe and rapidly progressive Marfan syndrome. 
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Figure	  1.4	   Various	  skeletal	  features	  of	  MFS.	  
(A)	  pectus	  carinatum;	  (B)	  pectus	  excavatum	  (Kotzot	  et	  al.,	  2009);	  (C)	  scoliosis	  and	  (D)	  
high-­‐arched	  palate.	  
 
Several craniofacial manifestations are frequently present, but are not specific enough to 
the disorder for inclusion in the major criteria. These include a long narrow skull 
(dolicocephaly), a high-arched palate, tooth crowding, retrognathia (recessed lower 
mandible) or micrognathia (small chin), malar flattening, and downward-slanting 
palpebral fissures. 
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1.1.3.4	   Pulmonary	  features	  
There are several pulmonary dysfunctions associated with MFS. Upper lobe fibrosis, 
bronchiectasis, emphysematous changes, multiple blebs, small pneumothorax, pleural 
fibrosis and pleural thickening have been associated with MFS (Gupta et al., 2010). 
Since tissue structure that comprises the pulmonary artery root is similar to the 
ascending aorta, dilatation of the pulmonary artery can occur in the root and is similar to 
the dilatation that occurs in the ascending aorta in Marfan patients (McKenna et al., 
2002). 
 
Figure	  1.5	   Levels	   of	   measurement	   on	   axial	   spin	   echo	   planes	   in	   a	   patient	   with	  
Marfan	  syndrome.	   	  
(A)	  Main	   pulmonary	   artery	   diameter	  measurement	   at	   the	   level	   of	   pulmonary	   artery	  
bifurcation.	   (B)	   Pulmonary	   artery	   root	   measurements:	   anterior-­‐right	   diameter,	  
anterior-­‐left	   diameter	   and	   right-­‐left	   diameter.	   Note	   the	   pectus	   carinatum	   (Nollen	   et	  
al.,	  2002).	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1.1.3.5	   Cardiovascular	  features	  
The cardiovascular system manifestations of MFS are predominantly in the valves and 
the aortic root, and the aortic wall stiffness is increased.  
Mitral valve prolapsed and tricuspid valve dilation occur commonly in mild to 
moderately affected MFS patients. In children with early commencement and severe 
Marfan syndrome, insufficiency of the mitral valve can cause congestive heart failure, 
pulmonary hypertension, and death in infancy; these manifestations are the principal 
causes of morbidity and mortality in young children with the disease (Sisk et al., 1983). 
Aortic root dilation and Sinus of Valsalva dilation are two other manifestations of MFS.  
 
Figure	  1.6	   Sinus	  of	  Valsalva	  dilation.	  
Components	   analyzed	   during	   assessment	   of	   aortic	   root	   dilatation	   are	   (1)	   the	   aortic	  
annulus;	   (2)	   the	   Sinuses	   of	   Valsalva;	   and	   (3)	   the	   sinotubular	   junction.	   The	   tubular	  
portion	  of	  the	  ascending	  aorta	  should	  also	  be	  assessed	  (Canadas	  et	  al.,	  2010).	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1.1.3.6	   Mitral	  valve	  disease	  in	  Marfan	  syndrome	  
The morphology of the diseased mitral valve in MFS patients is characterised by 
interchordal ballooning of the mitral leaflets, where one or both mitral valve leaflets 
prolapse into the left atrium during systole (Hayek et al., 2005). The affected leaflets are 
often enlarged, redundant, thick, and rubbery. The associated tendinous cords may be 
elongated, thinned, or even ruptured, and the annulus may be dilated. Histologically, 
there is attenuation of the collagenous fibrosa layer of the valve, on which the structural 
integrity of the leaflet depends, accompanied by marked thickening of the spongiosa 
layer with deposition of mucoid (myxomatous) material. Patients with MFS have a 
higher incidence of bileaflet prolapse or anterior leaflet prolapsed (Bhudia et al., 2006). 
MFS patients also have an increased risk of mitral valve annulus calcification (DePaepe 
et al., 1996). Consequences of mitral valve prolapse include regurgitation and can result 
in heart failure and pulmonary hypertension in the first years of life, the foremost cause 
of infant mortality among MFS patients (Judge et al., 2005).  
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1.1.3.7	   Aortopathy	  in	  Marfan	  syndrome	  
A localised abnormal dilation of the aorta, or aortic aneurysm, frequently occurs in the 
Sinuses of Valsalva of MFS patients, although it may extend to other fragments of the 
remaining aorta (see Figure 1.7) (Milewicz et al., 2005). Potentially fatal complications 
of aortic aneurysm are aortic regurgitation, rupture and dissection. Aortic dissection 
usually takes place after an intimal tear; resulting in blood splaying apart the laminar 
planes of the media to form a blood-filled channel within the aortic wall (see Figure 
1.7). Approximately 20% MFS patients suddenly died of aortic dissection before 
reaching hospital (Olsson et al., 2006). The mortality rate for untreated aortic dissection 
rises 1–3% per hour in the initial 24 hours. Without intervention, the mortality rate is ~ 
30% in the first week, ~ 80% in the second weeks, and ~ 90% in the first year (Olsson 
et al., 2006). Moreover, complications in the descending aorta are early manifestations 
in 15% MFS patients.  
The pathophysiological explanation for the characteristic localisation of aneurysm in the 
aortic root is uncertain, although it may be because the elastic fibre levels are high in 
this specific segment of the aorta. Since fibrillin-1 is involved in the assembly of elastic 
fibres during development, FBN1 mutations may contribute to abnormal elastic fibre 
formation (Dietz, H. C. et al., 1993; Eldadah et al., 1995). Additionally, the wall stress 
and cyclic torsion to which this segment is subjected during ventricular ejection likely 
contributes to increased risk of dilatation. 
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Figure	  1.7	   Anatomy	  of	  normal	  heart	  and	  Marfan	  syndrome	  heart.	  
Normal	   heart	   on	   left	   demonstrates	   a	   normal	   aortic	   root	   and	   ascending	   aorta.	   MFS	  
heart	   on	   right	   represents	   dilatation	   of	   the	   aortic	   root	   and	   ascending	   aorta	   labelled	  
aneurysm.	  http://faculty.southwest.tn.edu/rburkett/A&P2%20B18.jpg	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Figure	  1.8	   Aneurysm	  formation.	  
(A)	  Normal	  vessel.	   	  
(B)	   True	   aneurysm,	   saccular	   type.	   The	   wall	   focally	   bulges	   outward	   and	   may	   be	  
attenuated	  but	  is	  otherwise	  intact.	   	  
(C)	   True	   aneurysm,	   fusiform	   type.	   There	   is	   circumferential	   dilation	   of	   the	   vessel,	  
without	  rupture.	   	  
(D)	  False	  aneurysm.	  The	  wall	  is	  ruptured,	  and	  there	  is	  a	  collection	  of	  blood	  (hematoma)	  
that	  is	  bounded	  externally	  by	  adherent	  extravascular	  tissues.	   	  
(E)	  Dissection.	  Blood	  has	  entered	  (dissected)	  the	  wall	  of	  the	  vessel	  and	  separated	  the	  
layers.	  Although	  this	  is	  shown	  as	  occurring	  through	  a	  tear	  in	  the	  lumen,	  dissections	  can	  
also	  occur	  by	  rupture	  of	  the	  vessels	  of	  the	  vaso	  vasorum	  within	  the	  media.	   	  
(Robbins	  and	  Cotran	  Pathologic	  Basis	  of	  Disease-­‐	  8th	  Edition)	  
 
Aortic wall stiffness is an important factor for aneurysm formation. Professor Jeremy’s 
team has published precise data comparing differences in heart rate and aortic flow 
velocity, aortic diameter, aortic distensibility and aortic wall stiffness between MFS 
patients and controls. They found that in the Marfan group, individuals have higher 
levels of systemic arterial pulse pressure, aortic diameter, aortic wall stiffness and 
systemic pulse wave velocity. Interestingly, the Marfan group also has lower values for 
aortic distensibility and has a similar resting heart rate and aortic flow velocities 
(Jeremy et al., 1994) (Table 1.2). 
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 Control MFS 
Age (years) 25 ± 14 26 ± 12 
Systolic blood pressure (mm Hg) 116 ± 16 119 ± 19 
Diastolic blood pressure (mm Hg) 74 ± 12 70 ± 9 
Resting heart rate and aortic flow velocities Similar Similar 
Systemic arterial pulse pressure Low High 
Aortic diameter Low High 
Aortic wall stiffness Low High 
Systemic pulse wave velocity Low High 
Aortic dispensability High Low 
Table	  1.2	   Aortic	  wall	  stiffness	  measurements	  between	  Control	  and	  MFS	  group.	   	  
 
As the Marfan syndrome disease process progresses, the aortic wall stiffness continues 
to increase, at a rate greater than in aging normal subjects. It is associated with 
up-regulation of systolic blood pressure and pulse pressure (Westenberg et al., 2011). 
Increased wall stiffness is thought to increase the risk of the progression of aortic 
dilatation and dissection (Isselbacher, 2005). 
 
1.1.3.8	   Comparison	  of	  MFS	  with	  other	  syndromic	  forms	  
Table 1.3 to Table 1.5 list a comparison of various clinical parameters for the various 
forms of syndromic and non-syndromic thoracic arotic aneurysm. 
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 MFS LDS 
Vascular-type 
EDS 
TAAD BAV 
OMIM 154700 609192 130050 607086 109730 
Estimated 
prevalence 
1 in 5000 Rare 1 in 250000 1 in 500 1-2 in 100 
Penetrance 
High (~ 
100%) 
High (~ 
100%) 
High (~ 100%) 
Reduced 
(50%), 
especially in 
women 
Incomplete 
Average age of 
onset of aortic 
aneurysm 
Young Adulthood Childhood 
Variable 
adulthood 
Young 
Table	  1.3	   Details	  of	  various	  syndromic	  and	  non-­‐syndromic	  genetic	  aortopathies.	  
MFS:	  Marfan	  syndrome;	  LDS:	  Loeys	  Dietz	  syndrome;	  EDS:	  Ehlers–Danlos	  syndrome;	  
TAAD:	  Thoracic	  Aortic	  Aneurysm	  Dissection	  and	  BAV:	  Bicuspid	  Aortic	  Valve	  (Comeglio,	  
P.	  et	  al.,	  2007;	  Guo	  et	  al.,	  2007;	  Judge	  et	  al.,	  2008).	   	  
1.Dietz	  H.	  Marfan	  syndrome.	  Gene	  Reviews.	  
http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=marfan	  
2.	  Loeys	  BL,	  DietzHC.	  Loeys-­‐Dietz	  syndrome.	  Gene	  Reviews.	  
http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=loeys dietz.	  
3.	  Pepin	  MG,	  Byers	  PH.	  Ehlers-­‐Danlos	  syndrome,	  Vascular	  Type.	  Gene	  Reviews.	  
http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=eds4.	  
4.	  MilewiczDM,	  Tran-­‐Fadulu	  V.	  Thoracic	  aortic	  aneurysms	  and	  aortic	  dissections.	  Gene	  
Reviews.	  http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=taa	  
.	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 MFS LDS Vascular-type EDS TAAD BAV 
Thoracic aortic aneurysm and 
dissection 
yes yes yes yes  
Non-thoracic aortic aneurysms  yes yes yes yes 
Arachnodactyly yes yes    
Reduced arm span to height ratio 
of >1.05 
yes     
Pectus carinatum or excavatum yes yes    
Scoliosis yes yes    
Joint hypermobility yes yes yes   
Ectopia lentis yes     
Lumbosacral dural ectasia yes yes    
Bifid uvula or cleft palate  yes    
Craniosynostosis  yes    
Velvety and translucent skin  yes yes   
Easy bruising yes yes yes   
Widened, atrophic scars  yes yes   
Table	  1.4	   Possible	  symptoms	  of	  six	  genetic	  aortopathies.	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 MFS LDS 
Vascular-type 
EDS 
TAAD Comment 
FBN1 ~100%     
TGFΒR1  25%  1% Mutations in TGFΒR1/2 tend to lead to aortic 
dissection and rupture at an earlier age than 
mutations in ACTA2 or MYH11 TGFΒR2  75%  2.5% 
COL3A1   60%  
2/3 of pathogenic mutations in COL3A1 are 
glycine substitutions in the triple helical 
domain. 
Mutations in MYH11 have been reported in two 
families with TAAD and patent ductus 
arteriosus 
Mutations in ACTA2 have been reported in 
families with TAAD and livido reticularis, 
early-onset coronary artery disease, or 
premature ischemic stroke 
MYH11    <1% 
ACTA2    14% 
Table	  1.5	   Affected	  genes	  in	  genetic	  aortopathies.	  
MFS:	  Marfan	  syndrome;	  LDS:	  Loeys	  Dietz	  syndrome;	  EDS:	  Ehlers–Danlos	  syndrome;	  
TAAD:	  Thoracic	  Aortic	  Aneurysm	  Dissection	  and	  BAV:	  Bicuspid	  Aortic	  Valve	  (Comeglio,	  
P.	  et	  al.,	  2007;	  Guo	  et	  al.,	  2007;	  Judge	  et	  al.,	  2008).	   	  
1.Dietz	  H.	  Marfan	  syndrome.GeneReviews.	  
http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=marfan	   	  
2.	  Loeys	  BL,Dietz	  HC.	  Loeys-­‐Dietz	  syndrome.	  Gene	  Reviews.	  
http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=loeys-­‐dietz.	   	  
3.	  Pepin	  MG,	  Byers	  PH.	  Ehlers-­‐Danlos	  syndrome,	  Vascular	  Type.	  Gene	  Reviews.	  
http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=eds4	  
4.	  MilewiczDM,	  Tran-­‐Fadulu	  V.	  Thoracic	  aortic	  aneurysms	  and	  aortic	  dissections.	  Gene	  
Reviews.	  http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=taa	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1.1.4	   Drug	  therapy/intervention	  for	  MFS	  
Therapy for MFS aims to limit the risk of aneurysm enlargement and consequent 
rupture. However, there are limitations to the capacity of drug treatment to achieve this 
aim. Maintenance of blood pressure within the low/normal range, using β -blockers 
and/or ACE inhibitors is standard therapy. However, evidence is currently emerging 
that angiotensin receptor blockers appear to directly target excessive TFG-β signalling, 
which is the likely pathogenesis of MFS. However, the use of angiotensin receptor 
blockers in MFS is currently limited by a lack of quality evidence, with major trials 
currently underway to address this issue. 
1.1.4.1	   β-­‐adrenergic	  receptor	  blockers	  
β-blockers can decrease the risk of aortic dissection and are considered as the standard 
medical treatment for patients with MFS, although the actual mechanism of action is 
unclear (Table 1.6). The potential benefits of β-blocker treatment are thought to relate to 
a reduction in aortic wall stress as a consequence of their negative inotropic and 
chronotropic effects, leading to a final reduction in dP/dT (change in ventricular 
pressure over time, which is a measure of ventricular contractility and performance 
(Krayenbuehl et al., 1973)) (Figure 1.9). In addition, β-blockers have been reported, in a 
small study, to decrease circulating TGF-β levels, although the underlying mechanism 
behind this is also unclear (Matt et al., 2009). 
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 MFS LDS 
Vascular-type 
EDS 
TAAD BAV 
Beta blocker yes yes in trials yes  
Angiotensin II, type I receptor 
antagonist 
In trials    yes 
Prophylactic surgery yes yes no yes  
Table	  1.6	   Drug	  therapy	  therapy	  of	  aortic	  aneurysms.	  
MFS:	  Marfan	  syndrome;	  LDS:	  Loeys	  Dietz	  syndrome;	  EDS:	  Ehlers–Danlos	  syndrome;	  
TAAD:	  Thoracic	  Aortic	  Aneurysm	  Dissection	  and	  BAV:	  Bicuspid	  Aortic	  Valve	  (Comeglio,	  
P.	  et	  al.,	  2007;	  Guo	  et	  al.,	  2007;	  Judge	  et	  al.,	  2008).	   	  
1.	   Dietz	  H.	  Marfan	  syndrome.GeneReviews.	  
http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=marfan	   	  
2.	   Loeys	  BL,Dietz	  HC.	  Loeys-­‐Dietz	  syndrome.	  Gene	  Reviews.	  
http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=loeys-­‐dietz	  
3	   Pepin	  MG,	  Byers	  PH.	  Ehlers-­‐Danlos	  syndrome,	  Vascular	  Type.	  Gene	  Reviews.	  
http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=eds4	  
4.	   MilewiczDM,	  Tran-­‐Fadulu	  V.	  Thoracic	  aortic	  aneurysms	  and	  aortic	  dissections.	  
Gene	  Reviews.	  http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=taa
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Figure	  1.9	   Pathogenic	  targets	  for	  pharmacological	  treatment	  of	  Marfan	  syndrome	  
patients	  
Drugs	   can	  potentially	   act	  on	  various	   stages	   in	   the	  pathogenesis	  of	  progressive	  aortic	  
dilatation.	   ARB	   could	   attenuate	   the	   increased	   TGF-­‐β	   signalling	   in	  MFS	   pathogenesis.	  
Additionally,	  doxycycline	  could	  dampen	  the	  increased	  MMP-­‐2	  and-­‐9	  activity,	  and	  ACEi	  
could	  reduce	  the	  haemodynamic	  stress.	   	  
Abbreviations:	  ACEi,	  angiotensin-­‐converting-­‐enzyme	  inhibitor;	  ARB,	  angiotensin	  II	  type	  
I	  receptor	  blockers;	  AT1,	  angiotensin	  II	  type	  I	  receptor;	  MMP,	  matrix	  metalloprotease;	  
TGF-­‐β,	  transforming	  growth	  factor	  beta	  (Canadas	  et	  al.,	  2010).	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In some studies, β -blocker therapy has been reported to slow down the speed of 
progression of aortic dilation and decrease the incidence of cardiac events (Shores et al., 
1994), on the other hand, other groups have reported that β-blockers do not prevent 
development of dissection nor avoid the need for prophylactic surgery (Tierney et al., 
2007). β-blocker therapy may be more effective in patients with less aortic dilatation 
(Dean, 2007). However, current recommendations advise the early use of β-blockers in 
all MFS patients regardless of aortic diameter (Keane et al., 2008), with the objective of 
maintaining a resting heart rate < 60–70 bpm and a maximum exercise heart rate of < 
100 bpm (Keane et al., 2008). Dosage of β-blockers in paediatric patients is problematic 
due to adverse events, such as exacerbation of bronchospasmal crises or somnolence, 
which are more common in infancy (Gersony et al., 2007). 
Interestingly, treatment with a placebo or propranolol (a β -blocker) does not prevent 
elastic fibre fragmentation in MFS mice (Habashi et al., 2006). In addition, the 
β-blocker propranolol offered no protective mechanism in the aortic wall, with 
fragmentation of elastic fibres occurring just as it did in placebo treated mice (Habashi 
et al., 2006), raising questions as to the validity of β-blockers as routine treatment for 
MFS. 
 
1.1.4.2	   Blockade	  of	  the	  renin-­‐angiotensin	  system	  
The use of angiotensin converting enzyme inhibitors (ACEi) has been proposed as an 
alternative or adjunct treatment to β-blockers. The possible advantage of ACEi 
treatment is more effective control of blood pressure, in particular central pressure, with 
a consequent reduction in the stiffness of the aortic wall (Ahimastos et al., 2007). 
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Two major trials are currently underway to assess the efficacy of angiotensin receptor 
blockers (Moberg et al., 2012; Lacro et al., 2013). Blockade of the RAS independent of 
the control of blood pressure may also be helpful in the treatment of MFS (Habashi et 
al., 2006; Brooke et al., 2008). Angiotensin binds to two receptors within mammals, 
type 1 (AT1) and type 2 (AT2). AT1 receptors mediate most angiotensin II actions in 
adulthood, such as vasoconstriction, renal salt and water retention as well as aldosterone 
release and occur in both peripheral tissues and the brain (Stroth et al., 1999). AT2 
receptors are highly expressed in foetal life, with expression diminishing over the 
post-natal period. In adult mammals, AT2 receptors are expressed exclusively in 
adrenal, pancreatic, uterine, brain, heart and vascular endothelium, and have been 
implicated in anti-proliferation and apoptosis pathways (Stroth et al., 1999).  
Angiotensin II binding to AT1 receptors within the aortic wall causes proliferation of 
smooth muscle cells, favours fibrosis, boosts the expression of matrix metalloprotease 
(MMP)-2 and MMP-9 and reduces apoptosis (Keane et al., 2008). Angiotensin II effects 
are mediated in part by transforming growth factor β (TGF-β), as the binding of 
angiotensin II to AT1 receptors increases TGF-β levels. Consequently, there is 
increased expression of genes regulated by TGF-β and other proteins that participate in 
the signalling pathway (Keane et al., 2008; Matt et al., 2008). Abnormal TGF-β 
signalling has been implicated in the pathogenesis of MFS (see Section 1.4.2 Abnormal 
TGF-β signalling in MFS) (Neptune et al., 2003; Ng et al., 2004). In human MFS 
patients, a 50% reduction of plasma TGF-β levels was observed after two weeks 
treatment with the angiotensin II type I receptor blocker (ARB) losartan (Brooke et al., 
2008).  
In stark contrast to AT1 receptors, when angiotensin II binds to AT2 receptors it has an 
anti-proliferative effect within the aortic wall (Keane et al., 2008). Increased apoptosis 
is thought to contribute to the pathogenesis of aortic root aneurysms in MFS (Merk et 
al., 2012), offering a basic explanation for the histological changes of cystic medial 
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necrosis that are observed in the aortic wall (Nagashima et al., 2001). Increased 
apoptosis in samples of the aortic wall of MFS patients was reduced when AT2 
receptor, but not AT1 receptor, blockade occurred (Nagashima et al., 2001).  
Treatment with ACEi inhibits the production of angiotensin II, therefore reducing AT1 
and AT2 receptor signalling. It is proposed that the addition of an ACEi could offer 
more effective protection to the aortic wall compared to treatment with ARB alone (see 
Figure 1.9). The blockade of AT1 receptors would prevent excessive TGF-β-dependent 
signalling, while the blockade of AT2 receptors would reduce apoptosis via a 
mechanism independent of the TGF-β pathway (Canadas et al., 2010). There is, how-
ever, no experimental data to confirm this and the clinical implications of simultaneous 
blockade of both the AT1 and AT2 receptors in MFS patients are yet to be determined. 
1.1.4.3	   Doxycycline	  
Small doses of the tetracycline antibiotic, doxycycline (100 mg/kg/day), used as a 
non-specific inhibitor of a wide range of metalloproteinases (Xiong et al., 2008), has 
been found to be associated with superior endothelial and elastic function of the aortic 
wall in MFS mice (Chung, A. W. et al., 2008). Abnormal MMP activity has been 
implicated in MFS (see section 1.4.3 Pathogenesis: Matrix metalloproteinases 
contribute to aneurysm formation). Doxycycline treatment inhibits the expression of 
MMP-2 and MMP-9 in a mouse model of MFS (see Figure 1.9), reducing the 
fragmentation of elastic fibres, delaying the subsequent dissection of aortic aneurysms 
(Xiong et al., 2008), or preventing the event altogether (Chung, A. W. et al., 2008). 
Doxycycline treatment has not been formally tested in MFS patients; as such, further 
investigation is required. 
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1.2	   Histopathology	   and	   echo	   of	   genetic	   thoracic	  
aneurysm	  
The histological changes found in MFS appear to be part of a continuum of aneurysmal 
aortopathy. The observed changes in MFS patients represent the extremes of aortic 
abnormality (Losenno et al., 2012).  
The most common change detected in the aortic wall is the presence of Medial 
degeneration (MD). MD is characterised by a loss of VSMCs in the absence of 
inflammation, fibre fragmentation and disorganisation leading to the loss of the elastic 
lamina, with the accumulation of basophilic material (glucosaminoglycan) in cyst-like, 
lacunar lesions within cell-depleted areas of the ascending aortic media (Tadros et al., 
2009; Yuan, S. M. et al., 2011; Losenno et al., 2012). Notably, MD is the underlying 
histological abnormality in ascending aortic dilatation and dissection and hence, is 
known to occur in MFS, in addition to other congenital cardiac defects and connective 
tissue disorders (Keane et al., 2008). Originally, the term cystic medial necrosis was 
used to describe this tissue degeneration, however, because the lesions are neither cystic 
nor necrotic, the descriptive term ‘medial degeneration’ was adopted (He et al., 2006). 
The total thickness of the aortic media remains unchanged but the distance between the 
sequential elastic lamellae is greater and the lamellae themselves are thinner and more 
fragmented (Tadros et al., 2009; Jain et al., 2011). The degree to which these histologic 
abnormalities present is highly variable.  
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Figure	  1.10	   Histological	   appearance	   of	   aortic	   tissue	   from	   normal	   and	   bicuspid	  
aortic	  valve	  specimens.	   	  
The	  healthy	  aorta	  (A	  and	  B)	  has	  a	  highly	  organised	  medial	  layer	  composed	  of	  vascular	  
smooth	   muscle	   cells	   (stained	   red,	   white	   arrow),	   elastic	   plates	   stained	   black,	   and	  
collagen	   stained	   yellow.	   Patients	   with	   aortic	   valve	  malformations	   (C	   and	   D),	   exhibit	  
significant	   aortic	   tissue	   changes.	   Loss	   of	   smooth	   muscle	   and	   fibrosis	   open	   (arrows)	  
results	   in	   fragmentation	   of	   the	   elastic	   fibres	   (arrows).	  Mucopolysaccharide	   deposits	  
(stained	  green-­‐ish/blue)	  are	  evident	  in	  the	  media.	  L	  indicates	  lumen	  (Fedak,	  2002).	   	  
 
Progressive levels of histologic degeneration are observed in the aortic tissue of MFS 
patients (Keane et al., 2008). The medial layer of the aorta shows similar abnormalities, 
although more extensive, to those seen in BAV. Progressive fragmentation and disarray 
of elastic lamellae, paucity of VSMCs, and separation of muscle fibres by 
basophilic-staining proteoglycan (glucosaminoglycan) characterises severe MD (Figures 
1.10 and 1.11) (Cozijnsen et al., 2011; Jain et al., 2011). These changes are indicative 
of a continuous process of injury and repair and are associated with reduced 
distensibility and increased stiffness of the ascending aorta (Reed, 2000; Keane et al., 
2008). Additionally, the process is associated with increased expression of transforming 
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growth factor-β (TGF-β) and matrix metalloproteinases (MMP-2 and -9) (Hidalgo et al., 
2001; Chung, A. W. et al., 2007). It has been suggested that these altered expression 
levels are indicators of an ongoing inflammatory process, despite the very limited 
presence of inflammatory-related cells. This abnormal tissue homeostasis is believed to 
result in maladaptive remodelling of the vascular ECM. Altered vascular structure, 
irrespective of aetiology, is assumed to lead to an increased propensity for dilation, 
dissection or rupture of the aortic wall (Yetman et al., 2009; Canadas et al., 2010). 
 
Figure	  1.11	   Medial	  degeneration	  in	  Marfan	  syndrome	  aortic	  tissue.	   	  
A	  cross	  section	  of	  the	  aortic	  media	  taken	  from	  a	  Marfan	  syndrome	  patient	  (A)	  shows	  
significant	  fragmentation	  of	  the	  elastin	  fibres	  with	  areas	  devoid	  of	  elastin	  resembling	  
cyst-­‐like	   spaces	   (asterisks).	  A	   cross	   section	  of	   the	  normal	  aortic	  media	   (B)	   shows	   the	  
highly	   structured	  organisation	  of	   the	  elastic	   tissue.	  Elastin	   is	   stained	  black	   (Kumar	   et	  
al.,	  2010).	  
 
1.3	   Genetics	  of	  inherited	  thoracic	  aortopathy	  
Mutations in more than 40 genes have been identified as being associated with 
aortopathy. Mutant genes have been found causing Marfan, Loeys-Dietz, Ehlers-Danlos 
and familial TAAD syndromes, but mutations of few genes have been identified to be 
associated with bicuspid valve aortopathy. Nearly all mutations are autosomal dominant 
in manifestation. Mutations occur in multiple protein systems: ECM microfibrils 
(fibrillin, elastin, collagen III, fibulin), VSMC contractile (actin, myosin heavy chain, 
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myosin light chain kinase) and VSMC signalling (TGF-βR1 and 2, Smad3, NOTCH1, 
Jagged1) (Lindsay et al., 2011). The wide range of protein systems/mutant genes 
involved in various forms of genetic aortopathy makes the development of a unify 
hypothesis difficult, given that the final phenotypic consequences within the thoracic 
aorta are remarkably similar for these quite disparate syndromes/ mutant protein 
systems. 
 
1.3.1	   Genetics	  of	  MFS	  
MFS is a highly variable disorder of the connective tissue, inherited almost exclusively 
through autosomal dominant mutations in the gene FBN1 (Hayward et al., 1997; Judge 
et al., 2008; Ogawa et al., 2011), although case reports have defined rare recessive 
FBN1 mutations (Hilhorst-Hofstee et al., 2010). Additionally, 25 to 30% of cases are 
sporadic, arising from new mutations (Comeglio, Paolo et al., 2007; Keane et al., 2008). 
In <10% of patients presenting with typical MFS phenotypes, no mutations in FBN1 are 
identified (Dietz, H. C. et al., 2005; Dong et al., 2012), however, a number of these 
individuals exhibit an inactivating mutation in the TGF-β2 receptor (Faivre et al., 2007; 
Chung, B. H. et al., 2009).  
 
1.3.1.1	  Mutations	  in	  FBN1	  
Mutations in the fibrillin-1 gene (FBN1) represent the genetics behind the majority of 
MFS cases (Hayward et al., 1997; Judge et al., 2008; Ogawa et al., 2011). The first 
FBN1 mutation was identified in 1991 (Dietz, H. C. et al., 1991) and found to be 
associated with classical MFS (Beighton et al., 1988; DePaepe et al., 1996; Hayward et 
al., 1997). Since then, over 1,000 mutations distributed throughout the FBN1 sequence 
have been described (Ammash et al., 2008; Keane et al., 2008). The FBN1 gene is 
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230-kb in size and located on chromosome 15 (15q-21.1), displaying a coding sequence 
fragmented into 65 exons (Gao et al., 2010; Dong et al., 2012). It encodes the structural 
glycoprotein fibrillin-1 (Canadas et al., 2010; Dong et al., 2012; Micheal et al., 2012; 
Kuchtey et al., 2013; Zanjani et al., 2013). Fibrillin-1 monomers associate to form 
macro-aggregates termed microfibrils, which are a major component of connective 
tissue matrices and are widely distributed throughout the body (Zhang, H. et al., 1995; 
Faivre et al., 2007).  
The currently identified FBN1 mutations can be classified into four basic groups (Figure 
1.12) (Hayward et al., 1997; Faivre et al., 2007). In-frame missense mutations caused 
primarily by single nucleotide substitutions (56% of recorded cases). Premature 
termination codons (PTC) caused by nonsense or frame shift mutations (14% and 17% 
of recorded cases, respectively), mutations within the splice site, resulting in alternative 
splicing (11% of recorded cases), or inframe small insertions and deletions (2% of 
recorded cases). 
The mechanisms by which mutations in FBN1 result in the development of MFS 
remains uncertain (Faivre et al., 2007), although it is proposed that their occurrence 
results in a significant deficit in the physiological functioning of the fibrillin-1 protein. 
Besides classical MFS, FBN1 mutations are also responsible for other fibrillinopathies 
(Faivre et al., 2008). Mutations frequently appear in exons 2, 15, 22, 27, 46, 55, and 62 
but much less in exons 7, 41, and 65 (Faivre et al., 2008), although the reason for this 
pattern of occurrence remains to be clarified (Dong et al., 2012).  
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Figure	  1.12	   Types	  of	  FBN1	  mutations.	   	  
Mutations	   can	  be	   classified	   into	   four	   groups:	   (1)	  missense	  mutations;	   (56%).	   (2)	   PTC	  
caused	   by	   frameshift	   mutations;	   (17%)	   or	   nonsense	   mutations	   14%.	   (3)	   Splicing	  
mutations;	  (11%).	  (4)	  Deletions	  or	  insertions	  (2%) (Faivre	  et	  al.,	  2007).	   	  
 
There is a high degree of phenotypic variability that differs even between similar FBN1 
mutations, leaving no clear correlation between genotype and phenotype (Faivre et al., 
2007; Chung, B. H. et al., 2009; Micheal et al., 2012). Mutations causing exon skipping 
(Hayward et al., 1997), and mutations within exons 24-32 (Dietz, H. C. et al., 2005; 
Chung, B. H. et al., 2009) tend to predict a more severe phenotype associated with an 
early onset of clinical complications and a higher incidence of cardiovascular 
involvement (Liu et al., 1996; Hayward et al., 1997; Faivre et al., 2007). Additionally, 
the most severe form of the disorder, neonatal MFS, is largely caused by mutations in 
the central exon 24-32 region (neonatal or severe region) (Faivre et al., 2007).  
Rarely, disease-causing mutations can occur in FBN2, which is considered to be part of 
the cause in early elastogenesis (Zhang, H. et al., 1995). Mutations were found in 
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phenotypically related disorder patients and also were revealed among the individuals 
with congenital contractural arachnodactyly (Gao et al., 2010). It is widely accepted that 
FBN2 mutations in chromosome 5q23 cause congenital contractural arachnodactyly 
(CCA), named Beals syndrome. Beals syndrome is an autosomal dominantly inherited 
connective tissue disorder that shares skeletal phenotype with Marfan syndrome, such 
as marfanoid habitus, arachnodactyly, camptodactyly and kyphoscoliosis. However, 
CCA patients have crumpled appearance of ear helix and congenital contractures, and 
do not normally represent the ocular and cardiovascular symptoms found in MFS 
(Tuncbilek et al., 2006). Identification of human genetic disorders caused by mutations 
in FBN3 may provide important clues regarding unique and/or overlapping functions 
performed by fibrillin-3.  
 
1.3.2	   Genetics	  of	  BAV	  
It is currently suggested that there exists a heritable component to BAV, although this is 
not conclusive. However, determining the underlying genetic bases proves complicated, 
as BAV is most probably the result of mutations in various genes, thus showing various 
patterns of inheritance (Siu et al., 2010; Padang et al., 2012). Genetic studies have 
established familial clustering amongst patients, suggesting a Mendelian pattern of 
inheritance (Siu et al., 2010; Padang et al., 2012). (Huntington et al., 1997) found that 
36.7% of patients screened for BAV had >1 first-degree relative who was also 
diagnosed with BAV. This high occurrence of familial clustering is indicative of 
autosomal dominant inheritance with variable expressivity and reduced penetrance 
(Fedak, 2002; Braverman, 2011). Currently, the only published mutation and strongest 
genetic link occurs in the gene NOTCH1, a transmembrane receptor on chromosome 9 
(9q34.3) that has a role in determining cell outcomes in organogenesis (Garg, 2006; 
Mordi et al., 2012). It has been linked in cases of non-syndromic BAV to development 
and progression (Padang et al., 2012). Several other genetic loci have been postulated 
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including chromosomes 18q, 5q, and 13q, which are presumed to contain genes 
implicated in the development of BAV and associated cardiovascular malformations 
(Siu et al., 2010; Mordi et al., 2012). It is reasonable to assume that the genes 
responsible for BAV may, additionally, play a role in the development of associated 
thoracic aortopathy due to the shared embryological origin of the aortic valve and 
ascending aorta from the cardiac neural crest cells (Padang et al., 2012). As no specific 
genes have been discovered at present, further research is warranted. 
 
1.3.3	   Mutations	  in	  TGF-­‐β	  receptors	  
The association between FBN1 and TGF-β signalling has been highlighted by the 
identification of mutations in the TGF-β receptor gene (see 1.4.2 Abnormal TGF-β 
signalling) (Faivre et al., 2008). The TGFΒR2 gene, located on chromosome 3 
(3p24.2-25), and encoding the TGF-β type 2 membrane receptor subunit has been 
identified in a subgroup of MFS patients (Collod et al., 1994). Controversy surrounds 
the diagnosis of these patients as the majority fail to fulfill the establish Ghent nosology 
(Dietz, H. et al., 1995; Chung, B. H. et al., 2009; Boileau et al., 2012). Additionally, 
mutations in TGFΒR2 correspond with high phenotypic heterogeneity (Boileau et al., 
2012). Furthermore, mutations in the TGFΒR1 gene have also been identified in a small 
percentage of patients with MFS and comparable phenotypes (Matyas et al., 2006; 
Singh et al., 2006). 
The TGF-β receptor is a heterodimer consisting of type 1 and type 2 subunits, encoded 
by the genes TGFΒR1 and TGFΒR2, respectively (Kaartinen, 2003; Attias et al., 2009; 
Boileau et al., 2012). The majority of genetic abnormalities within TGFΒR2 are mis-
sense mutations affecting an intracellular kinase domain, and thereby reducing receptor 
signalling in response to TGF-β (Boileau et al., 2012). Interestingly, however, these 
patients display histological signs of TGF-β overactivity (El-Hamamsy et al., 2009).  
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1.4	   Pathogenesis	  of	  genetic	  aortopathy	  
1.4.1	   Pathogenesis	  of	  thoracic	  aortic	  aneurysms	  in	  MFS	  
A current theory for the origin of MFS thoracic aortopathy proposes that its occurrence 
is the result of an overall abnormality in the homeostasis of the ECM. Mutations in the 
fibrillin-1 protein result in weakened and disordered elastic fibre formation in aortic 
tissue, together with disruption of the microfibril network connecting the elastic 
lamellae to the adjacent interstitial cells (Jones et al., 2010). Hence, the structural 
integrity of the aortic wall is compromised. In addition, reduced or defective forms of 
the glycoprotein lead to abnormal TGF-β signalling and dysregulation of cell-matrix 
interactions (El-Hamamsy et al., 2009; Jones et al., 2010). It has been suggested that, 
together, these two pathways disrupt normal homeostasis and, subsequently, facilitate 
vascular remodelling. Pathological remodelling is thought to promote the characteristic 
histological feature of MD, namely, the loss of elastin and collagen and a reduction in 
medial cell numbers, possibly via the induction of apoptosis (Nagashima et al., 2001; 
Nataatmadja et al., 2006). There is evidence to suggest that the pathway leading to 
aortic wall destruction is further exacerbated through excessive protease activity of 
MMPs (Nataatmadja et al., 2006). These pathways disrupt the sophisticated structural 
morphology and limit tissue repair of the aorta, tending to aneurysmal development in 
MFS (Nataatmadja et al., 2006; Canadas et al., 2010).  
Since fibrillin-1 is involved in the assembly of elastic fibres, the initial theories 
proposed that the structural support provided by fibrillin-1 was altered through 
mutations in FBN1 (Dietz, H. C. et al., 1993; Eldadah et al., 1995). This progressive 
structural weakness intuitively explained the corresponding increase in dilatation of the 
aorta, in addition to the observed histological changes of the MFS aorta.  
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Two mechanisms were proposed to explain this pathology. The first mechanism 
suggests a negative dominance where defective fibrillin-1 molecules do not allow for 
the necessary formation of fibrillin-1 polymers, rendering the ECM microfibrils 
structurally abnormal (Dietz, H. C. et al., 1993; Eldadah et al., 1995). This structural 
irregularity may cause detachment of the VSMCs from the elastic laminae, with 
subsequent accelerated apoptosis and release of pathological MMPs (Padang et al., 
2012).  
The second mechanism proposes haploinsufficiency, in which reduction of total 
fibrillin-1 production below a specific critical threshold results in connective-tissue 
weakness because the affected allele, including the mutated FBN1 gene, is not 
functionally transcribed (Judge et al., 2004; Canadas et al., 2010; Jondeau et al., 2011) 
or produces a truncated protein that is not incorporated into ECM structures or is 
selectively and prematurely degraded. This second mechanism easily accounts for 
particular clinical features of MFS, including joint hyperlaxity, ectopia lentis and dural 
ectasia, although it cannot offer an explanation into other phenotypic manifestations 
such as the dysfunction of the atrioventricular valves or the disproportionate growth of 
long bones (Judge et al., 2004; Canadas et al., 2010; Jondeau et al., 2011).  
More recent evidence suggests that the pathogenesis underlying the full range of MFS 
manifestations is more complicated than solely a disordered microfibril matrix; in 
addition to directing elastogenesis and providing structural integrity to the elastic 
lamellae, fibrillin-1 is involved in the sequestration of latent TGF-β (Jones et al., 2010). 
 
1.4.2	   Abnormal	  TGF-­‐β	  signalling	  in	  MFS	  
TGF-β is now recognised as a key component in the pathogenesis of MFS, offering an 
explanation for many of the observed clinical features, including thoracic aortopathy. 
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TGF-β is a constitutively expressed, pleotropic cytokine, that takes part in the regulation 
of many cell functions including proliferation, differentiation and apoptosis (Isogai et 
al., 2003; Kaartinen, 2003). It plays a fundamental role in maintaining ECM 
homeostasis. TGF-β is a secreted protein that exists in at least three isoforms: TGF-β1, 
TGF-β2 and TGF-β3. TGF-β1 was the founding member of this family. The TGF-β 
family is part of a superfamily of proteins known as the transforming growth factor-β 
superfamily, which includes inhibins, activin, anti-Müllerian hormone, bone 
morphogenetic protein, decapentaplegic and Vg-1 (Piek et al., 1999). 
Most tissues exhibit significant constitutive expression of the gene encoding TGF-β. 
That contrasts with other anti-inflammatory cytokines such as IL-10, whose expression 
is minimal in unstimulated tissues and seems to require triggering by commensal or 
pathogenic flora (Li et al., 2012). TGF-β acts as an anti-proliferative factor in normal 
epithelial cells and at early stages of oncogenesis (Hill et al., 2009). TGF-β is secreted 
by many cell types, including macrophages, in a latent form in which it is complexed 
with two other polypeptides, latent TGF-β binding protein (LTBP) and 
latency-associated peptide (LAP). Serum proteinases such as plasmin catalyze the 
release of active TGF-β from the complex. This often occurs on the surface of 
macrophages where the latent TGF-β complex is bound to CD36 via its ligand, 
thrombospondin-1 (TSP-1). Inflammatory stimuli that activate macrophages enhance 
the release of active TGF-β by promoting the activation of plasmin. Macrophages can 
also endocytose IgG-bound latent TGF-β complexes that are secreted by plasma cells 
and then release active TGF-β into the extracellular fluid (Clarke et al., 2009). 
Latent TGF-β consists of the mature growth factor bound by non-covalent interactions 
to the TGF-β propeptide (latency associated peptide; LAP) (Isogai et al., 2003). This 
dimeric complex is referred to as the small latent complex (SLC) (Massam-Wu et al., 
2010). Once synthesised, the SLC is secreted into the ECM (Saharinen et al., 1999) 
where TGF-β is rendered biologically inactive, anchored to latent TGF-β binding 
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protein (LTBP) via LAP, as part of a larger latent complex (LLC) (Figure 1.13) (Isogai 
et al., 2003; Massam-Wu et al., 2010). These multimeric protein complexes bind 
directly to microfibrils through sequence complementary between LTBP and 
microfibrils (Gelb, 2006; Choudhury et al., 2009; Jondeau et al., 2011). Proteases 
release the SLC by cleavage of the LTBP–LAP bond, after receiving certain 
physiological stimuli such as mechanical stimuli, pH changes and signals from other 
cytokines. This release allows for the activation of TGF-β and facilitates the initiation 
process of signal transduction via the interaction between TGF-β and its apposite 
signalling receptors (Figure 1.13) (El-Hamamsy et al., 2009). Free active TGF-β in the 
ECM binds to the TGF-β receptor 2, with the subsequent recruitment and activation of 
the TGF-β receptor 1. This binding induces a signalling cascade of intracellular protein 
phosphorylation, beginning with receptor associated Smads (Smads 2 and 3). The 
Smad2–Smad3 complex follows the classic pathway of translocation to the nucleus, 
allowing for downstream activation of gene transcription (specific activators or 
repressors) (Neptune et al., 2003; El-Hamamsy et al., 2009).  
 
Figure	  1.13	   Fibrillin-­‐1	  interacts	  with	  LTBP-­‐1	  to	  control	  TGF-­‐β	  activity.	   	  
SLC	  is	  secreted	  into	  the	  ECM	  and	  binds	  to	  LTBP-­‐1	  as	  part	  of	  a	  LLC.	  This	  complex	  binds	  
directly	  to	  microfibrils	  and	  prevents	  the	  release	  of	  TGF-­‐β	  (Kaartinen,	  2003).	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As fibrillin-1 is the primary constituent of microfibrils, it determines the bioavailability 
of active TGF-β and its signalling pathways. Hence, in MFS, it is hypothesised that 
reduced or defective forms of fibrillin-1 lead to failed matrix sequestration of the LLC, 
with subsequent excessive activation and signalling of TGF-β (El-Hamamsy et al., 
2009). This excessive TGF-β signalling can activate the alternate p38 mitogen activated 
kinase (MAPK) pathway in VSMCs, leading to increased production of plasminogen 
activators and upregulation of MMP transcription, resulting in ECM degradation 
(Kaartinen, 2003; Kim et al., 2004; Carta et al., 2009).  
Transgenic mice models of MFS offer support for a cause-and-effect relationship 
between excessive TGF-β signalling and the observed clinical manifestations (Neptune 
et al., 2003; Ng et al., 2004; Habashi et al., 2006; Jondeau et al., 2011). Furthermore, 
the treatment of MFS mouse models with anti-TGF-β antibodies (that neutralise 
bioactive TGF-β) rescues the animal and prevents the development of aortic root 
aneurysm (Habashi et al., 2006), mitral valve dysfunction and emphysematous 
abnormalities (Neptune et al., 2003; Ng et al., 2004; Gao et al., 2010). In the same 
mouse model, treatment with anti-TGF-β antibodies revealed reduced fragmentation of 
the elastic fibres and a decreased rate of aortic root dilatation (Habashi et al., 2006; 
Jondeau et al., 2011).  
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Figure	  1.14	   Model	  of	  normal	  regulation	  of	  TGF-­‐β	  by	  microfibrils	  and	  perturbations	  
associated	  with	  microfibrillar	  deficiency	  in	  Marfan	  syndrome.	   	  
Normally,	   extracellular	   microfibrils	   bind	   the	   LLC	   of	   TGF-­‐β.	   This	   complex	   binding	  
sequesters	   TGF-­‐β	   and	   hence,	   suppresses	   the	   release	   of	   free	   active	   TGF-­‐β	   until	   its	  
required	   release.	   Once	   released,	   free	   active	   TGF-­‐β	   can	   interact	   with	   its	   cell	   surface	  
receptors	   to	   induce	   a	   signalling	   cascade	   of	   intracellular	   protein	   phosphorylation,	  
beginning	   with	   receptor	   associated	   Smads.	   The	   Smad	   complex	   follows	   the	   classic	  
pathway	  of	   translocation	  to	  the	  nucleus,	  allowing	   for	  downstream	  activation	  of	  gene	  
transcription.	  In	  the	  presence	  of	  defective	  microfibrils	  (e.g.	  MFS),	  failure	  to	  sequester	  
the	  LLC	  results	  in	  promiscuous	  activation	  of	  TGF-­‐β	  (lightening	  bolt).	  Free,	  active	  TGF-­‐β	  
is	  then	  able	  to	   interact	  with	   its	  cell	  surface	  receptors	   leading	  to	  the	  activation	  of	  the	  
alternate	  p38	  mitogen	  activated	  kinase	  (MAPK)	  pathway	  (Ramirez	  et	  al.,	  2010).	   	  
 
In view of these results, the theory that the TGF-β signal translation pathway activation 
may be one of the major pathways of MFS pathogenesis, through MMP activation, 
which promotes ECM proteolysis, is plausible (Lebreiro et al., 2010).  
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1.4.3	   Matrix	   metalloproteinases	   contribute	   to	   aneurysm	  
formation	  
MMPs mediate ECM destruction, subsequently resulting in weakening of the aortic wall 
and thus facilitating the formation of aneurysms (Barbour et al., 2007). The MMPs 
comprise a family of 27 extracellular proteases that are capable of remodelling, 
processing and degrading several constituents of the ECM and associated adhesion 
molecules (El-Hamamsy et al., 2009; Lebreiro et al., 2010). The expression and activity 
of MMPs within the vascular wall are regulated via endogenous tissue inhibitors 
(TIMPs), which act directly by binding to and inactivating MMPs (El-Hamamsy et al., 
2009; Jondeau et al., 2011). Hence, the balance between MMPs and TIMPs determines 
the overall effect on aortic wall matrix composition.  
Various studies have examined the MMP profile, reporting that disruption of this unique 
MMP: TIMP signature encourages vascular remodelling. Whereas healthy aortic tissue 
displays unremitting low expression of MMPs, altered MMP expression (particularly 
MMP-2, and 9 and TIMP-1 and 2) is consistently observed in MFS aortic specimens 
(Barbour et al., 2007). Research has identified an apparent correlation between 
expression of predominant MMPs and the degree of severity of the aneurysm. For 
example, MMP-2 shows high expression levels in minor aneurysms, while MMP-9 is 
highly expressed in larger aneurysms or before rupture (Aziz et al., 2007; Lebreiro et 
al., 2010). Thus, the ratios MMP-2: TIMP-2 and MMP-9: TIMP-1 may be indicators of 
proteolytic activity (Hidalgo et al., 2001; Chung, A. W. et al., 2007).  
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1.4.4	   Pathogenesis	  of	  thoracic	  aortic	  aneurysms	  in	  BAV	  
Despite its high prevalence, the underlying pathogenesis of abnormal valvulogenesis 
leading to the formation of aortic aneurysms in BAV remains elusive. Ongoing 
controversies exist in the literature, debating two broad theories that currently exist – 
the haemodynamic theory and the genetic theory. 
 
1.4.4.1	   The	  haemodynamic	  theory	   	  
The original explanation proposes that BAV-associated aortopathy is a subsequent 
occurrence of a hemodynamic phenomenon that results from the structurally defective 
bicuspid valve. As the restricted functioning (morphological stenosis) of the conjoined 
leaflets alters post-valvular blood flow, irregular biomechanics inside the ascending 
aorta are produced (Aicher et al., 2007; Losenno et al., 2012). Abnormally turbulent 
flow induces differential distribution of haemodynamic stress (shear stress) and friction 
on the aortic endothelium, consequently promoting remodelling of the vasculature. This 
flow-induced remodelling encourages aortic dilatation through increased expression of 
MMPs and growth factors that regulate matrix degradation and vascular smooth muscle 
apoptosis (Vallely et al., 2008; Padang et al., 2012). Support for this theory is offered 
by a number of studies that have demonstrated an association between substantial 
valvular malformation and aortic root size in BAV patients and mouse models. 
Different aortic cuspal fusions have been shown to generate unique flow orientations in 
the ascending aorta, which produce distinct aneurysmal arrangements of aortopathy and 
specific MMP: TIMP signatures (Tadros et al., 2009; Padang et al., 2012). 
However, other investigations have suggested that patients who present with totally 
functional bicuspid valves display large aortic diameters compared to those with 
tricuspid aortic valves, offering support to a second theory (Della Corte et al., 2007; 
Vallely et al., 2008; Losenno et al., 2012). 
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1.4.4.2	   The	  genetic	  theory	  
An alternate explanation is based on the observation that aortic dilatation can occur in 
patients with haemodynamically normal bicuspid valves or in post-valve replacement 
patients (Aicher et al., 2007; Tadros et al., 2009). Genetic studies have established an 
inherent structural alteration in the ascending aorta of BAV patients, although the 
causative genes linked to the arterial wall fragility remain largely unknown (Fedak, 
2002; Padang et al., 2012). This inherent structural alteration demonstrates similar 
histological and biomolecular changes to those observed in MFS aortas (Tadros et al., 
2009; Girdauskas et al., 2011; Michelena et al., 2011). This resemblance, along with the 
identified deficiency of fibrillin-1, suggests the potential contribution of abnormal 
TGF-β signalling to the pathogenic process (see 1.4.2 Abnormal TGF-β signalling) 
(Tadros et al., 2009; Yuan, S. et al., 2010; Girdauskas et al., 2011). Determining the 
genetics of BAV is complicated and it is likely due to genetic heterogeneity with 
variable inheritance (Siu et al., 2010; Padang et al., 2012).  
Although the two are acknowledged as being mutually exclusive, a combination of 
coexisting genetic and hemodynamic causative factors are likely contributes to 
aneurysm formation and subsequent progression in BAV aortas (Della Corte et al., 
2007; Padang et al., 2012).  
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1.5	   Proteins	  relevant	  to	  genetic	  thoracic	  aneurysm	  
1.5.1	   Fibrillin-­‐1	  
1.5.1.1	   Isoforms	  
Fibrillin is a 350 kDa calcium-binding glycoprotein found in extracellular microfibrils. 
In humans the fibrillin gene (FBN) chromosomal locations are: FBN1 15q21.1, FBN2 
5q23-q31, and FBN3 19p13.  
Fibrillin-1 was first isolated from elastic microfibrils in 1986 (Sakai et al., 1986) and is 
widely distributed through the body. Fibrillin-2 was discovered during the cloning of 
fibrillin-1 in 1991 (Lee, B. et al., 1991) and is predominantly expressed during 
embryogenesis, decreases after birth and is plays a minor role in elastogenesis in the 
aorta (Kelleher et al., 2004). The enigmatic fibrillin-3 was subsequently discovered in 
2004 by in silico genetic analysis (Corson et al., 2004) and is expressed mainly in 
neurological tissue. Having a sequence analogous to fibrillin-2, fibrillin-4 was found in 
zebrafish recently (Gansner et al., 2008). Mutations in fibrillins are associated with 
several different connective tissue diseases, such as Marfan syndrome (FBN1) (Xiong et 
al., 2008), ectopia lentis (Li et al., 2012), congenital contractural arachnodactyly (Beal’s 
syndrome) (FBN1 and FNB2) (Putnam et al., 1995) and Weill-Marchesani syndrome 
(FBN3) (Corson et al., 2004). 
 
1.5.1.2	   Number	  and	  type	  of	  domains	  
Fibrillin-1, -2 and -3 have 57 domains, 56 domains and 53 domains, respectively. 
Fibrillin-1 consists of 2871 amino acids, divided into 57 domains: 47 are epidermal 
growth factor-like (EGF) domains, which includes 43 calcium-binding EGF (cbEGF) 
domains (see Figure 1.14). Also there are 7 transforming growth factor-binding (TB) 
Chapter	  1	  -­‐	  Introduction	  
Yaxin	  Lu	   	   August	  2013	  
46	  
domains; 2 hybrid (HY) domains (HY domains are structurally similar to TB domains); 
as well as 1 unique–sequence proline-rich (PR) domain. There are also N- and 
C-terminal regions. EGF domains are found in many proteins, such as extracellular and 
secreted proteins (Bork et al., 1996), however, TB domains are unique to fibrillins and 
latent transforming growth factor β binding proteins (LTBPs) (Ramirez et al., 2010). 
This highly specific domain architecture is essential for establishing the elastomeric 
components of fibrillin-1, and hence, microfibrils within connective tissue. 
 
 
Figure	  1.15	   Schematic	  of	  fibrillin-­‐1	  structure.	  
The	  domain	  organisation	  of	  fibrillin-­‐1	  is	  divided	  into	  57	  functional	  domains,	  dominated	  
by	  47	  EGF	  domains	  of	  which	  43	  are	  cbEGF	  domains.	  These	  are	   interspersed	  by	  seven	  
TB	   domains.	   Additionally,	   fibrillin-­‐1	   contains	   two	   hybrid	   domains	   and	   a	   single	   PR	  
domain.	  There	  are	  also	  N-­‐	  and	  C-­‐terminal	  regions	  (Yuan,	  X.	  et	  al.,	  1997).	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The main sequence differences between the three fibrillin isoforms is located in the 
unique sequence domain, which is enriched for either proline (fibrillin-1) or glycine 
(fibrillin-2) or both proline and glycine (fibrillin-3) (Corson et al., 2004). Additionally, 
all isoforms contain an integrin-binding Arg-Gly-Asp (RGD) sequence in the 4th TB 
domain, but there is an additional RGD sequence in fibrillin-2 in the 3rd TB domain, and 
in fibrillin-3 in cbEGF domain 19. Integrin binding supports cell adhesion by interacting 
with the cell membrane-bound integrin receptors. Finally, fibrillin-1 contains the most 
putative N-glycosylation sites (residues 1067, 1149, 1369, 1484, 1581, 1669, 1703, 
1713, 1902, 2077, 2178, 2734, 2750 and 2767) (Chen, Q. et al., 2009) 
http://www.uniprot.org/uniprot/P35555. 
 
1.5.1.3	   cbEGF	  domains	  
Epidermal growth factor-like (EGF) domains are found in a wide variety of extracellular 
proteins including human fibrillin and Notch family proteins (Werner et al., 2000; 
Smallridge et al., 2003; Davis et al., 2012). The majority of EGF domains contain a 
Ca2+ binding consensus sequence and are known as cbEGF domains (43/47 EGF 
domains in fibrillin-1 and fibrillin-2; 42/44 EGF domains in fibrillin-3). cbEGF 
domains form multiple tandem repeats interspersed with TB domains.  
cbEGF domains are found in many extracellular and cell-surface proteins (e.g., 
urokinase (uPA), laminin Bl and the low density lipoprotein receptor (LDL receptor)) 
(Hearing et al., 1988). EGF domains are formed from a double-stranded anti-parallel 
β-sheet interspersed with random coil (Smallridge et al., 2003) (Figure 1.16).  
All the cbEGF domains commence with an aspartate (D) and contain 6 cysteines (C) 
that form 3 disulphide bonds (C1-C3, C2-C4 and C5-C6), which contribute to the 
stability of each individual domain. Ca2+ binds near the N-terminus and confers 
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structural rigidity to each domain, which is essential in fibrillin-1 functioning 
(Jovanovic et al., 2008). Hence, this conformation appears to be necessary for 
maintaining subsequent microfibril morphology and function (Werner et al., 2000; 
Jensen et al., 2005). 
 
 
Figure	  1.16	   The	   NMR	   structure	   of	   cbEGF12-­‐13	   (Left)	   and	   cbEGF32-­‐33	   (Right)	  
domains.	   	  
The	   schematic	   comparison	   of	   interdomain	   packing	   interactions	   for	   fibrillin-­‐1	  
(cb)EGF-­‐cbEGF	   domain	   pairs	   of	   known	   structure.	   The	   two	   structures	   were	  
superimposed	  on	   the	  backbone	  atoms	  of	   residues	   in	   the	  minor	  β-­‐hairpin	  of	   the	   first	  
domain	  and	  the	  major	  β-­‐hairpin	  of	  the	  second	  domain	  and	  then	  transposed.	  Calcium	  
atoms	   are	   shown	   as	   red	   spheres.	   In	   cbEGF12–13	   the	   packing	   interaction	   comprises	  
Arg1083	   (magenta)	   and	   Tyr1101	   (yellow)	   of	   cbEGF12	   and	   Glu1133	   and	   Gly1134	   of	  
cbEGF13	  (cyan).	  In	  cbEGF32–33	  this	  interaction	  comprises	  Tyr2147	  of	  cbEGF32	  (yellow)	  
and	   Ile2185	  and	  Gly2186	  of	  cbEGF33	   (cyan).	  The	  two	  structures	  are	  similar,	  with	   the	  
most	  significant	  differences	  localized	  to	  the	  N-­‐terminal	  region	  of	  the	  first	  domain.	  It	  is	  
likely	   that	   this	   region,	   as	   well	   as	   the	   C	   terminus	   of	   cbEGF13,	   will	   be	   affected	   by	  
pairwise	  domain	  interactions	  in	  the	  intact	  protein	  (Smallridge	  et	  al.,	  2003).	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The structural rigidity of the tandem repeating cbEGF domains appears to be essential 
for the function of fibrillin (Jensen et al., 2005). Structural rigidity within each domain 
is maintained by Ca2+ binding and the 3 disulphide bonds. The structural rigidity of the 
cbEGF domain pair is also dependent on conserved hydrophobic residues within the 
interdomain interface. Thus, key conserved residues have been identified in cbEGF 
domains that are related to these functions (Table 1.7 and Figure 1.17). 
Ca2+ chelation illustrates the importance of Ca2+ binding to the overall structure and 
assembly of fibrillin. Chelation reduces the overall length of fibrillin and reduces the 
“bead” periodicity of the rod-shaped fibrillin molecule by ~20% in solution (Reinhardt 
et al., 1996; Kielty et al., 2002).  
 
Figure	  1.17	   Key	  residues	  to	  maintain	  the	  structure	  of	  the	  cbEGF	  domain.	  
In	  cbEGF	  12-­‐13	  domains,	  Cys	  are	  labelled	  as	  blue	  and	  calcium	  binding	  sites	  are	  labelled	  
as	  pink.	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cbEGF domains Residues Function Reference 
Disulphide bounds C1-C3 C2-C4 C5-C6 
Stability of domain structural 
conformation. 
(Li et al., 2012) 
Ca2+ binding sites D/N-X-D/N-E/Q-Xm-D/N-Xn-Y/F 
Ca2+ is the key to build the 
interdomain linkage. 
(Lee, S. S. et al., 2004) 
Hydrophobic interface 
Tyr or Phe in the loop between C5-C6 in a N-terminus 
A pair of amino acid residues in the loop between C3-C4 of the following 
C-terminus 
The fold of tandemly arranged 
cbEGF modules is stabilized by 
hydrophobic interactions. 
(Downing et al., 1996) 
Interdomain interactions Ca2+ binding 
Stabilize the domain structural 
rigidity. 
(Handford et al., 2000) 
Table	  1.7	   Summary	  of	  cbEGF	  domains.
50	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1.5.1.4	   TB	  domains	  
The transforming growth factor β (TGF-β)-binding (TB) protein-like domain exists 
uniquely in the microfibril protein family: the fibrillins and latent transforming growth 
factor β-binding proteins (LTBPs) (Jovanovic et al., 2008). Amongst Homo sapiens, in 
fibrillin-1, -2 and -3 there are 9 TB domains (some researchers catalogue 2 hybrid 
domains as TB domains as well). A classical TB domain contains 8 conserved cysteine 
residues, which include an extraordinary cysteine triplet (Bork et al., 1996). A key 
function of TB domains is as a binding site for the storage of latent TGF-β within the 
TGF-β complex (Yuan, X. et al., 1997). 
The crystal structure of the TB4 domain reveals six-strands, which form a 
four-stranded-sheet and a two-stranded-sheet, respectively (Robertson et al., 2011) 
(Figure 1.18). Furthermore, the end of the α-helix is composed by the first two cysteines 
which form a triplet of Cys residues 1532-1589. The disulphide bonds form in a Cys 
1–3, 2–6, 4–7 and 5–8 pattern and are involved in the secondary structure formation and 
stabilize the general fold. Moreover, the TB4 domain does not bind calcium. 
Additionally, TB domains have been shown to facilitate specific protein–protein 
interactions imperative for the regulatory functions associated with the LTBP/fibrillin 
family and act as a binding site for the storage of latent TGF-β within the TGF-β 
complex (Robertson et al., 2011). 
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Figure	  1.18	   Three-­‐dimensional	   structures	   taken	   from	   TB4	   (PDB	   code	   1UZJ)	   of	  
human	  fibrillin-­‐1.	   	  
Structures	  are	  rainbow	  coloured	  with	  the	  N-­‐termini	  in	  blue	  through	  to	  the	  C-­‐termini	  in	  
red.	  Disulphides	  are	  also	  shown	  as	  stick	  representations	  with	  carbon	  atoms	  coloured	  
green	  and	  sulphur	  atoms	  coloured	  yellow.	   	  
 
 
Figure	  1.19	   Key	  residues	  to	  maintain	  the	  structure	  of	  the	  TB	  domain.	  
In	  cbEGF	  4	  domain,	  Cysteines	  are	  labelled	  as	  purple	  and	  α-­‐helixes	  are	  labelled	  as	  green	  
and	  β-­‐sheets	  are	  labelled	  as	  blue.	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TB domains Residues Function Reference 
Disulphide bounds 
C1-C3 C2-C6 C4-C7 
C5-C8 
Stability of domain 
structural conformation 
(Handford et al., 
2000) 
Hydrophobic interface 
LTBP-1 (residues 
1018-1080) 
play a role in its 
interaction with the 
TGF-βeta1 
latency-associated peptide 
(Yuan, X. et al., 
1997) 
Interdomain 
interactions 
RGD sites in TB4 
At the end of the TB6 
β-hairpin formed by 
strands B and C which 
points into solution 
Integrin binding 
(Yuan, X. et al., 
1997) 
Linker regions 
Between TB modules 
and adjacent domains in 
fibrillin-1 consist of 6-8 
residues at the 
N-terminal side and 
11-19 residues on the 
C-terminal side of the 
8cys TB domain 
Proper alignment of 
molecules within the 
assembled microfibril 
(Handford et al., 
2000) 
Table	  1.8	   Summary	  of	  TB	  domains.	  
Fragment:	  TB6	  domain,	  residues	  2059-­‐2111.	  Model	  from	  Yuan’s	  team	  is	  from	  residue	  
2054	  to	  2125.	  
 
1.5.1.5	   Hybrid	  domains	  
The hybrid domain is unique to fibrillin and LTBPs (Jovanovic et al., 2008; Robertson 
et al., 2011; Davis et al., 2012), with two functional domains present near the 
N-terminal of fibrillin-1 (Jensen et al., 2009). The two hybrid (HY) domains are locate 
in the N-terminus of fibrillin-1 and assume a structure similar to TB domains. Both of 
HY and TB domains have 8 conserved Cys residues. The major difference between 
those two types of domain is TB domains include a Cys triplet in the amino acid 
sequence; whilst HY domains do not. In fibrillin-1, there are two HY domains: residues 
184-236 (HY1 domain) and residues 851-902 (HY2 domain). An additional Cys is 
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located in HY1 domain, which does not occur in the HY2 domain (Handford et al., 
2000). The hybrid domain functions to mediate intermolecular disulfide bonding 
between fibrillin-1 monomers (Pereira et al., 1993; Reinhardt et al., 2000). 
 
1.5.1.6	   N-­‐	  and	  C-­‐terminal	  domains	  
The N- and C-terminal domains are both proline and cysteine rich displaying sequence 
homologies with the respective segments of the LTBPs and fibulins to which they bind 
(Ramirez et al., 2010). The N-terminus comprises a hydrophobic core consisting of a 
conserved tryptophan, similar to TB domains (Yuan, X. et al., 1997; Lee, S. S. et al., 
2004), whilst the C-terminus contains a disulphide-stabilised β -sheet that is similar to 
EGF domains (Knott et al., 1996). Within each of the two domains similar stretches of 
β-sheet are present, with either a three- or four-stranded segment displayed near the 
N-terminus and a two-stranded section of β -sheet near the C terminus (Jensen et al., 
2009). The C-terminal portion drives formation of the disulphide-bonded globular 
structures of fibrillin-1 (Ramirez et al., 2010). These interact with the N-terminal 
portion of an adjacent fibrillin to regulate linear assembly and facilitate correct 
assembly of fibrillin-1 monomers in the microfibril (Hubmacher et al., 2008; Ramirez et 
al., 2010). 
 
1.5.1.7	   Proline-­‐rich	  domain	  
The single proline-rich domain lies toward the N-terminal, between the two 
cysteine-rich regions of fibrillin-1. It comprises 58 amino acids and is characterised by 
unusually high proline content (42%) (Pereira et al., 1993). The proline-rich domain is 
likely to be unstructured (Ashworth et al., 1999).  
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1.5.1.8	   cbEGF-­‐TB	  domain	  interactions	  
A previous study of the Ca2+ binding properties of TB-cbEGF pairs showed that Ca2+ 
afﬁnity was strongly inﬂuenced by the presence of a hydrophobic interdomain interface 
(Jensen et al., 2009). This places the second Ca2+-binding site adjacent to the 
inter-domain region of a tandem pair, which facilitates the important conserved 
hydrophobic packing interaction between the two domains (Downing et al., 1996; 
Jovanovic et al., 2008). These are important because many disease mutations are in or 
adjacent to these residues. Additionally, many of the mutations substitute one of the six 
predictably spaced cysteine residues that interact via intradomain disulphide linkage, 
highly conserved residues within the calcium-binding consensus sequence, or residues 
important for interdomain hydrophobic packing interactions.  
TB-cbEGF domain pairs show a wide range of calcium Kd values, from 16 ± 1 nM in 
the case of the TB4-cbEGF23 domain pair to 1.6 mM in the case of the TB6-cbEGF32 
domain pair. The very high calcium affinity observed for the TB4-cbEGF23 pair is the 
result of an extensive hydrophobic interface between the domains, involving two 
separate hydrophobic packing sites on each of the domains (Jensen et al., 2005; Lee et 
al., 2004). The first of these (L1) involves hydrophobic residues between Cys-2 and 
Cys-3 of the TB domain packing with residues between Cys-1 and Cys-2 (‘‘loop 1’’) of 
the cbEGF domain. The second site resembles a cbEGF-cbEGF interaction, with the 
turn between Cys-3 and Cys-4 of the cbEGF domains packing against a Gly-X motif 
(where X is often aromatic) found after Cys-8 of the TB domain. Although the length of 
the linker region between the TB and cbEGF domains was originally thought to 
determine the degree of flexibility between these domains, based on the structure of the 
isolated fibrillin-1 TB6 domain (Yuan et al., 1997), it has since been shown that the 
hydrophobic interactions between domains have a far greater influence on interdomain 
interactions (Jensen et al., 2005). 
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1.5.1.9	   Biological	  functions	  of	  fibrillin-­‐1	  
Fibrillin-1 serves as a structural component of 10-12 nm calcium-binding microfibrils 
that form a sheath surrounding amorphous elastin (Sakai et al., 1986). Fibrillin-2 is 
considered to take part during early elastogenesis (Zhang, H. et al., 1995). Mutations 
have been found in fibrillin-2 in phenotypically-related disorders, such as congenital 
contractural arachnodactyly (Gao et al., 2010). Although the exact function of fibrillin-3 
is still unclear, it is believed to be located primarily in the brain and it is associated with 
the Weill–Marchesani syndrome (Corson et al., 2004). 
Microfibrils widely exist in tissues that do not express elastin; nevertheless, vertebrate 
and invertebrate fibrillin assembles into fibrillin-rich microfibrils, which in turn 
envelope elastin to form elastic fibres (Hubmacher et al., 2010). Elastic fibres are 
comprised of the interaction between microfibrils and polymerized tropoelastin 
monomers (Kielty et al., 2002), lysyl oxidase and elastin (Trask et al., 2000), emilin 
(Doliana et al., 1999) and fibulin-2 (Reinhardt et al., 1996) (Raghunath et al., 1999). 
Immunohistochemical and biochemical studies have found the majority of microfibrils 
consist of latent TGF-β binding protein (LTBP), fibulin, bone morphogenetic proteins 
(BMP), decorin, versican, microﬁbril-associated glycoprotein (MAGP-1) and elastin. 
These associations involve biochemical and functional properties in microfibrils (Kielty 
et al., 2002). In addition, there is evidence that the loss of fibrillins results in 
dysregulated TGF-β and BMP signaling (Neptune et al., 2003) (Habashi et al., 2006) 
(Cohn et al., 2007). Also, the phenotype of MAGP-1 null mice alter TGF-β signaling 
(Arteaga-Solis et al., 2001). 
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1.5.2	   Protein-­‐protein	  interactions	  
1.5.2.1	   Fibrillin	  self	  assembly	  
The major structural components of the extracellular matrix are fibrillin-rich 
microfibrils, which provide elasticity in most connective tissues. However, the location, 
distribution and elastic properties of fibrillin molecules associated with microfibrils 
remain unclear.  
Fibrillin-1 monomers are secreted by fibroblasts (Rossi et al., 2010) and polymerise to 
form insoluble microfibrils structured in a head-to-tail arrangement within the ECM 
(Jensen et al., 2009; Ramirez et al., 2010; Jensen et al., 2012). Microfibrils show a 
typical bead-on-the-string ultra-structure with periodicities of approximately 55 nm by 
electron microscopy (Kielty et al., 2002; Jovanovic et al., 2008; Jensen et al., 2009; 
Ramirez et al., 2010) (Figure 1.20).  
 
Figure	  1.20	   Rotary-­‐shadowed	   image	   of	   a	   fibrillin	   microfibril	   extracted	   from	  
connective	  tissue.	  
The	  bead-­‐to-­‐bead	  periodicity	  is	  approximately	  55	  nm	  (Ramirez	  et	  al.,	  2010).	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Fibrillin-1 (roughly 143-160 nm in length) is the major component of microfibrils. 
Several models have been proposed for the molecular organisation of fibrillin 
monomers within microfibrils (Glab et al., 2008). These models can be broadly 
categorised into two groups – those with a single folded fibrillin-1 monomer per 
interbead distance, and those with monomers extending in a staggered fashion across 
two interbead distances (Figure 1.21) (Jensen et al., 2009; Ramirez et al., 2010; Jensen 
et al., 2012). Both models propose around eight fibrillin-1 monomers per 10-12nm cross 
sectional area (Hubmacher et al., 2008; Jensen et al., 2012) (Figure 1.21).  
Folding/pleating model – the lateral model (N-N or C-C) or head-to-toe (N-C) parallel 
alignment and fibrillin is highly folded to form the bead structures (Reinhardt et al., 
1996). Other binding molecules may also contribute to the mass of the beads (Sherratt et 
al., 1997). Unfolding of the fibrillin within the beads allows reversible extension (Kielty 
et al., 2002). Significant folding and overlap of the N- and C-termini has been proposed 
(Baldock et al., 2006). Currently, this model has been shown to provide the best fit. 
A staggered model – unfolded fibrillin monomers span two or three interbead regions, 
with a 12 nm overlap between successive fibrillin monomers (Downing et al., 1996) and 
a 30% stagger between adjacent monomers, leading to a 55 nm periodicity. However, 
the extensibility of the microfibril would require domain linker extensibility (Lee, S. S. 
et al., 2004). 
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Figure	  1.21	   Models	  of	  microfibril	  organisation.	  
(A)	   A	   single	   folded	   fibrillin-­‐1	   monomer	   (pale	   blue)	   assembles	   per	   56	   nm	   interbead	  
distance.	   	  
(B)	   Each	   fibrillin-­‐1	   monomer	   extends	   in	   a	   staggered	   fashion	   across	   two	   interbead	  
distances,	  overlapping	  with	  successive	  monomers.	  Dotted	  circles	  correspond	  to	  beads.	  
Black	   elements	   –	   TB	   domains;	   magenta	   elements	   –	   hybrid	   domains.	   Adapted	   from	  
(Jensen	  et	  al.,	  2012).	  
Some	  current	  models	  hypothesized	  a	  head-­‐to-­‐tail	  alignment	  with	  roughly	  eight	  fibrillin	  
monomers	  in	  cross	  section	  is	  the	  static	  organization	  of	  fibrillins	  in	  microfibrils;	  but	  the	  
orientation	  of	  these	  models	  has	  not	  been	  identified	  (Hubmacher	  et	  al.,	  2008).	   	  
 
The cell surface and its surrounding regions were firstly considered as the formation 
sites of microfibrils from monomeric fibrillin, which involves disulphide bond 
formation (Reinhardt et al., 2000). The fibrillin-1 self assembly model is assumed as the 
lateral (N-to-N and C-to-C) and head-to-tail (N-to-C) self-interaction.(Ashworth et al., 
1999; Trask et al., 1999; Lin et al., 2002; Marson et al., 2005). Thus, fibrillin-1 
monomers are able to mediate elongation of the immature microfibril through its N-to-C 
self-interaction properties (Lin et al., 2002; Marson et al., 2005). There are two epitopes 
located in:  
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i) the region between the unique N-terminal and cbEGF2 domain;  
ii) the region between TB/8-Cys-7 and the unique furin proprotein processing binding 
sites on C-terminus, respectively (Marson et al., 2005).  
In addition, both N-N and C-C interactions are thought to laterally align the fibrillin 
molecules in microfibrils (Ashworth et al., 1999; Trask et al., 1999; Marson et al., 
2005). 
 
1.5.3	   Fibrillin	  expression,	  activation	  and	  turnover	  
Fibrillin-1 and fibrillin-2 are distinct but overlapping patterns of expression. Fibrillin-2 
is generally expressed earlier in development than fibrillin-1 and might be 
predominantly important in elastic fibre formation (Zhang, H. et al., 1995). Fibrillin-3 
was isolated from brain, and whether it forms microfibrils has not been revealed yet 
(Corson et al., 2004). Fibrillin-1 and -2 are the principal structural components of 
microfibrils.  
The expression of the FBN2 gene is correlated with that of the tropoelastin gene, and 
FBN2 is required for the deposition of tropoelastin. However, the mechanism involved 
in the remodelling of elastic system fibres is still unknown (Tsuruga et al., 2007). A 
significant element in the physiological and pathological turnover of fibrillin molecules 
and microfibrils in the extracellular matrix is matrix metalloproteinases (MMPs). 
Degradation of fibrillin substrates by MMP-2, MMP-3 and MMP-13 may possibly 
contribute to physiological fibrillin remodelling, since they are primarily expressed by 
stromal cells constitutively or after growth factor induction. MMP-9 and MMP-12 are 
major products of macrophages and hence may be particularly vital in the pathological 
turnover of fibrillin-rich microfibrils in the context of inflammation (Ashworth et al., 
1999). 
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1.5.4	   Fibrillin-­‐1	  associated	  proteins	  
In addition to the their elastomeric role, fibrillin-1 microfibrils regulate tissue 
homeostasis through interactions with several proteins (Figure 1.22) including the latent 
transforming growth factor-β-binding proteins (LTBPs) (Faivre et al., 2007; Hirani et 
al., 2007; Jensen et al., 2012), fibulins (Reinhardt et al., 2000; El-Hallous et al., 2007; 
Ramirez et al., 2010), microfibril-associated glycoprotein (MAGP-1 and -2) (Jensen et 
al., 2009; Ramirez et al., 2010; Jensen et al., 2012), bone morphogenic protein (BMP), 
decorin, and the proteoglycans versican and perlecan (Jensen et al., 2009; Massam-Wu 
et al., 2010; Ramirez et al., 2010; Davis et al., 2012; Jensen et al., 2012). In particular, 
the LTBPs, fibulin and MAGP interact with fibrillin-1 to assist in regulating TGF-β 
signalling (Kaartinen, 2003; Choudhury et al., 2009). Abnormalities in endogenous 
TGF-β signalling are implicated in the pathogenesis of MFS.  
	  
Figure	  1.22	   Fibrillin-­‐1	  associated	  proteins.	  
Fibrillin-­‐1	  associates	  with	  a	  range	  of	  proteins	  including	  LTBPs,	  fibulins,	  MAGP-­‐1	  and	  -­‐2,	  
BMP,	  decorin,	  and	   the	  proteoglycans	  versican	  and	  perlecan.	  However,	   LTBPs,	   fibulin,	  
and	  MAGP	   interact	  with	   fibrillin-­‐1	   to	   assist	   in	   regulating	   TGF-­‐β	   signalling	   (Kuo	   et	   al.,	  
2007).	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Figure	  1.23	   Known	  protein	  and	  proteoglycan	  interactions	  of	  fibrillin-­‐1	  with	  various	  
other	  ECM	  components	  
Yellow	   bars	   represent	   the	   regions	   of	   fibrillin	   to	   which	   the	   interactions	   have	   been	  
mapped	  (Robertson	  et	  al.,	  2011).	  
 
1.5.4.1	   LTBPs	  
The four latent TGF-β binding proteins (LTBPs) belong to the fibrillin superfamily and 
contain contiguous arrays of cbEGF domains and TB domains (Saharinen et al., 1999). 
LTBP-1, 3 and 4 form disulphide bonds with LAP (latency-associated proteins, which 
are the pro-peptide of TGF-β), which is subsequently cleaved in the Golgi prior to 
secretion, but continues to bind to TGF-β due to its high affinity), thus these 3 bind 
TGF-β. However, LTBP-2 does not bind TGF-β, but is important for microfibril 
assembly.  
All LTBPs have long and short forms distinguished by alternate splicing. LTBP-1S 
exists in numerous organs; however, LTBP-1L is mainly expressed in heart, kidney, 
lung, testes and placenta (Rifkin, 2005) (Noguera et al., 2003). LTBP-2 is abundant in 
lung, placenta, heart, liver and muscle (Moren et al., 1994); LTBP-3 is expressed 
chiefly in heart, lung and bone (Yin et al., 1995); as well as LTBP-4 is predominantly 
expressed in heart, aorta, uterus and small intestine (Saharinen et al., 1998). Although 
the correlation of LTBP-1 with clinical diseases has not been determined, LTBP-2 
ablation in mice is lethal at birth, LTBP-3 is related to bone abnormalities and late 
emphysema and LTBP-4 is considered to be a critical factor in early emphysema and 
small bowel cancer (Rifkin, 2005). 
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The overall structure of all four LTBPs is comparable, consisting of an N-terminal 
region, a ‘hinge’ domain, a central cluster of EGF-like tandem repeats and a C-terminal 
region (Saharinen et al., 1999; Robertson et al., 2011). LTBPs are thought to have two 
functions. Firstly, they are necessary for the secretion of the TGF-β SLC (Massam-Wu 
et al., 2010) and secondly, they direct bound latent TGF-β to ECM microfibrils (Isogai 
et al., 2003; Ono et al., 2009; Massam-Wu et al., 2010). Hence, the interactions 
between LTBPs and fibrillin-1 are essential for appropriate sequestration and 
extracellular control of TGF-β (Annes, 2003). 
LTBP-1 has been found to possess a central role in the processing and secretion of 
TGF-β (Saharinen et al., 1999). LTBP-1 binding targets the SLC to the ECM through 
LTBP-mediated association with microfibrils, allowing TGF-β to be sequestered within 
the ECM until release (Figure 1.24) (Annes, 2003). In LTBP-1, the TGF-β binding 
region has been localised to the C-terminal region (Saharinen et al., 1999; Isogai et al., 
2003; Robertson et al., 2011). Additionally, this C-terminal region interacts with the 
N-terminus of fibrillin-1 (Massam-Wu et al., 2010; 2010). The N-terminal region of 
LTBP-1 is responsible for associating with the matrix (Dallas et al., 1999; Saharinen et 
al., 1999). The LTBP-1/fibulin-1 binding is further stabilised through the formation of a 
ternary complex, involving fibulin-4.  
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Figure	  1.24	   Proposed	  model	  of	  TGF-­‐β	  sequestration	  and	  release.	   	  
(A)	  illustrates	  the	  proposed	  theory	  behind	  TGF-­‐β	  sequestration.	  LTBP-­‐1	  binds	  through	  
its	   C-­‐terminal	   region	   to	   fibrillin	   microfibrils.	   This	   bond	   is	   stabilised	   through	   the	  
formation	  of	  a	  ternary	  complex	  via	  fibulin-­‐4	  interactions	  with	  the	  N-­‐terminal	  of	  LTBP-­‐1.	   	  
(B)	   illustrates	   the	  proposed	   theory	  behind	  TGF-­‐β	   release.	  MAGP-­‐1	   inhibits	  binding	  of	  
LTBPs	   C-­‐terminal	   to	   fibrillin,	   thereby	   enhancing	   release	   of	   active	   TGF-­‐β.	   Thick	   black	  
lines	  indicate	  molecular	  interactions	  (Massam-­‐Wu	  et	  al.,	  2010).	  
 
Both LTBP-1 and -4 are expressed in the aorta, but LTBP-4 is expressed at a higher 
level. The binding site between LTBP-1 and LTBP-4 is the hybrid domain 1 of 
fibrillin-1 (Ono et al., 2009). In addition, LTBP interacts with the extracellular matrix 
via its N-terminus. The latency-associated peptide (LAP) and TGF-β complex forms a 
disulphide-bond with TB2 domain of LTBP-1 (Saharinen et al., 1996) (Gleizes et al., 
1996). LAP is linked to LTBP-1 by a disulphide bond(s) involving Cys 33 of LAP and 
unknown cysteine(s) in the TB2 domain of LTBP-1. The other cysteine residues Cys 
224 and Cys 226 are required for the dimerization of LAP and thus for TGF-β 
inactivation.  
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1.5.4.2	   Microfibril	  associated	  glycoproteins	  
Microfibril-associated glycoprotein (MAGP) family contains 4 isoforms: MAGP-1, -2, 
-3 and -4. MAGP-1 is associated with microfibrils and is expressed universally in 
mesenchymal and connective tissue cells during formation (Henderson et al., 1996; 
Kielty et al., 1997). Other than fibrillin, it is the unique integral molecule has been 
identified in ECM (Charbonneau et al., 2003). MAGP-2 and -1 have structural 
similarities (Gibson et al., 1998; Segade et al., 2002). Immuno localization studies 
shown MAGP-1 is located on the beads of microfibrils (Henderson et al., 1996). 
The binding of MAGP-1 to fibrillin-1 inhibits the binding of the C-terminus of LTBP-1 
to the N-terminus of fibrillin-1, thereby enhancing release of active TGF-β (Figure 1.24) 
(Massam-Wu et al., 2010). Fibulin-4 plays an opposing, stabilising role, by 
simultaneously binding LTBP-1 and fibrillin-1, to prevent TGF-β release (Charbonneau 
et al., 2003; Massam-Wu et al., 2010). 
MAGP-2 is cell adhesion molecule containing an RGD sequence. It is functionally 
involved in cell signalling during microfibril assembly and elastinogenesis (Gibson et 
al., 1998). 
 
1.5.4.3	   Fibulin	  
Fibulin belongs to extracellular glycoprotein superfamily, having 7 isoforms. Fibulin-1 
is associated with the elastin core (Roark et al., 1995), fibulin-2 (Reinhardt et al., 1996) 
and -4 (Kobayashi et al., 2007) are found in the microfibrils, and fibulin-2 (Reinhardt et 
al., 1996) and -5 (Kobayashi et al., 2007) occur at the interface between the elastin core 
and the microfibrils. The secondary structure of fibulin isoforms are similar to cbEGF 
domains, plus a fibulin-type C-terminus is comprised with 120-140 amino acid residues 
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(Argraves et al., 2003; Timpl et al., 2003; Chu et al., 2004). In terms of size, fibulin-1, 
-2 and -6 are larger than fibulin-3, -4, -5 and -7, with an additional anaphylatoxin (AT) 
motif at their N-termini. On the other hand, fibulin- 3, -4 and -5 contain five cbEGF 
motifs preceded by a modified cbEGF domain at their N-termini. Hence fibulin-1 to -5 
all present a rod structure with globules at one end (fibulin-3, -4 and -5) (Kobayashi et 
al., 2007) or both ends (fibulin-1 and -2) (Sasaki et al., 1995) (Pan et al., 1993), when 
viewed by rotary-shadowing electron microscopy. 
Presently, seven fibulins have been identified to associate with fibrillin-1 and hence, 
play a role in elastic fibre assembly and function (Yanagisawa et al., 2002; Moltzer et 
al., 2011). In particular, abnormal fibulin-4 expression has been implicated in MFS as 
contributing to the disruption of tissue homeostasis with the subsequent development of 
thoracic aortic aneurysms. Fibulin-4 is localised on microfibrils (Yanagisawa et al., 
2002) and is highly expressed in the outer medial layers adjacent to the adventitia in 
large blood vessels, including the aorta (Huang et al., 2010; Moltzer et al., 2011).  
Several studies have shown that mice depleted of fibulin-4 exhibit elastic fibre defects, 
including fragmentation (McLaughlin et al., 2006; Hanada et al., 2007; Horiguchi et al., 
2009), in addition to exhibiting enhanced aortic TGF-β activity (Hanada et al., 2007). 
Furthermore, mice displaying a systemic 4-fold decreased expression of fibulin-4 
develop aneurysms in the ascending thoracic aorta (Hanada et al., 2007; Moltzer et al., 
2011). There is still uncertainty as to how fibulin-4 correlates with increased TGF-β 
signalling, although it has been proposed that fibulin-4 in a key mediator in the 
association of full-length LTBP-1 with fibrillin-1 by forming a stable ternary complex 
between them (Figure 1.24) (Massam-Wu et al., 2010; Moltzer et al., 2011). Hence, the 
formation of this ternary complex indirectly mediates microfibril TGF-β sequestration, 
by stabilising the link and preventing the premature release of TGF-β (Massam-Wu et 
al., 2010).  
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Several extracellular molecules, including microfibril-associated glycoproteins, are 
involved in releasing latent TGF-β from the ECM by disrupting LAP-mediated latency 
via prevention of the LTBP-1/fibrillin-1 link (Annes, 2003). 
 
1.5.4.4	   Perlecan	  
The proteoglycan perlecan is an essential modulator of the vascular extracellular matrix 
in the basement membrane and maintains the endothelial barrier (Broekelmann et al., 
2005). It is a key factor for maintaining vascular homeostasis via the inhibition of SMC 
proliferation, and is thus assumed to assist of maintain vascular homeostasis (Iozzo, 
1998; Garl et al., 2004). In addition, perlecan may accelerate the activity of fibroblast 
growth factor 2 (FGF2), hence stimulating endothelial growth and regeneration (Iozzo, 
1998).  
Perlecan domains I and II bind the central region of fibrillin-1 with high affinity (see 
Figure 1.22). Perlecan null mice show fewer microfibrils at the dermal-epidermal 
junction, implying that the functional significance of perlecan is in anchoring 
microfibrils to the basement membrane and in the biogenesis of microfibrils 
(Tiedemann et al., 2005). 
 
1.5.4.5	   Versican	  
The C-terminus of versican binds to fibrillin microfibrils, between cb-EGF domains 11 
and 21 of fibrillin-1 (Isogai et al., 2002). All isoforms of versican are found in blood 
vessels and contribute to the hydrated viscoelastic matrix (Cattaruzza et al., 2002). 
Versican expression increases during intimal hyperplasia associated with atherosclerosis 
and restenosis, and correlates with smooth muscle cell migration and proliferation 
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(Evanko et al., 1999). Furthermore, regression of restenosis is associated with loss of 
versican (Farb et al., 2004). ADAMTS proteases cleave versican into smaller fragments. 
These fragments have been implicated in promoting regression of VSMC proliferation 
during neointimal formation (Salter et al., 2010). Thus, the likelihood that ADAMTS 
cleavage of versican contributes to vascular pathology is high (Stanton et al., 2011). 
 
1.5.4.6	   Integrins	  
All three fibrillins can bind integrins via an RGD (Arg-Gly-Asp) integrin binding motif 
located within a flexible loop on a conserved β-hairpin of the TB4 domain. Fibrillin-2 
and -3 have an additional RGD motif in TB3 and cbEGF18, respectively, although the 
functionality of this site is unknown (Lee, S. S. et al., 2004). Recombinant fibrillin-1 
domain fragments containing TB4 have been shown to bind integrin α5β3 with 
high-affinity (Kd ∼40 nM), whereas integrins α5β6 and α5β1 bind with 
moderate-affinity (Kd ∼450 nM) and low-affinity (Kd >1 µM), respectively (Jovanovic 
et al., 2008). Integrin interactions with fibrillin mediate cell binding to microfibrils and 
appears to be involved in signalling leading to cell attachment, spreading and focal 
contact formation, all functions that are particularly important within the elastic 
lamellae within the aorta (see Figure 1.25) (Jovanovic et al., 2008).  
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Figure	  1.25	   Integrins	  contribute	  to	  cell	  adhesion	  
Integrins	   bind	  microfibrils,	   contributing	   to	   cell	   adhesion.	  Microfibrils	   have	   also	   been	  
shown	  to	  interact	  with	  a	  variety	  of	  other	  proteins	  and	  ECM	  components	  (Robertson	  et	  
al.,	  2011).	  
 
1.5.4.7	   Bone	  Morphogenetic	  Protein	  
BMPs are a group of growth factors that are secreted and targeted to the ECM. BMP is 
secreted as a homodimer that associates non-covalently via the N-terminal BMP 
pro-peptide. BMP can be sequestered by fibrillin-1 and -2, by binding between the 
pro-domain of BMP and the N-terminal region of fibrillin-1, up to and including the 
first TB and proline-rich domain (Sengle et al., 2008). There may be a specific 
interaction with the N-terminal unique region of fibrillin-1 (see Figure 1.25) (Sengle et 
al., 2008). The binding of BMP/pro-BMP directly to fibrillin-1 contrasts with the 
binding of latent TGF-β, which occurs via the LTBP/TGF-β complex (the LLC) (see: 
Section 1.5.4.1: Fibrillin associated proteins: LTBP). While specific deficiency of 
fibrillin-2 and BMP-7 results in syndactyly (Arteaga-Solis et al., 2001) a role for BMP 
in aneurysmal disease has not been defined, beyond the simple observation that 
fibrillin-1 deficiency results in perturbation of both TGF-β and BMP signaling (Ramirez 
et al., 2010). 
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1.6	   Possible	   mechanism	   of	   thoracic	   aortic	   aneurysm	  
formation	  
1.6.1	   Role	  of	  microfibrils	  in	  the	  aortic	  wall	  
It was initially thought that extracellular microfibrils containing mutant fibrillin directly 
impaired mechanical strength of the aortic wall, but the microfibrils are not load-bearing 
in the vertebrate aorta. Instead, the microfibrils appear to transmit haemodynamic load 
information to the vascular smooth muscle cells (VSMC) in the aortic media. In silico 
structure-function studies in our laboratory show that >80% of described point 
mutations in FBN1 result in distorted structure and impaired rigidity of the involved 
domain of fibrillin, which would impair microfibrillar sensing of haemodynamic load.  
 
1.6.2	   How	   does	   the	   stretch	   sensor	   work	   –	   abnormal	   stretch	  
increases	  TGF-­‐β	  
Importantly, the VSMC can respond to changes in loading conditions (e.g. stretch) by 
increasing secretion of cytokines and growth factors, including TGF-β, in a process of 
mechano-chemical signal transduction. Intrinsic tone in the VSMC, determined by 
actin-myosin interactions, would determine an operating set-point for ideal balance 
between haemodynamic load and stimulus to aortic remodelling. Perturbation, through 
change in load or alteration of the set-point (e.g. resulting from abnormal actin or 
myosin function), would alter VSMC responses. 
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1.6.3	   Excess	  TGF-­‐β	  increases	  MMPs	  
It is known that TGF-β secretion is increased in TAAD and tissue sequestration of 
TGF-β by FBN1-LTBP1 (latent TGF-β binding protein 1) may also be abnormal in 
Marfan syndrome. Furthermore, TGF-β, acting through myofibroblast cell-surface 
receptors, coupled to both Smad and MAPK35 systems, can stimulate both extracellular 
preoteolysis (e.g. via metalloproteinases) and increased synthesis of extracellular matrix 
ground substance, leading to the vascular remodelling observed as cystic medial 
necrosis. 
 
1.6.4	   Common	  pathway	  in	  congenital	  aneurysm	  
It is therefore possible to now develop a hypothesis for aneurysm formation which takes 
account of previous disparate findings and which points to new targets for both 
diagnosis and management. 
It is likely that a common pathological pathway underlies the development of TAAD 
and that this pathway can be activated at several points and includes a number of 
modulating factors. Activated at several points: congenital aneurysm can arise from 
mutations in many genes (most common is FBN=MFS) but mutations can also occur 
down the track. 
In contrast to all previous studies, which have focused upon single genes, this project 
will illuminate the larger “genetic switchboard” associated with TAAD by documenting 
gene variations and tissue expression in the families of structural, regulatory and 
effector proteins contributing to vascular remodelling, in order to define the final 
common pathway and its key activation and modulation points. 
Chapter	  1	  –	  Introduction	  
Yaxin	  Lu	   	   August	  2013	  
72	  
Definition of the degree of activation, or otherwise, of specific effector pathways of 
aortic remodelling will allow tailored treatment intervention, optimised to an individual 
circumstances and monitoring of treatment response through measurement of key 
biomarkers. 
 
Figure	  1.26	   Proposed	  mechanism	  of	  thoracic	  aortic	  aneurysm	  formation. 
(FBN1=fibrillin	  1;	  COL3A1=collagen	   type	  3;	  MFAP2=microfbril	   associated	  glycoprotein	  
2;	   ACTA2=smooth	   muscle	   actin;	   MYH11=vascular	   myosin	   heavy	   chain;	  
AGTR1=angiotensin	   receptor	   type	   1;	   KCa=Ca	   sensitive	   K	   channel;	   VOC=voltage	  
operated	   channel;	   TGF-­‐ΒR=TGF-­‐β	   receptor;	   LTBP1=latent	   TGF-­‐β	   binding	   protein;	  
MMP=matrix	  metalloproteinase).	  
 
1.7	   Biomarkers	  of	  genetic	  aortopathy	   	  
1.7.1	   The	  clinical	  need	  for	  circulating	  biomarkers	   	  
Thoracic aortic aneurysm and dissection (TAAD) affects people of all ages. In older 
patients, hypertension and atherosclerosis underlie aneurysm formation. In younger 
patients, aneurysms result from mutations in genes coding key proteins in the aortic 
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wall. In developed nations, TAAD is now one of the top causes of cardiovascular death 
in younger adults. The spectrum of TAAD due to a genetic aortopathy includes Marfan 
syndrome, bicuspid aortic valve (BAV) aneurysm syndrome and familial isolated 
thoracic aneurysm (FTAD). Collectively, these aortic syndromes affect approximately 1 
in 500 to 1 in 1,000 people (Jeremy, 2011). 
Genetic thoracic aortic aneurysm and dissection kills people in various age groups, 
especially in young generations. One in six patients with a genetic aortopathy is dead by 
50. Those at risk are often unaware, until either death or dissection occurs, or an 
incidental diagnosis is made on cardiac imaging. Aortic aneurysm and dissection are 
often inherited. Diagnosis of people at risk is critical but difficult, as there may be no 
clinical signs or obvious aortic enlargement in young patients. The spectrum of diverse 
gene mutations associated with the disease, the variable phenotype and the fact that 
many gene mutations are as yet unknown, limits diagnosis by genetic screening. The 
foundation of diagnosis remains clinical examination and imaging of the aorta, 
particularly the aortic root just above the aortic valve. In patients with clear physical 
features, such as those of classic Marfan syndrome, diagnosis can be straightforward, 
although prognosis is much more difficult. All too often, however, diagnosis is not 
straightforward. Patients with FTAD usually have no physical features and those with 
bicuspid aortic valve aneurysm syndrome also have no external features and may have 
no heart murmur. Diagnosis therefore rests upon measurement of aortic diameter. In 
adolescents and young adults, the aorta may be diseased but not yet dilated, and when 
the aortic diameter is measured as being within the upper normal range, both the patient 
and their medical practitioner are left in doubt. The risk of both false positive and false 
negative diagnosis is high for many patients at risk of genetic aortopathy and the 
consequences of misdiagnosis can be dramatic (Elefteriades et al., 2010). 
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1.7.2	   Potential	  uses	  for	  circulating	  biomarkers	  
There is currently no suitable circulating biomarkers available to improve clinical 
diagnosis or risk stratification, thus, better diagnostic tools are urgently required. There 
is a need for improved diagnostic accuracy, better risk-stratification and more effective 
therapeutic intervention for individuals and their families. Matrix metalloproteinases 
contribute to aneurysm formation and animal studies suggest their potential utility as 
biomarkers of thoracic aortic disease (Matt et al., 2009). In addition, normal TGF-β1 
signalling pathway plays a vital role in the progression of microfibrils and aortic 
aneurysm formation (Ramirez et al., 2010). 
Ideally, a suitable biomarker (or group of biomarkers) would assist the clinical 
management of thoracic aortopathy in the following ways:  
1. Biomarkers should reflect disease activity and aortic remodelling, both chronically 
and in response to challenge, such as haemodynamic stress.  
2. Drug treatments that ameliorate aortic remodelling should be associated with 
resolution of abnormal biomarker profiles.  
3. Biomarker profiles should correlate with rate of change in aortic size due to 
remodelling (severity of disease). 
 
A current hypothesis is that the common mechanism behind genetic aortopathy 
formation involves abnormal TGF-β signalling (El-Hamamsy et al., 2009). 
Furthermore, substantial evidence exists that the final pathway for aortic wall damage is 
through excessive protease activity, causing the characteristic histological features of 
cystic medial necrosis, namely, loss of extra-cellular matrix, especially collagen and 
elastin, and a reduction in medial cell numbers, possibly via the induction of apoptosis 
(Nataatmadja et al., 2006). In the search for circulating biomarkers capable of 
predicting disease progression and severity, prospective candidates would include 
TGF-β and relevant extra-cellular proteases, the matrix metalloproteinases (MMPs) and 
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their regulators, the tissue inhibitors of MMPs (TIMPs). Although MFS is caused by a 
mutation in FBN1, we chose not to investigate fibrillin-1 as a biomarker, since there is 
no evidence that the level of expression of fibrillin-1 within the aorta is altered, and the 
physico-chemical properties of fibrillin-1 make it unlikely to be released into the 
circulation (fibrillin-1 is very large and has an elongated, multi-domain structure). 
1.7.3	   Matrix	  metalloproteinases	  (MMP)	  -­‐2,	  -­‐3	  and	  -­‐9	  
MMPs mediate extra-cellular matrix (ECM) destruction, leading to weakening of the 
aortic wall and aneurysm formation (Barbour et al., 2007). The MMPs are a family of 
27 extracellular proteases that are capable of degrading all constituents of the aortic 
ECM. The expression and activity of MMPs within the vascular wall are regulated at 
several levels, including at transcription, post-translation and effector antagonism via 
endogenous tissue inhibitors (TIMPs). Perturbation of these regulatory mechanisms will 
influence aortic wall remodelling, leading to aneurysm formation. 
MMP-2, -3 and -9 and TIMP-1 and -2 have been implicated in aortic aneurysm 
formation (Barbour et al., 2007). MMP-2 and -9 are gelatinases which can proteolyse 
denatured collagens, while MMP-3 is a stromelysin that can degrade intact collagen 
(Raffetto et al., 2008). Within the aortic wall, MMP-2 and MMP-3 are primarily derived 
from vascular smooth muscle cells (Barbour et al., 2007; Raffetto et al., 2008), while 
MMP-9 is primarily derived from chronic inflammatory cells, largely within the 
adventitia (Barbour et al., 2007). All the TIMPs are able to inhibit all the MMPs to 
some extent, but TIMP-2 most effectively inhibits MMP-2 and TIMP-1 most effectively 
inhibits MMP-9 (Hidalgo et al., 2001). Thus, the ratios MMP-2/TIMP-2 and 
MMP-9/TIMP-1 may be indices of the balance of the proteolytic activity (Chung, A. W. 
et al., 2007). Activation of the MMPs is a complex process, of which one component is 
TGF-β signalling (Barbour et al., 2007). 
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Excessive TGF-β signalling leads to increased production of plasminogen activators and 
the release of MMP-2 and -9 in the matrix, resulting in extracellular matrix degradation 
(Laiho et al., 1986; Kim et al., 2004). Based on these previous studies we selected 
MMP-2. MMP-3 and MMP-9 as potential biomarkers of MFS. 
 
1.7.4	   Transforming	  growth	  factor	  (TGF)-­‐β1	  
Transforming growth factor-β (TGF-β) is a cytokine that participate in the regulation of 
cell proliferation, differentiation and apoptosis. A major role of it is maintaining 
extracellular matrix homeostasis. A current hypothesis is that the common mechanism 
behind genetic aortopathy formation involves abnormal TGF-β signalling (El-Hamamsy 
et al., 2009). Furthermore, substantial evidence exists that the final pathway for aortic 
wall damage is through excessive protease activity, causing the characteristic 
histological features of cystic medial necrosis, namely, loss of extra-cellular matrix, 
especially collagen and elastin, and a reduction in medial cell numbers, possibly via the 
induction of apoptosis (Nataatmadja et al., 2006). Reduced or mutated forms of 
fibrillin-1 lead to the failure of matrix sequestration of the large latent complex leads to 
promiscuous activation and signalling of TGF-β (El-Hamamsy et al., 2009). Through 
abnormal TGF-β pathway, genes downstream of TGF-β induce phenotypic 
consequences in MFS. Based on these previous studies we selected TGF-β1 as a 
potential biomarker of MFS. 
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1.7.5	   Tissue	  Inhibitor	  of	  Metalloproteinases	  (TIMPs)	  
The matrix metalloproteinases are inhibited by specific endogenous tissue inhibitors of 
metalloproteinases (TIMPs), which comprise a family including four members: 
TIMP-1, -2, -3 and -4 (Murphy, 2011). Overall, all MMPs are inhibited by TIMPs once 
they are activated but the gelatinases (MMP-2 and MMP-9) can form complexes with 
TIMPs when the enzymes are in the latent form. The complex of latent MMP-2 
(pro-MMP-2) with TIMP-2 serves to facilitate the activation of pro-MMP-2 at the cell 
surface by MT1-MMP (MMP-14), a membrane-anchored MMP. The role of the 
pro-MMP-9/TIMP-1 complex is still unknown. 
All the TIMPs are able to inhibit all the MMPs to some extent, but TIMP-2 most 
effectively inhibits MMP-2 and TIMP-1 most effectively inhibits MMP-9 
(Phatharajaree et al., 2007). Thus, the ratios MMP-2:TIMP-2 and MMP-9:TIMP-1 may 
be indices of the balance of the proteolytic activity (Perez et al., 2005). Activation of 
the MMPs is a complex process, of which one component is TGF-β signalling. Changes 
in plasma MMP levels are likely to be accompanied by consonant changes in TIMP 
levels. Based on these previous studies we selected TIMP-1 and TIMP-2 as potential 
biomarkers of MFS. 
 
1.8	   ACE	  polymorphism	  
Documentation of the mechanism of aneurysm formation can open to us a path to 
improved patient care. Diagnosis and risk stratification for individuals suffering from 
genetic aortopathy can be personalised through description of the “genetic switchboard” 
(see Section 1.6.4: Common pathway in congenital aneurysm) defining their 
predisposition towards aneurysm formation and progression. This switchboard will 
include genes encoding the structural proteins in the aortic media, particularly the 
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microfibrils, as well as proteins involved in tension development in the VSMC. Other 
contributors to the switchboard will be genes for signalling proteins, such as growth 
factors, and their receptors and activation pathways, as well as effector proteins such as 
metalloproteinases. Genetic polymorphisms in relevant pathways are likely to 
contribute to risk stratification; an example of such a polymorphism is the ACE 
insertion/deletion (I/D) polymorphism. 
The ACE I/D polymorphism was first discovered by Rigat et al., who concluded that it 
accounted for approximately half of the total variance in serum ACE levels (Rigat et al., 
1990), where the DD genotype exhibits the highest levels of circulating ACE. Since 
then it has been the subject of much excitement and controversy. The 
angiotensin-converting enzyme (ACE) is part of the renin-angiotensin system (RAS) 
(Figure 1.27), which is a major cardiovascular regulatory system (Kennon et al., 1999). 
It has been suggested to be crucial in the development of both abdominal aortic 
aneurysms (AAAs) and TAAs (Lu et al., 2012). Genetic variability in the RAS might, 
thus, play a role in the development of TAAs, allowing individualized treatment of 
patients at risk of acute aortic syndromes. Recent studies have shown that the ACE I/D 
polymorphism represents a marker of increased susceptibility to atherosclerotic 
abdominal aortic aneurysm (AAA) (Yeung et al., 2002; Fatini et al., 2005; Lucarini et 
al., 2009). Two studies have investigated the association of the I/D polymorphism of the 
ACE gene with thoracic aortic aneurysm (TAA) in patients with either non-Marfan’s 
syndrome-related diseases (Lesauskaite et al., 2011), or an aortic valve abnormality 
(Foffa et al., 2012), revealing that the D allele of the ACE gene conferred a risk of 
TAAs. 
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Figure	  1.27	   Overview	  of	  the	  RAS	  system.	   	  
Ang	  (1-­‐7),	  Ang	  III	  and	  Ang	  IV	  are	  breakdown	  products	  of	  Ang	  II.	  They	  exert	  their	  own	  
effects	  that	  are	  distinct,	  and	  often	  opposite	  those	  of	  Ang	  II.	  These	  effects	  are	  mediated	  
via	   newly	   recognized	   receptors-­‐	   MasR	   and	   AT4R.	   ACE	   2	   is	   a	   new	   pathway	   for	   the	  
formation	  of	  Ang	  (1-­‐7)	  (Elton	  et	  al.,	  2010).	  
 
The mechanism by which the ACE I/D polymorphism alters ACE concentration is 
unclear, since polymorphism is the insertion of 287 nucleotides in the intron 16. The 
ACE-16 I>D polymorphisms influences the level of circulating ACE and consequent 
activity. Since this polymorphism occurs in the intronic region, a possible explanation 
for its phenotypic effects is that there is linkage disequilibrium between the D allele and 
another variant within the ACE gene that causes elevated concentration ACE in the 
body as well as increased levels in the heart. Because of ACE’s key role in the RAS, 
excess expression leads to unfavourable cardiovascular effects (including myocardial 
infarction, left ventricular hypertrophy, hypertension, diabetic and IgA nephropathy, 
carotid artery thickening and lacunar cerebral stroke) that makes the ACE I>D 
polymorphism a primary genetic risk factor (Schunkert, 1997).  
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Although the insertion/deletion polymorphism (Intron 16 I>D) is widely studied and has 
shown a wide range of associations with cardiovascular disorders, its location in a 
non-coding region (Intron 16) makes it unlikely to be the actual functional variant. The 
established physiological significance of the I/D polymorphism is linked to plasma ACE 
levels (the higher level of circulating ACE being associated with the D allele), but an 
intronic polymorphism is unlikely to influence levels of expression of ACE. Thus, it is 
more likely that the actual functional polymorphism is another ACE polymorphism in 
close linkage disequilibrium with the I/D polymorphism. There are at least 10 
polymorphisms so far identified within the ACE gene, and there is considerable 
evidence that one or more of these other polymorphisms are in close linkage 
disequilibrium with I/D (Sayed-Tabatabaei et al., 2006).  
In a complex analysis utilizing clade distributions across many species, the probability 
of particular polymorphisms amongst these 10 being the functional polymorphism/s was 
evaluated. Polymorphisms within the ACE gene were identified and put into two 
groups: (i) five polymorphisms in the 5’ region, and, (ii) three in the coding sequence 
and 3’ untranslated sequence (UTR). All polymorphisms in the 5’ group remained 
significantly associated with ACE levels, therefore suggesting the existence of two 
quantitative trait loci (QTL) acting additively on ACE levels (Villard et al., 1996). Due 
to strong linkage disequilibrium over the chromosomal region, there are various 
haplotypes present that may contribute to ACE activity (Sayed-Tabatabaei et al., 2006). 
A segregation-linkage analysis raised the possibility that the -16 I>D polymorphism or 
the 4656C>T polymorphism might be one of the presumed QTLs. These results imply 
that other functional polymorphisms should be found on the ACE gene since at least 
one of the two putative QTLs was not found (Villard et al., 1996). The presence of 
functional polymorphisms in the 5’ region was also discovered, supporting previous 
reports that two ACE-linked QTLs control ACE activity (McKenzie et al., 2005; 
Sayed-Tabatabaei et al., 2006). This suggests an importance in the use of haplotypes 
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instead of just the I/D polymorphism when undertaking association studies of ACE gene 
variants and clinical manifestations. However, for the studies reported in this thesis we 
have focused on utilizing the relatively straight forward approach of studying the ACE 
I/D polymorphism, primarily because of its apparently strong linkage disequilibrium 
association with which ever ACE polymorphisms are actually causing the phenotype 
(elevated levels of ACE).  
The mechanism via which an increase in circulating ACE may contribute to thoracic 
aneurysm formation is relatively unclear. It has been suggested that predisposing 
genetic factors make a substantial contribution (30-40%) to arterial mechanical 
properties (Snieder et al., 2000), particularly arterial stiffening. A number of 
polymorphisms in the RAS have been proposed or shown to be associated with arterial 
stiffening, include the ACE I/D polymorphism (Agrotis et al., 2009). It has been 
proposed that the beneficial effects of ACE inhibition in reducing arterial stiffness went 
beyond simple blood pressure reduction, and included effects on vascular smooth 
muscle cell hypertrophy (Levy et al., 1993) and changes in collagen accumulation 
(Benetos et al., 1997). 
1.9	   Summary,	  Hypotheses	  and	  Aims	  
1.9.1	   Summary	  
Genetic thoracic aortic aneurysm and dissection kills young people. One in six patients 
with a genetic aortopathy is dead by 50. Those at risk are often unaware, until either 
death or dissection occurs, or an incidental diagnosis is made on cardiac imaging. Aortic 
aneurysm and dissection are often inherited. Diagnosis of people at risk is critical but 
difficult, as there may be no clinical signs or obvious aortic enlargement in young 
patients. Better diagnostic tools are urgently required. There is a need for improved 
diagnostic accuracy, better risk-stratification and more effective therapeutic intervention 
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for individuals and their families. TGF-β has been implicated in the pathogenesis of 
MFS, including inducing excessive matrix metalloproteinase activity, which contributes 
to aneurysm formation. Animal studies have suggested the potential utility of MMPs 
and TGF-β as biomarkers of thoracic aortic disease.  
 
1.9.2	   Hypothesis	  
1. The levels of circulating biomarkers will reflect disease activity and aortic 
remodelling.  
2. Biomarker profiles will correlate with rate of change in aortic size due to 
remodelling (severity of disease).  
3. The D allele of the ACE I/D polymorphism will be over-represented in patients 
with more severe MFS. 
 
1.9.3	   Aims	   	  
1. Establish a biobank of blood samples for patients with genetic aortopathy, and 
matched controls. The patients and control will be well clinically characterised to 
facilitate appropriate comparisons and correlations. 
2. Measure levels of circulating biomarkers in MFS patients and controls, to 
determine the potential clinical usefulness of the biomarkers for diagnostic and 
prognostic purposes. 
3. Genotype patients with MFS and controls for the ACE I/D polymorphism to 
correlate the genotype with MFS disease severity. 
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Chapter	  2	  
Materials	  and	  Methods	  
 
2.1	   Patient	  cohort	  
Patients attending the Marfan Clinic at Royal Prince Alfred Hospital, Sydney over a 
24-month period were invited to take part in the study. The study was approved by the 
Royal Prince Alfred Hospital Human Research Ethics Committee and all participants 
were required to give written informed consent before any research procedures are 
undertaken. During the course of the project a total of 150 blood samples were collected 
from a total of 78 patients, which including 16 repeat samples from patients that had 
previously been sampled. After the application of the exclusion criteria, we included 89 
blood samples from 52 MFS patients and 37 control individuals.  
Of the 52 MFS patients recruited 15 had required surgical replacement of their aorta 
prior to enrolment in the study. These 15 patients are referred to in this thesis as 
MFS-surgical (MFS-S) patients, and are considered to generally have a more severe 
phenotype or disease, since their aortas had dilated to such a significant extent that their 
aortas has required surgical replacement. The remaining 37 MFS patients are referred to 
in this thesis as MFS-non surgical (MFS-NS) had not undergone aortic surgery, and so 
were considered generally to have a less severe phenotype (disease). 
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All patients had a full medical and family history obtained and underwent detailed 
physical examination. Exclusion criteria included acute aortic dissection, inflammatory 
or connective tissue disease of the aorta, and those with hypertensive or atherosclerotic 
disease, diabetes mellitus, systemic inflammatory disease (e.g. rheumatoid arthritis), 
and renal failure (GFR < 60 mL/min/1.73m2). 
Table 2.1 lists the basic demographics of the controls and MFS patients tested. There 
was no statistically significant difference between the two groups for age and gender.  
 Age Gender Surgery BSA (m2) Aortic diameter (mm) Z-score 
Control 
(n=37) 38 ± 15 
15F 
22M No 1.87 ± 0.22 32.55 ± 4.29 0.31 ± 1.13 
MFS-NS 
(n=37) 37 ± 14 
18F 
19M No 2.04 ± 0.23 41.70 ± 4.31 3.06 ± 1.56 
MFS-S 
(n=15) 40 ± 15 
9F 
6M Yes 1.89 ± 0.19 N/A N/A 
Table	  2.1	   Demographic	  and	  treatment	  analysis	  for	  all	  patients	  
 
2.1.1	   Measurement	  of	  aortic	  geometry	  
Aortic geometry was measured by echocardiography, with particular attention to 
measurement of the aortic diameter at the level of the aortic valve, the Sinuses of 
Valsalva and the ascending aorta. All measurements were made according to standard 
criteria by the clinical staff at RPAH, with expert review by specialist cardiologists 
where required. Aortic mechanics (stiffness, distensibility and pulse wave velocity) 
were calculated according to published methods. Simultaneous blood pressure and 
aortic waveform were measured as previously described (Jeremy et al., 1994).  
Trans-thoracic echocardiography was performed in the left decubitus position, with 
aortic imaging in accord with American Society of Echocardiography criteria (Lang et 
al., 2005). The parasternal long-axis view of the aortic root, including the Sinuses of 
Valsalva and sinotubular junction was used for analysis (Figure 2.1). Quality control 
required that the aortic valve cusps and at least 2 cm of the aortic sinuses cranial to the 
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plane of insertion of the aortic cusps had to be visible. The anterior and posterior aortic 
walls had to be clearly defined throughout the cardiac cycle. Aortic root geometry was 
measured at end-diastole (immediately prior to aortic valve opening) and peak systolic 
ejection (measured as time from aortic valve opening to peak systolic velocity on 
continuous wave Doppler interrogation of aortic outflow). Maximum cross-sectional 
diameter of the Sinuses of Valsalva was measured at end-diastole and compared with 
predicted normal for age and body size (Roman et al., 1989). Aortic root dilatation was 
defined as diameter more than 2 standard deviations greater than the predicted normal 
mean diameter. Aortic diameters were indexed to body surface area for comparison 
between groups (Cruz et al., 2013). 
 
Figure	  2.1	   64	   multidetector	   computed	   tomography	   angiographic	   image.	   Right,	  
coronary	  artery	  calcium	  (CACS)	  image.	  
AAO,	   DAO,	   RPA,	   and	   PA	   represent	   the	   ascending	   aorta,	   descending	   aorta,	   right	  
pulmonary,	   and	  pulmonary	   artery	  on	   the	  CACS	   scanning	   image.	   Lines	  A,	   B,	   C,	   and	  D	  
represent	   AAOD,	   DAOD,	   PAD,	   and	   CAPD	   on	   the	   angiographic	   image.	   White	   arrow	  
depicts	   the	   calcium	   foci	   and	   the	   black	   arrow	   points	   to	   the	   sclerosis	   aortic	   wall.	   D,	  
diameter;	  AAO,	  ascending	  aorta;	  DAO,	  descending	  aorta;	  PA,	  pulmonary	  artery;	  RPA,	  
right	  pulmonary	  artery;	  CAPD,	  chest	  anteroposterior	  diameter	  (Mao	  et	  al.,	  2008).	  
 
2.1.2	   Measurement	  of	  body	  surface	  area	  (BSA)	  and	  calculation	  of	  
Z-­‐score	  
The body surface area (BSA) is the measured or calculated surface of a human body. 
For many clinical purposes BSA is a better indicator of metabolic mass than body 
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weight because it is less affected by abnormal adipose mass. Nevertheless, there have 
been several important critiques of the use of BSA in determining the dosage of 
medications with a narrow therapeutic index, for example, many chemotherapy 
medications. It is calculated from the height and weight of the patient.  
The aortic diameter was used to calculate the Z-score, which is the aortic diameter 
corrected for age and body surface area (BSA), where a value of -2 to 2 is considered as 
normal (Roman et al., 1989). 
The formula used by our clinic for the calculation of BSA was the Dubois and Dubois 
formula (Roman et al., 1989).  
BSA (m²)=0.007184 x H0.725 x W0.425  
BSA – body surface area 
H – height in cm 
W – weight in kg 
 
The BSA can then be used to check whether the measured aortic diameter is within 
normal limits. Nomograms have been generated to determine the normal range of aortic 
diameter (Figure 2.2). There are 3 nomograms for different age ranges (Child, Adult 
< 40 y, Adult > 40 y) (Roman et al., 1989).  
 
Figure	  2.2	   Nomograms	  of	  normal	  BSA	  distribution.	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A more accurate comparison of aortic diameter can be achieved by calculating the 
Z-score, which takes into account both age and BSA. The Z-score represents the 
number of standard deviations (derived from normal population data) the measured 
aortic diameter differs from the normal population aortic diameter. Consequently, a 
Z-score in the range -2 to 2 represents the normal range (i.e. the normal range is 
considered to lie within two standard deviations from the mean). The formulae for the 
Z-score are:  
Age up to 15: 
 Z=(Measured root diameter – predicted AR) / 0.18 
Mean predicted AR (cm) for BSA=1.02 + 0.98 × BSA 
Standard Deviation of control cohort (cm)=0.18 cm 
Age 20 to 40: 
 Z=(Measured root diameter – predicted AR) / 0.24 
Mean predicted AR (cm) for BSA=0.97 + 1.12 × BSA  
Standard Deviation of control cohort (cm)=0.24 cm 
Age > 40 
 Z=(Measured root diameter – predicted AR) / 0.37 
Mean predicted AR (cm) for BSA=1.92 + 0.74 × BSA 
Standard Deviation of control cohort (cm)=0.37 cm 
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2.1.3	   Revised	  Ghent	  criteria	  for	  diagnosis	  of	  MFS	  
The diagnosis of Marfan syndrome was made according to the Ghent criteria (De Paepe 
et al., 1996), taking account of the revisions published in 2010 (Loeys et al., 2010) (see 
Section 2.3.1: Revised Ghent criteria of diagnosis of MFS). A control group included 
individuals referred to the Clinic who had no evidence of aortopathy.  
The application of the revised Ghent criteria uses the following process: 
1. Patients who have a family are reviewed differently from patients who do not (Figure 
2.3) 
2. To make the diagnosis of MFS the patient must meet one of the 7 criteria listed in 
Figure 2.4 
3. In assessing these criteria, the systemic features are scored according to the list in 
Figure 2.5 
4. Figure 2.6 explains some of the criteria used to assess whether a FBN1 mutation is a 
causal mutation. 
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In the absence of family history:  
1) Aortic Z-score ≥ 2 AND Ectopia Lentis=MFS 
2) Aortic Z-score ≥ 2 AND FBN1=MFS 
3) Aortic Z-score ≥ 2 AND Systemic score (≥ 7pts)=MFS 
4) Ectopia Lentis AND FBN1 mutation known to cause an aortic aneurysm=MFS 
 
However, 
Ectopia Lentis with or without Systemic score AND with an FBN1 not known with 
Aortic aneurysm or no FBN1=Ectopia Lentis Syndrome 
Aortic Z-score < 2 AND Systemic score ≥5 without Ectopia Lentis=MASS 
Mitral Valve Prolapse AND Aortic Z-score < 2 AND Systemic score < 5 without 
Ectopia Lentis=Mitral Valve Prolapse Syndrome 
 
In the presence of family history: 
5) Ectopia Lentis AND Family History of MFS (as defined above)=MFS 
6) Systemic score (≥ 7pts) AND Family History of MFS (as defined above)=MFS 
7) Aortic Z-score ≥ 2 (above 20 yrs old) or ≥3 (below 20 yrs old) + Family History of 
MFS (as defined above)=MFS 
Figure	  2.3	   Revised	  Ghent	   criteria	   for	  diagnosis	  of	  Marfan	   syndrome	  and	   related	  
conditions.	  
Aortic	  diameter=aortic	  diameter	  at	  the	  Sinuses	  of	  Valsalva	  above	  indicated	  Z-­‐score	  or	  
aortic	  root	  dissection	  (see	  Figure	  2.1)	  
FBN1=fibrillin-­‐1	  mutation	  (as	  defined	  in	  Figure	  2.6)	  
FBN1	   mutation	   known	   to	   cause	   aortic	   aneurysm=FBN1	   mutation	   that	   has	   been	  
identified	  in	  an	  individual	  with	  aortic	  aneurysm	  
FBN1	   mutation	   not	   known	   to	   cause	   aortic	   aneurysm=FBN1	   mutation	   that	   has	   not	  
previously	  been	  associated	  aortic	  root	  aneurysm	  or	  dissection	  
MASS=myopia,	   mitral	   valve	   prolapse,	   aortic	   root	   dilatation,	   striae,	   skeletal	   findings,	  
aortic	  aneurysm	  syndrome	  
MFS=Marfan	  syndrome	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1) Wrist AND thumb sign – 3 (wrist OR thumb sign– 1) 
2) Pectus carinatum deformity– 2 (pectus excavatum or chest asymmetry – 1) 
3) Hindfoot deformity – 2 (plain pes planus – 1) 
4) Pneumothorax – 2 
5) Dural ectasia – 2 
6) Protrusio acetabuli – 2 
7) Reduced US/LS AND increased arm/height AND no severe scoliosis – 1 
8) Scoliosis or thoracolumbar kyphosis – 1 
9) Reduced elbow extension – 1 
10) Facial features (3/5) – 1 (dolichocephaly, enophthalmos, downslanting 
palpebral fissures, malar hypoplasia, retrognathia) 
11) Skin striae – 1 
12) Myopia > 3 diopters – 1 
13) Mitral valve prolapse (all types) – 1 
Maximum total: 20 points; score 7 indicates systemic involvement; US/LS, upper 
segment/lower segment ratio. 
Figure	  2.4	   Scoring	  of	  systemic	  features.	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1) Mutation previously shown to segregate in Marfan family 
2) De novo (with proven paternity and absence of disease in parents) mutation (one 
of the five following categories) 
3) Nonsense mutation 
4) Inframe and out of frame deletion/insertion 
5) Splice site mutations affecting canonical splice sequence or shown to alter 
splicing on mRNA/cDNA level 
6) Missense affecting/creating cysteine residues 
7) Missense affecting conserved residues of the EGF consensus sequence 
((D/N)X(D/N)(E/Q)Xm(D/N)Xn(Y/F) with m and n representing variable 
number of residues; D aspartic acid, N asparagine, E glutamic acid, Q 
glutamine, Y tyrosine, F phenylalanine) 
8) Other missense mutations: segregation in family if possible + absence in 400 
ethnically matched control chromosomes, if no family history absence in 400 
ethnically matched control chromosomes 
9) Linkage of haplotype for n6 meioses to the FBN1 locus 
Figure	  2.5	   Criteria	  for	  causal	  FBN1	  mutation.	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2.2	   Ethics	  
The Human Research Ethics Committee of Royal Prince Alfred Hospital approved the 
use of de-identified clinical data and echocardiography studies in the Clinic database for 
this study. 
 
2.3	   Collection	  and	  storage	  of	  blood	  
Peripheral venous blood was obtained by venepuncture, during the patient consultation, 
into standard EDTA and heparin tubes. Within 4 hours (stored on ice) the blood was 
separated into plasma, buffy coat (containing white cells) and red blood cells by 
centrifugation at 1,000 g. Additionally, platelets were immediately removed from the 
plasma by a second high g (10,000 g) centrifugation step, since platelets contain both 
TGF-β and MMP-9 within their cytoplasmic granules and could perturb the results if 
released (R&D Systems manufacturers instructions). White cells were also further 
purified by Ficoll gradient separation of monocytes. All components were aliquoted and 
stored at -80°C till required for assay.  
 
2.4	   Blood	  samples	  
18 mL of venous blood was collected in both EDTA and heparin anticoagulant tubes 
separated into plasma by low speed centrifugation at 1,000 g for 15 minutes within 2 
hours at 4˚C. Half of the plasma was further centrifuged at higher speed (10,000 g for 
10 minutes) to thoroughly remove platelets. Platelet-rich and –poor plasma samples 
were aliquoted and stored at -80˚C until use. Prevent frozen-and-thawing cycles no 
more than twice. 
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Blood stored on ice and processed within 4 hours of collection 
↓ 
Centrifugation: 1,000 g 15 mins 
↓ 
1.5 mL plasma transferred to 6 Eppendorf tubes, 3 tubes stored at -80oC 
↓ 
3 tubes of plasma centrifuged at 10,000 g 10 mins  
(to remove platelets), then stored at -80oC 
↓ 
Cell pellets are mixed with 15 mL RPMI 1640 media 
↓ 
Cell suspension applied on the top of 10 mL Ficoll solution 
↓ 
Centrifugation: 2,500 rpm 15 mins 
↓ 
Harvest middle layer of cells (WBC) into a new Falcon tube and wash with RPMI 1640 
media by centrifugation: 1,500 rpm  5 mins (twice) 
↓ 
Resuspend cells in 3 mL RPMI 1640 
↓ 
Divided into 3 tubes with 1 mL each 
↓ 
White cells counting by haemocytometer 
↓ 
Centrifugation: 10,000 rpm 3 mins 
↓ 
Discard the supernatant and retain the pellet 
↓ 
Add 1 mL RNA later (to preserve good quality RNA) 
↓ 
Store in -80°C freezer 
Figure	  2.6	   Protocol	   for	   plasma	   processing	   and	   Ficoll	   purification	   of	   monocytes	  
from	  whole	  blood	  samples.	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2.5	   Analysis	  of	  TGF-­‐β1,	  MMPs	  and	  TIMPs	  concentration	  
The plasma concentrations of MMP-2, -3 and -9 were determined by Enzyme-Linked 
Immunosorbent Assay (ELISA, R&D system, USA), using the method provided by the 
manufacturer. The principles if the ELISA assay are described in Figure 2.7, and the 
assay procedure is described in Figure 2.8.  
All samples that were analysed by ELISA assays were re-analysed in at least one 
subsequent separate assay, and the repeatability was found to be approximately 80%. 
 
 
Figure	  2.7	   Principle	  of	  ELISA	  assays.	  
STEP	  1	   A	   microplate	   pre-­‐coated	   with	   capture	   antibody	   is	   provided.	   Samples	   or	  
standards	  are	  added	  and	  any	  analyte	  present	   is	  bound	  by	   the	   immobilized	  antibody.	  
Unbound	  materials	  are	  washed	  away.	  
STEP	  2	   An	   HRP-­‐labeled	   antibody	   (detection	   antibody)	   is	   added	   and	   binds	   to	   the	  
captured	  analyte.	  Unbound	  detection	  antibody	  is	  washed	  away.	  
STEP	  3	   Tetramethylbenzidine	   (TMB)	   substrate	   solution	   is	   added	   to	   the	   wells	   and	   a	  
blue	   colour	  develops	   in	   proportion	   to	   the	   amount	  of	   analyte	  present	   in	   the	   sample.	  
Colour	   development	   is	   stopped,	   which	   turns	   the	   colour	   in	   the	   wells	   to	   yellow.	   The	  
absorbance	   of	   the	   colour	   at	   450	   nm	   is	   measured,	   producing	   a	   signal	   that	   is	  
proportional	  to	  the	  amount	  of	  analyte	  bound.	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Prepare reagents, working standards and samples. 
↓ 
Add 100 µL Assay Diluent to each well. 
↓ 
Add 50 µL Standard, control or sample to each well; incubate 2 h at RT on a horizontal 
orbital microplate shaker at 500 rpm. 
↓ 
Aspirate and wash 4x with 400 µL Wash Buffer. 
↓ 
Add 200 µL Conjugate to each well. Incubate 2 h at RT on the shaker. 
↓ 
Aspirate and wash 4x with 400 µL Wash Buffer. 
↓ 
Add 200 µL Substrate Solution to each well. Incubate 30 mins at RT on the bench top 
(Protect from light). 
↓ 
Add 50 µL Stop Solution to each well. Read at 450 nm within 30 mins (λ correction 540 
or 570 nm). 
 
Figure	  2.8	   Assay	  procedure	  summary.	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Chapter	  3	  
Biomaker:	  MMP-­‐3	  
 
3.1	   Introduction	  
Genetic thoracic aortic aneurysm and dissection kills young people. One in six patients 
with a genetic aortopathy is dead by 50. Those at risk are often unaware, until either 
death or dissection occurs, or an incidental diagnosis is made on cardiac imaging. Aortic 
aneurysm and dissection are often inherited. Diagnosis of people at risk is critical but 
difficult, as there may be no clinical signs or obvious aortic enlargement in young 
patients. Better diagnostic tools are urgently required. There is a need for improved 
diagnostic accuracy, better risk-stratification and more effective therapeutic intervention 
for individuals and their families. We can improve patient care for individuals with 
genetic aortopathy by application of new plasma biomarkers for more accurate 
diagnosis and prognosis. 
Matrix metalloproteinases contribute to aneurysm formation and animal studies suggest 
their potential utility as biomarkers of thoracic aortic disease. MMP-3 has been 
implicated in thoracic aortic aneurysm formation (Barbour et al., 2007). It is a 
stromelysin that can degrade intact collagen (Raffetto et al., 2008) and is secreted from 
vascular smooth muscle cells (Barbour et al., 2007; Raffetto et al., 2008).  
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A moderate elevation in MMP-3 within the circulation has been observed in patients 
suffering from atherosclerotic aneurysms (Karapanagiotidis et al., 2009), and MMP-3 is 
believed to decrease within the aortic tissue of patients suffering from thoracic 
aneurysm associated with a bicuspid aortic valve (Ikonomidis et al., 2012; Jackson et 
al., 2012). No data are available for either tissue expression or circulating levels of 
MMP-3 in patients with MFS. Consequently, we sought to evaluate MMP-3 as a 
potential circulating biomarker of MFS. 
3.2	   Materials	  and	  Methods	  
3.2.1	   Subjects	  
Patients attending the Marfan Clinic at Royal Prince Alfred Hospital, Sydney over a 24 
month period were invited to take part in the study. The study was approved by the 
Royal Prince Alfred Hospital Human Research Ethics Committee and all participants 
were required to give written informed consent before any research procedures are 
undertaken. After the application of the exclusion criteria, we included 89 blood 
samples from 52 MFS patients and 37 control individuals. All patients had a full 
medical and family history obtained and underwent detailed physical examination. 
Exclusion criteria included acute aortic dissection, inflammatory or connective tissue 
disease of the aorta, and those with hypertensive or atherosclerotic disease, diabetes 
mellitus, systemic inflammatory disease (e.g. rheumatoid arthritis), and renal failure 
(GFR < 60 ml.min-1). 
Aortic geometry was measured by echocardiography, with particular attention to 
measurement of the aortic diameter at the level of the aortic valve, the Sinuses of 
Valsalva and the ascending aorta. All measurements were made according to standard 
criteria (see Section 2.1.3: Revised Ghent criteria for diagnosis of MFS) by the clinical 
staff at RPAH, with expert review by specialist cardiologists where required. Aortic 
mechanics (stiffness, distensibility and pulse wave velocity) were calculated according 
to published methods (Jeremy et al., 1994). Simultaneous blood pressure and aortic 
waveform were measured as previously described.  
Chapter	  3	  –	  Biomarker:	  MMP-­‐3	  
Yaxin	  Lu	   	   	   August	  2013	  
98	  
The aortic diameter was used to calculate the Z-score, which is the aortic diameter 
corrected for age and body surface area (BSA), where a value of -2 to 2 is considered as 
normal (Devereux et al., 2012). 
The body surface area (BSA) is the measured or calculated surface of a human body. 
For many clinical purposes BSA is a better indicator of metabolic mass than body 
weight because it is less affected by abnormal adipose mass. It is calculated from the 
height and weight of the patient. Details of the calculation are provided in Chapter 
2.1.2. 
The diagnosis of Marfan syndrome was made according to the Ghent criteria (De Paepe 
et al., 1996), taking account of the revisions published in 2010 (Loeys et al., 2010) (see 
Chapter 2.1.3). A control group included individuals referred to the Clinic who had no 
evidence of aortopathy.  
 
3.2.2	   Ethics	  
The Human Research Ethics Committee of Royal Prince Alfred Hospital approved the 
use of de-identified clinical data and echocardiography studies in the Clinic database for 
this study. 
 
3.2.3	   Collection	  and	  storage	  of	  blood	  
Methods used for collection, separation and storage of blood and its relevant 
components are described in Chapter 2 (2.4). Briefly, peripheral venous blood was 
obtained by venepuncture, during the patient consultation, into standard EDTA and 
heparin tubes. Within 4 hours (stored on ice) the blood was separated into plasma, buffy 
coat (containing white cells) and red blood cells by centrifugation at 1,000 g. 
Additionally, platelets were immediately removed from the plasma by a second high g 
Chapter	  3	  –	  Biomarker:	  MMP-­‐3	  
Yaxin	  Lu	   	   	   August	  2013	  
99	  
(10,000 g) centrifugation step, since platelets contain both TGF-β and MMP-9 within 
their cytoplasmic granules and could perturb the results if released (R&D Systems 
manufacturers instructions). White cells were also further purified by Ficoll gradient 
separation of monocytes. All components were aliquoted and stored at -80°C till 
required for assay.  
 
3.2.4	   ELISA	  
All potential biomarkers were analysed using a colorimetric ELISA assay system (see 
Chapter 2.5 for details). Commercial Quantikine ELISA kits were purchased from R&D 
Systems (USA), as detailed below. 
 
3.2.5	   Kits	  used	  
Circulating levels of human MMP-3 using the Human Total MMP-3 ELISA 
Immunoassay DMP300 purchased from R&D Systems (USA). 
 
3.2.6	   Statistical	  Analysis	  
The GraphPad Prism Version 6 (GraphPad Software, Inc. USA) was used to analyse the 
data and graph the data obtained. Data were expressed as averages with standard errors 
of the mean. All correlations were made as linear regressions using Spearman 
non-parametric correlation (GraphPad Prism only calculates the more rigorous r2 value 
from the Pearson correlation coefficient). Statistical significance was determined using 
unpaired two tailed t-test with Welch’s correlation. Results were considered to be 
significant if p<0.05.  
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3.3	   Results	  
3.3.1	   General	  description	  of	  cohort	  
During the course of the project a total of 78 patients, which including 16 repeat 
samples from patients that had previously been sampled. After the application of the 
exclusion criteria, we included 89 blood samples from 52 MFS patients and 37 control 
individuals. Essentially, only patients who had a definite diagnosis of MFS, based 
primarily on revised Ghent criteria, were included. All patients and all controls 
underwent echocardiographically determined aortic diameter measurement. All control 
individuals underwent a full clinical assessment.  
The MFS patients were divided into two groups, those who had undergone surgical 
replacement of their aortic root (MFS-S, 15 patients) and those who had not (MFS-NS 
37 samples). The surgical group can be generally regarded as a group that has a more 
severe form of MFS, since their aorta had dilated relatively rapidly, necessitating early 
replacement.  
The clinical assessment of participants included notation of age, gender, height and 
weight (which yields body surface area – see Section 2.1.2), and ascending aortic 
diameter (which yields aortic Z-score – see Section 2.1.2).  
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Table 3.1 lists the demographics of the controls and MFS patients tested. There was no 
statistically significant difference between the two groups for age (p=0.98).  
Groups BSA (m2) Aortic diameter (mm) Z-score 
Control (n=37) 1.87 ± 0.22 32.55 ± 4.29 0.31 ± 1.13 
MFS-NS (n=37) 2.04 ± 0.23 41.70 ± 4.31 3.06 ± 1.56 
MFS-S (n=15) 1.89 ± 0.19 N/A N/A 
Table	  3.1	   Patient	  demographics.	   	  
MFS-­‐NS:	   Marfan	   syndrome	   without	   aortic	   surgery.	   MFS-­‐S:	   Marfan	   syndrome	   with	  
aortic	  surgery.	  
 
Groups Age Gender Surgery β-blockers Angiotensin-II blockers 
Control 
(n=37) 38 ± 15 
15F 
22M No None None 
MFS-NS 
(n=37) 37 ± 14 
18F 
19M No n=16 n=10 
MFS-S 
(n=15) 40 ± 15 
9F 
6M Yes n=10 n=2 
Table	  3.2	   Medications	  on	  use	  for	  different	  groups.	  
MFS-­‐NS:	   Marfan	   syndrome	   without	   aortic	   surgery.	   MFS-­‐S:	   Marfan	   syndrome	   with	  
aortic	  surgery.	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3.3.2	   Comparison	   of	   demographic	   data	   within	   and	   between	  
groups	  
3.3.2.1	   Body	  surface	  area	  as	  a	  function	  of	  age	  
People often increase their weight as they become older (Verheijden et al., 2007). 
Figure 3.1 shows there was no significant increase in BSA as a function of age in either 
the control (r2<0.01, p=0.95) or MFS groups (r2=0.02, p=0.4). 
 Ctrl (r2) Ctrl (p) MFS-NS (r2) MFS-NS (p) 
Age vs. BSA <0.01 0.95 0.02 0.40 
Age vs. Aortic diameter 0.08 0.11 0.18 0.01 
Age vs. Z-score <0.01 0.99 0.02 0.41 
BSA vs. Aortic diameter 0.42 <0.0001 0.02 0.39 
Table	  3.3	   Correlations	  between	  demographic	  data	  using	  linear	  regression	  
 
 
Figure	  3.1	   Body	  Surface	  Area	  (BSA)	  as	  a	  function	  of	  age.	   	  
Plot	  curve	  with	  95%	  confidence	  band.	  
There	  was	   no	   statistically	   significant	   correlation	   between	   BSA	   and	   age	   in	   either	   the	  
Control	   (Left)	   and	   or	  MFS	   (Right)	   individuals.	   The	   linear	   regressions	   (5%	   confidence	  
intervals)	  are	  shown.	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3.3.2.2	   Aortic	  diameter	  as	  a	  function	  of	  age	  
The major life threatening complication of MFS is thoracic aortic aneurysm formation, 
and concomitant increase in risk of life-threatening dissection as the diameter of the 
ascending thoracic aortic increases (see Section 1.4.3: Matrix metalloproteinases 
contribute to aneurysm formation). Moreover, it is known that, within the normal 
population, thoracic aortic diameter slowing increases with age, although usually within 
the normal range (Isselbacher, 2005).  
Figure 3.2 shows the aortic root diameter in control and MFS patients, as a function of 
age. There is no significant increase in aortic diameter in the control group (r2=0.08; 
p=0.11). However, consistent with expected disease progression with age, a significant 
rise in the aortic root diameter is observed in the MFS group (r2=0.18; p=0.01). 
 
 
Figure	  3.2	   Aortic	   root	   diameter	   (mm)	   as	   a	   function	   of	   age	   (y)	   in	   both	   Control	  
(Left)	  and	  MFS-­‐NS	  (Right)	  groups.	   	  
Plot	  curve	  with	  95%	  confidence	  band.	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3.3.2.3	   Aortic	  diameter	  as	  a	  function	  of	  BSA	  
The thoracic aortic diameter is also dependant on the size of the patient (Body Surface 
Area) (Elefteriades, 2008). Figure 3.3 shows that, as expected, in the control group, 
aortic diameter increases with BSA (r2=0.42; p<0.0001). However, in the MFS group, 
no correlation was seen between the aortic diameter and BSA (r2=0.02; p=0.39), since 
in MFS aortic diameter is primarily a function of severity of disease, rather than the size 
of the patient. 
 
Figure	  3.3	   Aortic	   root	  diameter	   (mm)	  as	   a	   function	  of	  BSA	   (m2)	   in	   both	  Control	  
(Left)	  and	  MFS-­‐NS	  (Right)	  groups.	  
Plot	  curve	  with	  95%	  confidence	  band.	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3.3.3	   Comparison	  of	  demographic	  data	  between	  each	  group	  
3.3.3.1	   Body	  Surface	  Area	  
A diagnostic feature of MFS patients is that they are particularly tall and slim, as a 
consequence of skeletal abnormalities, compared to the general population, so it might 
be expected that they will exhibit a higher BSA (Kiotsekoglou et al., 2008), compared 
to controls. Figure 3.4 and Table 3.4 shows that the MFS patients had a significantly 
higher BSA, compared to controls (MFS 2.04 ± 0.04 m2; Control: 1.87 ± 0.04 m2; 
p=0.0017). 
 Control MFS-NS MFS-S p 
BSA (m2) 1.87 ± 0.04 2.04 ± 0.04 1.89 ± 0.19 0.0017 
Aortic diameter (mm) 32.55 ± 0.75 41.70 ± 0.71 N/A <0.0001 
Z-score 0.31 ± 0.20 3.06 ± 0.26 N/A <0.0001 
Table	  3.4	   Clinical	  demographics	  of	  the	  controls	  and	  MFS	  patients	  
 
 
Figure	  3.4	   Comparison	  of	  BSA	  (m2)	  in	  Control	  and	  MFS-­‐NS	  groups.	  
The	  mean	  and	  SEM	  are	  shown.	  p	  values	  calculated	  by	  unpaired	  two	  tailed	  t-­‐test	  using	  
Welch’s	  correction.	  (***	  p<0.001)	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3.3.3.2	   Aortic	  diameter	  and	  Z-­‐score	  
Table 3.4 and Figure 3.5 shows that, as expected, the average aortic root diameter for 
MFS patients was significantly higher than the control group (MFS: 41.70 ± 0.71; 
Control: 32.55 ± 0.75; p<0.0001).  
 
 
Figure	  3.5	   Comparison	  of	  Aortic	  diameter	  (mm)	  in	  Control	  and	  MFS-­‐NS	  groups.	   	  
The	  mean	  and	  SEM	  are	  shown.	  p	  values	  calculated	  by	  unpaired	  two	  tailed	  t-­‐test	  using	  
Welch’s	  correction.	  (***	  p<0.001)	  	  
The Z-score is a measurement of the aortic diameter that has been corrected for age and 
BSA, where a value of 0 is normal, and positive values correspond to larger than normal 
aortic diameter. The normal range for Z-score is considered to be -2 to 2. Table 3.4 and 
Figure 3.6 show that, as expected, the average Z-score for MFS patients was 
significantly higher than the control group (MFS: 3.06 ± 0.26; Control: 0.31 ± 0.20; 
p<0.0001). Furthermore, in the MFS group, the majority of Z-scores were clustered 
between 2 and 6, while in the control group the majority of Z-scores were clustered 
between 2 and -2.  
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Figure	  3.6	   Comparison	  of	  Z-­‐score	  in	  Control	  and	  MFS-­‐NS	  groups.	  
The	  mean	  and	  SEM	  are	  shown.	  p	  values	  calculated	  by	  unpaired	  two	  tailed	  t-­‐test	  using	  
Welch’s	  correction.	  (***	  p<0.001)	  
 
3.3.4	   MMP-­‐3	  as	  a	  biomarkers	  of	  MFS	   	  
The aim of these experiments was discover potential circulating biomarkers for MFS, to 
assist the clinician with diagnosis and prognosis. Additionally, biomarkers may be 
potentially useful for monitoring response to drug therapy. The biomarkers that were 
investigated in this thesis were: TGF-β1, MMP-3, -2 and -9, TIMP-1 and -2. The results 
for MMP-3 are described in this Chapter. The rationale for the selection of these 
potential biomarkers is outline in Section 1.4.3.  
To establish that there was no variation in levels of biomarkers due to errors in assay 
conditions, we performed repeat measurements for some of the patient samples, and 
found that in all cases variation between assays was less than 15%.  
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3.3.4.1	   Estimation	  of	  normal	  range	  
A crucial aspect of our analysis was to determine the expected normal values for 
MMP-3 using the manufacturer’s data and published experimentally determined values. 
The manufacturer, R&D Systems, provided their predicted normal range, determined 
from 35 “control persons”, for whom no clinical data were available. The values for 
MMP-3 are listed in Table 3.5. In addition to the normal ranges provided by the 
manufacturer, we consulted the literature to evaluate the range of values that had been 
experimentally obtained for control groups. An example is listed in Table 3.5.  
The control values obtained for MMP-3 were all in good agreement. The 
manufacturer’s range (~2 – 45 ng/mL) bracketed the control value obtained in this study 
and a similar study (~10 ng/mL). 
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Biomarker 
R&D Systems 
Sample 
preparation 
Platelet removal 
recommended 
R&D Systems 
normal range 
(ng/mL) 
Our Control result 
(ng/mL) 
Published Control 
results (ng/mL) Reference 
MMP-3 Heparin plasma (n=35) No 1.88 — 45.9 9.56 ± 0.86; (n=37) 10.66 ± 1.77; (n=15) 
(Karapanagiotidis et al., 
2009) 
 
Table	  3.5	   Normal	  ranges	  for	  biomarkers	  tested.	   	  
The	  normal	  range	  calculated	  by	  the	  manufacturer	  (R&D	  Systems)	  is	  shown	  and	  compared	  to	  the	  Control	  value	  obtained	  in	  this	  thesis	  and	  
a	  published	  control	  value.	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3.3.4.2	   Circulating	  MMP-­‐3	  is	  lower	  in	  females	  than	  in	  males	  
Figure 3.7 and Table 3.6 show the average circulating MMP-3 levels in MFS patients 
and controls, when stratified by gender. As discussed in Section 3.3.4.1, the average 
control value we obtained (9.561 ± 0.855 ng/mL) was in good agreement with the 
normal range quoted by the manufacturer (R&D Systems) (1.88 − 45.9 ng/mL). These 
data reveal an obvious gender difference in the expression of MMP-3, in both the 
control and MFS groups, with the average level of MMP-3 expression being 
significantly and consistently lower in females compared to males. Specifically, the 
circulating level of MMP-3 is approximately 50% lower in females compared to males 
in both control individuals (Males: 11.92 ± 1.04 ng/mL; Females: 6.10 ± 0.92; 
p=0.0002) and MFS patients (Males: 8.89 ± 0.92 ng/mL; Females: 4.29 ± 0.45; 
p<0.0001). 
 
MMP-3 levels (ng/mL) 
Groups  Females ± SEM Males ± SEM p 
Control 6.10 ± 0.92; n=15 11.92 ± 1.04; n=22 0.0002 
MFS 4.29 ± 0.45; n=27 8.89 ± 0.92; n=25 <0.0001 
Table	  3.6	   Gender	   differences	   in	   circulating	   MMP-­‐3	   levels	   (ng/mL)	   control	   and	  
MFS	  subjects.	  
The	  mean	   and	   SEM	   are	   shown.	   p	   values	   calculated	   by	   unpaired	   two	   tailed	  Welch’s	  
correction.	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Figure	  3.7	   Circulating	   MMP-­‐3	   levels	   in	   MFS	   stratified	   by	   gender,	   compared	   to	  
controls.	  
Circulating	  MMP-­‐3	   level	   (ng/mL)	   ±	   SEM.	   p	   values	   calculated	   by	   unpaired	   two	   tailed	  
t-­‐test	  using	  Welch’s	  correction.	  ***	  p<0.001	  
 
3.3.4.3	   Circulating	  MMP-­‐3	  is	  reduced	  in	  MFS	  patients	  
Figure 3.8 and Table 3.7 clearly show that the average level of circulating MMP-3 is 
significantly lower (by approximately 30%) in MFS patients compared to controls, both 
overall and when stratified by gender. Specifically, the average circulating levels of 
MMP-3 are lower in MFS patients (males and females taken together) compared to 
controls (males and females taken together) (Control: 9.56 ± 0.86; MFS: 6.50 ± 0.59; 
p=0.004; Figure 3.8).  
When these data are stratified by gender, average MMP-3 levels are also observed to be 
lower in MFS patients of each gender, when compared to the respective gender controls, 
however, the difference is not significant for the female gender (Control male: 11.92 ± 
1.04; MFS male: 8.89 ± 0.92; p=0.034; Figure 3.9); (Control female: 6.10 ± 0.92; MFS 
female: 4.29 ± 0.45; p=0.091; Figure 3.9). On the other hand, a difference was observed 
between MFS-NS females and control females (Control female: 6.10 ± 0.92; MFS-NS 
female: 3.84 ± 0.46; p=0.039; Figure 3.8). 
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MMP-3 levels (ng/mL) 
Gender Control ± SEM MFS ± SEM p 
Both (Male + Female) 9.56 ± 0.86; n=37 6.50 ± 0.53; n=52 0.004 
Females 6.10 ± 0.92; n=15 4.29 ± 0.45; n=27 0.091 
Males 11.92 ± 1.04; n=22 8.89 ± 0.92; n=25 0.034 
    
Gender Control ± SEM MFS-NS ± SEM p 
Both (Male + Female) 9.56 ± 0.86; n=37 6.28 ± 0.64; n=37 0.003 
Females 6.10 ± 0.92; n=15 3.84 ± 0.46; n=18 0.039 
Males 11.92 ± 1.04; n=22 8.59 ± 0.90; n=15 0.020 
    
Gender Control ± SEM MFS-S ± SEM p 
Both (Male + Female) 9.56 ± 0.86; n=37 7.05 ± 1.33; n=15 0.124 
Females 6.10 ± 0.92; n=15 5.20 ± 0.97; n=9 0.507 
Males 11.92 ± 1.04; n=22 9.82 ± 2.76; n=6 0.502 
Table	  3.7	   Circulating	   MMP-­‐3	   levels	   in	   MFS	   stratified	   by	   gender	   and	   disease	  
severity,	  compared	  to	  controls.	   	  
Circulating	  MMP-­‐3	   level	   (ng/mL)	   ±	   SEM.	   p	   values	   calculated	   by	   unpaired	   two	   tailed	  
t-­‐test	  using	  Welch’s	  correction.	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Figure	  3.8	   Circulating	  MMP-­‐3	  levels	  in	  both	  genders,	  females	  and	  males.	   	  
Circulating	  MMP-­‐3	   level	   (ng/mL)	   ±	   SEM.	   p	   values	   calculated	   by	   unpaired	   two	   tailed	  
t-­‐test	  using	  Welch’s	  correction.	  (*	  p<0.05;	  **	  p<0.01)	  
 
3.3.4.4	   MMP-­‐3	  levels	  as	  a	  function	  of	  disease	  severity	  
The MFS patients were further divided into patients who had relatively more severe 
disease, since they had required surgical replacement of their aorta – MFS-Surgical 
(MFS-S) compared to MFS patients who had not yet required surgery (MFS-NS). 
When the MFS group was divided into surgical and non-surgical groups, a significant 
difference was still seen in circulating MMP-3 levels between the non-surgical MFS 
group and the controls (MFS-NS: 6.28 ± 0.64; Control: 9.56 ± 0.86; p=0.003) Table 
3.8), including after stratification by gender.  
However, no significant difference was observed between controls and MFS patients 
who had undergone surgery (MFS-S: 7.05 ± 1.33; Control: 9.56 ± 0.86; p=0.124; Table 
3.8), including after stratification by gender. Notably, the average circulating MMP-3 
level in the surgical MFS groups showed a consistent trend towards higher values 
compared to the non-surgical group, although this trend was not significant (Surgical 
MFS: 7.05 ± 1.33; Non-surgical MFS: 6.28 ± 0.64; p=0.610; Table 3.8), including after 
stratification by gender.  
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MMP-3 levels (ng/mL) 
MFS-NS vs. MFS-S MFS-NS ± SEM MFS-S ± SEM p 
All (Female + Male) 6.28 ± 0.64; n=37 7.05 ± 1.33; n=15 0.61 
Female 3.84 ± 0.46; n=18 5.20 ± 0.97; n=9 0.23 
Male 8.59 ± 0.90; n=19 9.82 ± 2.76; n=6 0.69 
Table	  3.8	   Circulating	   MMP-­‐3	   levels	   in	   MFS	   stratified	   by	   disease	   severity	   and	  
gender.	   	  
Circulating	  MMP-­‐3	   level	   (ng/mL)	   ±	   SEM.	   p	   values	   calculated	   by	   unpaired	   two	   tailed	  
t-­‐test	  using	  Welch’s	  correction.	  
 
 
Figure	  3.9	   MMP-­‐3	  levels	  (ng/mL)	  in	  MFS	  stratified	  by	  gender	  and	  disease	  severity,	  
compared	  to	  controls.	  
Circulating	  MMP-­‐3	   level	   (ng/mL)	   ±	   SEM.	   p	   values	   calculated	   by	   unpaired	   two	   tailed	  
t-­‐test	  using	  Welch’s	  correction.	  (*	  p<0.05;	  **	  p<0.01)	  
 
Thus, although it is clear that there is a significant reduction in the level of circulating 
MMP-3 in patients with MFS, compared to controls, theses data also suggest that the 
extent of reduction is smaller in the MFS patients who have a more severe form of MFS 
(the surgical MFS patients) compared to the non-surgical MFS patients. However, since 
there is no significant difference in the average circulating MMP-3 level between 
surgical and non-surgical MFS patients, this difference only represents a trend, which 
may have become significant if a larger number of MFS surgical and non-surgical 
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patients had been recruited to the study.  
3.3.4.5	   Correlations	   between	   circulating	   MMP-­‐3	   levels	   and	   clinical	  
parameters	  
Circulating MMP-3 levels were further analysed to determine whether there was any 
correlation between MMP-3 and measured clinical parameters, including those that are 
predictors of disease severity. The parameters considered were age, BSA, aortic 
diameter and Z-score (Table 3.9). We found a weak, but significant, correlation between 
circulating MMP-3 levels and BSA, in both the Control and MFS non-surgical groups 
(Table 3.9; Figures 3.10). MMP-3 levels were observed to be higher in larger patients 
(higher BSA).  
MMP-3 Correlation Ctrl (r2) Ctrl (p) MFS-NS (r2) MFS-NS (p) 
Age (y) 0.02 0.420 0.002 0.790 
BSA (m2) 0.24 0.004 0.13 0.028 
Aortic diameter (mm) 0.12 0.053 0.01 0.494 
Z-score 0.01 0.672 0.02 0.460 
Table	  3.9	   Linear	   regression	   comparison	   of	   MMP-­‐3	   levels	   vs.	   Age,	   BSA,	   Aortic	  
diameter	  and	  Z-­‐score	  in	  Control	  and	  MFS-­‐NS	  groups.	  
 
Figure	  3.10	   MMP-­‐3	  levels	  (ng/mL)	  as	  a	  function	  of	  BSA	  (m2)	  in	  both	  Control	  (Left)	  
and	  MFS-­‐NS	  (Right)	  groups.	  
Plot	   curve	  with	   95%	   confidence	   band	   (Control:	   r2=	   0.24;	  *p<0.05;	  MFS-­‐NS:	   r2=	   0.13;	  
*p<0.05).	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The correlation observed for MMP-3 and BSA was also observed in males when 
non-surgical MFS patients were stratified by gender (Figure 3.11). However, no 
correlation was observed in female non-surgical MFS patients (Figure 3.11).  
MMP-3 Correlation Males Ctrl (r2) Ctrl (p) MFS-NS (r2) MFS-NS (p) 
Age (y) 0.11 0.17 0.18 0.07 
BSA (m2) 0.32 0.01 <0.01 0.93 
Aortic diameter (mm) 0.14 0.11 <0.01 0.99 
Z-score <0.01 0.87 0.05 0.35 
Table	  3.10	   Linear	   regression	  of	  MMP-­‐3	   levels	   vs.	  Age,	   BSA,	  Aortic	   diameter	   and	  
Z-­‐score	  in	  Males	  in	  Control	  and	  MFS-­‐NS	  groups.	  
 
 
Figure	  3.11	   MMP-­‐3	   levels	   (ng/mL)	   as	   a	   function	   of	   BSA	   (m2)	   in	   Control	   Males	  
group.	  
Plot	  curve	  with	  95%	  confidence	  band.	  (r2=0.32;	  **	  p=0.01)	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There was no correlation between any other clinical parameters and circulating MMP-3 
levels (Table 3.11) 
MMP-3 Correlation Females Ctrl (r2) Ctrl (p) MFS-NS (r2) MFS-NS (p) 
Age (y) 0.19 0.11 <0.01 0.92 
BSA (m2) 0.04 0.47 0.01 0.71 
Aortic diameter (mm) 0.12 0.25 <0.01 1.00 
Z-score 0.19 0.14 <0.01 0.93 
Table	  3.11	   Linear	   regression	  of	  MMP-­‐3	   levels	   vs.	  Age,	   BSA,	  Aortic	   diameter	   and	  
Z-­‐score	  in	  Females	  in	  Control	  and	  MFS-­‐NS	  groups.	  
 
3.4	   Discussion	  
We have evaluated MMP-3, since it is a circulating biomarker known to be relevant to 
vascular disease (Barbour et al., 2007), to determine whether circulating MMP-3 
correlated with various aspects of MFS disease. Specifically, we sought to determine 
whether MMP-3 may be useful for diagnosis, or for the prediction of severity of the 
disease, which in turn would be useful for determining prognosis, particularly with 
respect to predicting increased risk of aortic aneurysm dissection. 
The results of this study found that MMP-3 appeared to have clinical utility. A 
significant difference in MMP-3 was observed between MFS patients and controls, with 
MMP-3 levels being lower in MFS groups compared to controls. Additionally, a strong 
gender difference was observed in MMP-3, with MMP-3 levels being consistently 
lower in females, in both control and MFS groups. However, the very substantial 
overlap of values between controls and MFS patients, makes the usefulness of the 
individual level of circulating MMP-3 not very promising for diagnosis. On the other 
hand, serial circulating MMP-3 levels in an individual patient may transpire to be useful 
for monitoring response to therapy. This aspect of the use of circulating MMP-3 levels 
will be the subject of future studies. 
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The known gender difference in MFS severity (Brown et al., 1975) led us to stratify our 
patients by gender. We observed a strong gender difference in MMP-3 levels, as 
mentioned above.  
We evaluated whether circulating biomarker levels correlated with the clinical 
parameters of age, BSA, aortic diameter and Z-score. We found that MMP-3 levels 
increase with BSA, in both control and MFS groups. 
The most interesting change in a circulating biomarker in MFS patients that we 
observed was our two-fold discovery that MMP-3 is reduced in MFS patients, 
compared to controls, and that a substantial gender difference exists in MMP-3 levels, 
with females having lower levels. 
 
3.4.1	   Gender	  difference	  in	  the	  expression	  of	  MMP-­‐3	  
Clinical studies have showed important gender differences in the phenotype of 
individuals with MFS. Our experience demonstrates a 60:40 male to female ratio 
amongst nearly 250 Marfan patients enrolled in our clinic. Additionally, a significantly 
higher level of morbidity has been noted amongst men compared to women (Detaint et 
al., 2010), specifically, men have a ~10% higher risk of aortic dilatation and double the 
risk for aortic events. Our observation that MMP-3 is consistently higher in males may, 
at least in part, contribute towards this gender difference in severity. There are several, 
non-exclusive, potential mechanisms through which females may be relatively protected 
from the adverse consequences of gene mutations associated with genetic aortopathy. 
Firstly, estrogens may act via membrane receptors to regulate the transcription of key 
genes modulating signalling or effector pathways in genetic aortopathy (or androgens 
may have a converse effect). Murine studies have shown that the expression of several 
key genes encoding proteins implicated in the pathogenesis of TAAD is regulated via 
estrogen receptors (Schnoes et al., 2008). These genes include those encoding elastin, 
MMP-3, TGF-β2, VSMC α-2 actin and myosin 11 heavy chain, and integrin αV. Such 
a role in regulating gene transcription may well underlie our findings of gender 
differences in plasma MMP-3 levels. 
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Secondly, estrogens may act via the receptors to directly activate key intracellular 
kinases to influence signalling cascades without changes in nuclear transcription. In 
addition to the known role of estrogen receptors (ERα and ERβ) in mediating activation 
or repression of gene transcription via estrogen response elements, it is now known that 
estrogen binding to membrane bound ER results in the formation of calveolar signalling 
complexes on the inner plasmalemma (Bjornstrom et al., 2005). Among the major 
intracellular signalling pathways, which are influenced in this manner, are the JNK and 
p38 MAPK pathways, which are also known to mediate TGF-β signalling in the VSMC. 
Recent studies suggest that such non-genomic signalling is an important contributor to 
vascular responses to estrogens and in protection against vascular injury (Moens et al., 
2012). 
Thirdly, estrogens may modulate the expression of key genes associated with matrix 
remodelling at the post transcriptional level via changes in miRNA binding of target 
mRNA in the aortic wall. It is now increasingly recognized that microRNA binding of 
mRNA is an important post-transcriptional regulatory mechanism and many human 
miRNAs are now known. Accumulating evidence shows that microRNAs can modulate 
VSMC phenotype (Albinsson et al., 2011). There is early evidence that miRNAs play a 
role in modulating gene expression in both atherosclerotic and genetic aortic disease 
(Boon et al., 2011). Recent murine studies have implicated miR29b in the pathogenesis 
of aortic aneurysm in Marfan syndrome (Merk et al., 2012). This miR is known to 
influence expression of genes involved in extracellular matrix remodelling and in 
VSMC apoptosis. Interestingly, whilst TGFβ has been associated with down-regulation 
of miR-29, estradiol has been associated with upregulation of miR-29 in hepatic injury 
(Zhang, Y. et al., 2012). Other studies suggest roles for miRNA in vascular responses to 
stress, including miR-155 in angiotensin II receptor 1 expression (Zheng et al., 2010); 
reduced miR-125b, miR-145 and mIR-155 in the thoracic aorta of rats with chronic 
kidney disease (Chen, N. X. et al., 2013). 
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3.4.2	   Circulating	  MMP-­‐3	  levels	  fall	  in	  patients	  with	  MFS	  
The level of MMP-3 was observed to fall in MFS patients compared to controls. This 
would seem to be a paradoxical result, since intuitively the expectation is that tissue 
levels of destructive MMPs would rise, to cause the ECM destruction that is part of 
cystic medial necrosis. Furthermore, the level of MMP-3 has been observed to rise in 
both atherosclerotic aortic tissue and in the circulation of patients with atherosclerotic 
thoracic aortic aneurysm (Karapanagiotidis et al., 2009) (Table 3.12). Clearly the 
underlying mechanisms between atherosclerosis and the cystic medial necrosis of 
genetic aortopathy are different, suggesting that the regulation of the expression of 
MMP-3 is substantially different in these two processes.  
 
 Normal ng/mL Disease ng/mL Disease Reference 
MMP-3 Not stated Decreased Marfan (Ikonomidis et al., 2006) 
MMP-3 10.66 ± 1.77 17.64 ± 3.64 
Aneurysm (cause 
unknown, probably 
atherosclerosis) 
(Karapanagiotidis et al., 
2009) 
MMP-3 9.56 ± 0.86 6.50 ± 0.59 MFS This thesis  
MMP-3 9.56 ± 0.86 6.28 ± 0.64 MFS-NS This thesis 
MMP-3 9.56 ± 0.86 7.05 ± 1.33 MFS-S This thesis 
Table	  3.12	   Comparison	  of	  data	  from	  various	  studies	  
 
Little is known of the specific pathways that regulate MMP-3 expression. Presumably, 
the fall in MMP-3 expression in thoracic aortopathy represents a compensatory 
mechanism by the aortic wall to try to limit damage to the wall in genetic aortopathy. 
MMP-3 is known to proteolyse a number of proMMPs into their active form (Visse et 
al., 2003). These include proMMP-1, -3, -7, -8, -9 and -13. Thus, from a teleological 
point of view, MMP-3 would appear to be a key regulator of overall MMP activity 
within tissue, which would further imply that tight control over MMP-3 may be 
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essential for normal tissue homeostasis. Thus, we speculate it is possible that the 
regulatory mechanisms within the aortic wall that are responding to its damage may 
well be directed towards reducing MMP-3 activity. 
The reduction we have observed in circulating MMP-3 is consistent with a reduction in 
tissue MMP-3 mRNA and protein expression that has been observed in some forms of 
BAV, another form of genetic aortopathy of complex genetic aetiology (Ikonomidis et 
al., 2012; Jackson et al., 2012). 
Finally, BSA was observed to correlate with MMP-3 level. The intuitive explanation for 
this observation is that the larger aortic surface in larger individuals may allow for a 
higher level of release of MMP-3 into the circulation. The possibility that greater strain 
is placed on the aortic wall in larger persons is unlikely, given that aortic peak flow 
velocity does not increase with BSA in healthy individuals ((Gardin et al., 1987)).  
 
3.5	   Conclusions	  
Our data have shown that the levels of circulating MMP-3 are significantly higher in 
males compared to females. Paradoxically, the levels of circulating MMP-3 fall in MFS 
patients, presumably as a compensatory mechanism to limit pathological extra-cellular 
matrix remodelling. These data are new and novel findings, and may explain, in part, 
the more severe disease that is seen in males compared to females in MFS. Finally, 
while the average MMP-3 levels in MFS and controls are significantly different, the 
large scatter of levels between individuals makes the use of this test of limited value for 
diagnosis. However, serial determinations of MMP-3 levels in individuals may be of 
use for monitoring response to therapy, for example, pharmacological interventions. 
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Chapter	  4	  
Additional	  Biomarkers	  
 
4.1	   Introduction	  
In Chapter 3 we explained the clinical need for biomarkers of MFS, and reported the 
discovery of the suitability of circulating MMP-3 as a biomarker of MFS. A number of 
other potential biomarkers were considered for investigation, based on the probable 
involvement of these biomarkers in the pathogenesis of genetic aortopathy, including 
MFS. The additional biomarkers selected for investigation were TGF-β1, MMP-2, 
MMP-9, TIMP-1 and TIMP-2.  
A current hypothesis is that the common mechanism behind genetic aortopathy 
formation involves abnormal TGF-β signalling (El-Hamamsy et al., 2009). 
Furthermore, substantial evidence exists that the final pathway for aortic wall damage is 
through excessive protease activity, causing the characteristic histological features of 
cystic medial necrosis, namely, loss of extra-cellular matrix, especially collagen and 
elastin, and a reduction in medial cell numbers, possibly via the induction of apoptosis 
(Nataatmadja et al., 2006). In the search for circulating biomarkers capable of 
predicting disease progression and severity, prospective candidates would include 
TGF-β and relevant extra-cellular proteases, the matrix metalloproteinases (MMPs) and 
their regulators, the tissue inhibitors of MMPs (TIMPs).  
Transforming growth factor-β (TGF-β) is a soluble peptide growth factor involved in 
many cellular processes, including differentiation, wound healing, angiogenesis and 
apoptosis (Jones et al., 2009). TGF-β is primarily involved in stimulating collagen 
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production and deposition within the ECM, and pathological TGF-β signalling is known 
to be involved in pathological fibrosis of the liver, heart and lung (Jones et al., 2009). 
TGF-β is a pleiotropic growth factor, with signalling functions which are highly 
dependent on the signalling milieu within the tissue. Several groups have examined the 
levels of TGF-β in aneurysm tissue and in blood. TGF-β has been reported to be 
elevated in aneurysm tissue from MFS in both a mouse model (Matt et al., 2009) and in 
humans (Gomez et al., 2009; Matt et al., 2009). Additionally, an elevation in average 
TGF-β in blood has been observed in MFS in both the mouse model and humans 
(Gomez et al., 2009; Matt et al., 2009). Finally, circulating levels of TGF-β have been 
reported to fall in response to therapy with an angiotensin receptor blocker in mice 
(Gomez et al., 2009; Matt et al., 2009), and in humans to fall in response to an ACE 
inhibitor (Ahimastos et al., 2010), a beta-blocker and an angiotensin receptor blocker 
(Gomez et al., 2009; Matt et al., 2009).  
MMPs mediate extra-cellular matrix (ECM) destruction, leading to weakening of the 
aortic wall and aneurysm formation (Barbour et al., 2007). The MMPs are a family of 
27 extracellular proteases that are capable of degrading all constituents of the aortic 
ECM. The expression and activity of MMPs within the vascular wall are regulated at 
several levels, including at transcription, post-translation and effector antagonism via 
endogenous tissue inhibitors (TIMPs). Perturbation of these regulatory mechanisms will 
influence aortic wall remodelling, leading to aneurysm formation. MMP-2 and -9 and 
TIMP-1 and -2 have been implicated in aortic aneurysm formation (Barbour et al., 
2007). MMP-2 and -9 are gelatinases which can proteolyse denatured collagens 
(Barbour et al., 2007; Raffetto et al., 2008). Within the aortic wall, MMP2 is primarily 
derived from vascular smooth muscle cells (Barbour et al., 2007; Raffetto et al., 2008), 
while MMP-9 is primarily derived from chronic inflammatory cells, largely within the 
adventitia (Barbour et al., 2007). All the TIMPs are able to inhibit all the MMPs to 
some extent, but TIMP-2 most effectively inhibits MMP-2 and TIMP-1 most effectively 
inhibits MMP-9 (Hidalgo et al., 2001). Thus, the ratios MMP-2:TIMP-2 and 
MMP-9:TIMP-1 may be indices of the balance of the proteolytic activity (Chung, A. W. 
et al., 2007). Activation of the MMPs is a complex process, of which one component is 
TGF-β signalling (Barbour et al., 2007). 
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In light of the clear involvement of TGF-β1, MMP-2, MMP-9, TIMP-1 and TIMP-2 in 
the pathogenesis of thoracic aortopathy, we sought to evaluate these molecules as 
potential circulating biomarkers of MFS. 
4.2	   Materials	  and	  Methods	  
4.2.1	   Subjects	  
Patient demographics are described in Chapter 3 (section 3.2.1). Briefly, patients 
attending the Marfan Clinic at Royal Prince Alfred Hospital, Sydney over a 24 month 
period were invited to take part in the study. We included 89 blood samples from 52 
MFS patients and 37 control individuals.  
 
4.2.2	   Ethics	  
The Human Research Ethics Committee of Royal Prince Alfred Hospital approved the 
use of de-identified clinical data and echocardiography studies in the Clinic database for 
this study. 
 
4.2.3	   Collection	  and	  storage	  of	  blood	  
The collection and storage of blood was described in Chapter 2 (section 2.4). Briefly, 
peripheral venous blood was obtained by venepuncture, during the patient consultation, 
into standard EDTA and heparin tubes. The blood was separated into plasma and buffy 
coat (further purified by Ficoll gradient separation of monocytes). Additionally, 
platelets were immediately removed from the plasma by a second high g (10,000 g) 
centrifugation step, since platelets contain both TGF-β and MMP-9 within their 
cytoplasmic granules and could perturb the results if released (R&D Systems 
manufacturers instructions). All components were aliquoted and stored at -80°C till 
required for assay.  
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4.2.4	   ELISA	  
All potential biomarkers were analysed using a colorimetric ELISA assay system (see 
Chapter 2.5 for details). Commercial Quantikine ELISA kits were purchased from R&D 
Systems (USA), as detailed below. 
 
4.2.5	   Kits	  used	  
Table 4.1 shows all the Quantikine ELISA kits that purchased from R&D Systems 
(USA). 
 Quantikine® ELISA Catalog Number Manufacture 
TGF-β1 Human TGF-β1 Immunoassay DB100B R&D Systems (USA) 
MMP-3 Human MMP-3 Immunoassay DMP300 R&D Systems (USA) 
MMP-2 Human MMP-2 Immunoassay DMP2F0 R&D Systems (USA) 
MMP-9 Human MMP-9 Immunoassay DMP900 R&D Systems (USA) 
TIMP-1 Human TIMP-1 Immunoassay DTM100 R&D Systems (USA) 
TIMP-2 Human TIMP-2 Immunoassay DTM200 R&D Systems (USA) 
Table	  4.1	   Details	  of	  ELISA	  kits	  used	  for	  this	  study.	  
 
4.2.6	   Statistical	  Analysis	  
The GraphPad Prism Version 6 (GraphPad Software, Inc. USA) was used to analyse the 
data and graph the data obtained. Data were expressed as averages with standard errors 
of the mean. All correlations were made as linear regressions using Spearman 
non-parametric correlation. Statistical significance was determined using unpaired two 
tailed t-test with Welch’s correlation. Results were considered to be significant if 
p<0.05.  
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4.3	   Results	  
4.3.1	   General	  description	  of	  cohort	  
The general description of the cohort is described in Chapter 3 (section 3.3.1). Briefly, 
89 blood samples from 52 MFS patients and 37 control individuals were included. The 
MFS patients were divided into two groups, those who had undergone surgical 
replacement of their aortic root (MFS-S, 15 patients) and those who had not (MFS-NS 
37 samples). The surgical group can be generally regarded as a group that has a more 
severe form of MFS, since their aorta had dilated relatively rapidly, necessitating early 
replacement.  
The clinical assessment of participants included notation of age, gender, height and 
weight (which yields body surface area – see Section 2.1.2), and ascending aortic 
diameter (which yields aortic Z-score – see Section 2.1.2).  
 
4.3.2	   Comparison	  of	  demographic	  data	  within	  each	  group	  
The comparisons of demographic data were described in Chapter 3 (section 3.3.2). 
Briefly, no correlation was seen between age and body surface area (BSA) in control or 
MFS patients. However, a correlation was seen between Aortic diameter and age in 
MFS patients. A correlation was also observed between BSA and aortic diameter in 
control subjects. 
 
4.3.3	   Comparison	  of	  demographic	  data	  between	  each	  group	  
Additionally, when demographic data were compared between groups (see Section 
3.3.3: Comparison of demographic data between each group), BSA, aortic diameter 
and Z-score were observed to be significantly increased in MFS compared to controls. 
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4.3.4	   Biomarkers	  of	  MFS	   	  
The aim of these experiments was discover potential circulating biomarkers for MFS, to 
assist the clinician with diagnosis and prognosis. Additionally, biomarkers may be 
potentially useful for monitoring response to drug therapy. The biomarkers that were 
investigated in this Chapter were: TGF-β1, MMP-2 and -9, TIMP-1 and -2. The 
rationale for the selection of these potential biomarkers is outline in Section 4.1.  
To establish that there was no variation in levels of biomarkers due to errors in assay 
conditions, we performed repeat measurements for some of the patient samples, and 
found that in all cases variation between assays was less than 15%.  
 
4.3.4.1	   Estimation	  of	  normal	  range	  
A crucial aspect of our analysis was to determine the expected normal values for the 
biomarkers tested using the manufacturer’s data and published experimentally 
determined values. The manufacturer, R&D Systems, provided their predicted normal 
ranges, determined from a variable number of “control persons”, for whom no clinical 
data were available. The values for the biomarkers are listed in Table 4.2. In addition to 
the normal ranges provided by the manufacturer, we consulted the literature to evaluate 
the range of values that had been experimentally obtained for control groups. Examples 
are listed in Table 4.2.  
Additionally, the presence of platelets can perturb the values obtained for circulating 
TGF-β1 and MMP-9, since both these molecules are present within cytoplasmic 
granules in platelets, and can be variably released if the platelets are not removed prior 
to assay. Our research protocol included the removal of platelets during preparation of 
the samples (see Section 2.3: Collection and storage of blood).  
 
Chapter	  4	  –	  Additional	  Biomarkers	  
Yaxin	  Lu	   	   	  August	  2013	  
128	  
 
Biomarkers R&D Systems Sample preparation 
Platelet removal 
recommended 
R&D Systems 
normal range 
(ng/mL) 
Our Control result 
(ng/mL) 
Published Control 
results (ng/mL) Reference 
TGF-β1 
EDTA plasma 
(platelet-poor) 
(n=10) 
Yes 0.90 – 1.65 1.24 ± 0.10; (n=37) 
1.17 ± 0.33; 
(n=30) (Ogawa et al., 2013) 
MMP-2 Heparin plasma (n=35) No 155 – 323 
430.14 ± 18.85; 
(n=37) 
171.37 ± 11.39; 
(n=15) 
(Karapanagiotidis et al., 
2009) 
MMP-9 
Heparin plasma 
(platelet-poor) 
(n=37) 
Yes 13.2 – 105 117.14 ± 8.59; (n=37) 
400.13 ± 77.90; 
(n=15) 
(Karapanagiotidis et al., 
2009) 
TIMP-1 EDTA plasma (n=60) No 44 – 304 
108.67 ± 5.98; 
(n=37) 
138.14 ± 69.08; 
(n=20) (Hellenthal et al., 2012) 
TIMP-2 
EDTA plasma 
(n=37) No 19 – 254 
90.51 ± 4.52; 
(n=37) 
160 ± 30; 
(n=130) (Palei et al., 2012) 
Table	  4.2	   Normal	  ranges	  for	  biomarkers	  tested.	   	  
The	  normal	  range	  calculated	  by	  the	  manufacturer	  (R&D	  Systems)	   is	  shown	  and	  compared	  to	  the	  Control	  value	  obtained	   in	  this	  thesis	  and	  a	  
published	  control	  value.	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The normal range for TGF-β1 provided by R&D Systems (0.90 – 1.65 ng/mL), a 
control value published recently (1.17 ng/mL) and the control value we obtained (1.24 
ng/mL) were all in good agreement. 
The normal range for MMP-2 provided by R&D Systems (155 – 323 ng/mL) is quite 
large, while a published control value was ~ 170 ng/mL). The control value we obtained 
was at the upper limit of the normal range (~ 430 ng/mL). 
The normal range for MMP-9 provide by R&D Systems was dependant on the sample; 
for heparin plasma 13.2 – 105 ng/mL but for serum 169 – 705 ng/mL. The assay 
recommends removal of platelets that we complied with. We used EDTA plasma and 
obtained a normal value of 116, slightly above the normal range for heparin plasma, but 
well below the range for serum. A published normal value for MMP-9 was ~ 400 
ng/mL.  
The normal ranges for TIMP-1 and TIMP-2 provided by R&D Systems were 
approximately 30 – 300 ng/mL which compares very well with our value for TIMP-1 of 
~ 110 ng/mL and for TIMP-2 of ~ 90 ng/mL. These values were also in good agreement 
with published control values (TIMP-1: 140 ng/mL; TIMP-2: 160 ng/mL). 
 
4.3.4.2	   Circulating	  levels	  of	  TGF-­‐β1	  in	  MFS	  
Abnormal TGF-β signalling has been strongly implicated in the pathogenesis of MFS 
(Pardali et al., 2012), with studies suggesting that the activity of TGF-β is elevated 
within the aortic wall of MFS patients (Ikonomidis et al., 2006). Furthermore, a study 
has observed an elevation in circulating TGF-β in mouse models of MFS (Matt et al., 
2009) and in MFS patients (Matt et al., 2009), although other groups have failed to 
detect this (Ogawa et al., 2013).  
Table 4.3 shows show the data for total TGF-β1 levels in the circulation of MFS 
patients and controls. As discussed in Section 4.3.4.1, the average control value we 
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obtained (1.24 ng/mL) was in good agreement with the normal range quoted by the 
manufacturer (R&D Systems) (0.90 – 1.65 ng/mL). For our patient cohort, there is no 
significant difference between the control group and the MFS groups (all MFS patients 
group and Surgical and Non-Surgical MFS patients groups considered individually) 
(Table 4.3). Despite no significant difference being observed between control and MFS 
patients, close examination of the data does reveal a consistent trend towards a slightly 
higher TGF-β level in MFS, but this trend is on average only approximately 10% higher 
than controls. Thus, if a difference does exist, our data suggest that it is small. With a 
larger sample size, it is possible that this trend could become significant.  
Additionally, the data show that for the most severe MFS group, the Surgical group, the 
average TGF-β1 level is substantially higher than both controls and the MFS 
non-surgical group (by approximately 30%), but is still not statistically significantly 
elevated, again, probably because of the small sample size (15 patients). 
TGF-β1 Levels (ng/mL) 
Groups Control ± SEM MFS ± SEM p 
Ctrl vs. MFS 1.24 ± 0.10; n=37 1.37 ± 1.09; n=52 0.37 
Ctrl vs. MFS-NS 1.24 ± 0.10; n=37 1.22 ± 0.85; n=37 0.90 
Ctrl vs. MFS-S 1.24 ± 0.10; n=37 1.76 ± 0.30; n=15 0.12 
 MFS-NS ± SEM MFS-S ± SEM p 
MFS-NS vs. MFS-S 1.22 ± 0.85; n=37 1.76 ± 0.31; n=15 0.10 
Table	  4.3	   Comparison	  of	  circulating	  TGF-­‐β1	  levels	  (ng/mL)	  in	  patients	  with	  MFS,	  
compared	  to	  controls.	   	  
MFS	  patients	  were	  further	  stratified	  into	  patients	  who	  had	  undergone	  surgery	  (MFS-­‐S)	  
and	  those	  who	  had	  not	  (MFS-­‐NS).	  The	  mean	  and	  SEM	  are	  shown.	  p	  values	  calculated	  
by	  unpaired	  two	  tailed	  Welch’s	  correction.	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A gender difference in the severity of MFS has been observed, where males have been 
shown to develop a more severe form of the disease (Gray et al., 1998). The cause of 
this gender difference is unknown. Consequently, we analysed the TGF-β1 data 
stratified by gender. Table 4.4 shows that there were no significant differences in 
TGF-β1 levels based on gender, both within groups (Table 4.4) and between controls 
and MFS groups (Tables 4.5 and 4.6).  
TGF-β1 (ng/mL) 
Groups Female ± SEM Male ± SEM p 
All 1.36 ± 0.08; n=42 1.28 ± 0.13; n=47 0.61 
Control 1.45 ± 0.15; n=15 1.09 ± 0.14; n=22 0.08 
MFS 1.31 ± 0.09; n=27 1.45 ± 0.21; n=25 0.54 
MFS-NS 1.31 ± 0.12; n=18 1.13 ± 0.12; n=19 0.29 
MFS-S 1.30 ± 0.15; n=9 2.45 ± 0.65; n=6 0.14 
Table	  4.4	   Gender	  difference	  between	  different	  groups	  in	  TGF-­‐β1	  levels.	  
The	  mean	   and	   SEM	   are	   shown.	   p	   values	   calculated	   by	   unpaired	   two	   tailed	  Welch’s	  
correction.	  
 
TGF-β1 Males (ng/mL) 
Groups Control ± SEM MFS ± SEM p 
Ctl vs. MFS  1.09 ± 0.13; n=22 1.45 ± 0.21; n =25 0.16 
Ctl vs. MFS-NS 1.09 ± 0.13; n=22 1.13 ± 0.12; n =19 0.83 
Ctl vs. MFS-S 1.09 ± 0.13; n=22 2.45 ± 0.65; n =6 0.10 
 MFS-NS ± SEM MFS-S ± SEM p 
MFS-NS vs. MFS-S 1.13 ± 0.12; n=19 2.45 ± 0.65; n =6 0.10 
Table	  4.5	   Comparison	  of	  TGF-­‐β1	  levels	  in	  males	  among	  Control	  and	  MFS	  groups.	  
The	  mean	   and	   SEM	   are	   shown.	   p	   values	   calculated	   by	   unpaired	   two	   tailed	  Welch’s	  
correction.	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TGF-β1 Females (ng/mL) 
Groups Control± SEM MFS± SEM p 
Ctl vs. MFS 1.45 ± 0.15; n =15 1.31 ± 0.09; n =27 0.43 
Ctl vs. MFS-NS 1.45 ± 0.15; n =15 1.31 ± 0.12; n =18 0.49 
Ctl vs. MFS-S 1.45 ± 0.15; n =15 1.30 ± 0.15; n =9 0.47 
 MFS-NS ± SEM MFS-S ± SEM p 
MFS-NS vs. MFS-S 1.31 ± 0.12; n =18 1.30 ± 0.15; n =9 0.93 
Table	  4.6	   Comparison	   of	   TGF-­‐β1	   levels	   in	   females	   among	   Control	   and	   MFS	  
groups.	  
The	  mean	   and	   SEM	   are	   shown.	   p	   values	   calculated	   by	   unpaired	   two	   tailed	  Welch’s	  
correction.	  
 
Circulating TGF-β1 levels were further analysed to determine whether there was any 
correlation between TGF-β1 and measured clinical parameters, including those that are 
predictors of disease severity. The parameters considered were age, BSA, aortic 
diameter and Z-score (Table 4.7). We found a weak, but significant, correlation between 
circulating TGF-β1 levels and age, but only in the Control group (Figure 4.1). There 
was no correlation between any other clinical parameters and circulating TGF-β1 levels 
(Table 4.7) 
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TGF-β1 Correlation Ctrl(r2) Ctrl (p) MFS-NS (r2) MFS-NS (p ) 
Age (y) 0.14 0.03 0.10 0.06 
BSA (m2)  0.06 0.15 0.03 0.32 
Aortic diameter(mm) 0.02 0.49 <0.0001 0.99 
Z-score 0.02 0.41 0.02 0.32 
Table	  4.7	   Linear	   regression	   of	   TGF-­‐β1	   levels	   vs.	   Age,	   BSA,	   Aortic	   diameter	   and	  
Z-­‐score	  in	  Control	  and	  MFS-­‐NS	  groups.	   	  
 
 
Figure	  4.1	   TGF-­‐β1	  levels	  (ng/mL)	  as	  a	  function	  of	  Age	  (y)	  in	  Control	  group.	  
Plot	  curve	  with	  95%	  confidence	  band	  (r2=	  0.14;	  *p=0.03).	  
 
4.3.4.3	   MMP-­‐2	  
MMP-2 is a gelatinase with type IV collagenase activity that is able to digest collagen 
during extra-cellular matrix remodelling (see Section 1.7.3: Matrix metalloproteinases 
(MMP)-2, -3 and -9). MMP-2 is known to be expressed within the aortic wall (Singh et 
al., 2006) and has been shown to become elevated in the presence of aortic 
atherosclerotic disease (Koullias et al., 2004; Taketani et al., 2005; Sinha et al., 2006), 
and in genetic aortopathy, where it is substantially elevated in both MFS and BAV 
(Segura et al., 1998; Ikonomidis et al., 2006; Nataatmadja et al., 2006; Barbour et al., 
2007; Chung, A. W. et al., 2007; Schmoker et al., 2007; Ikonomidis et al., 2012; 
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Jackson et al., 2012). MMP-2 levels can also be measured within the circulation, 
however, the limited data that are available is contradictory, with reports that in 
atheromatous aneurysm disease MMP-2 may become slightly elevated (Lindholt et al., 
2000; Karapanagiotidis et al., 2009) or slightly reduced (Sangiorgi et al., 2006). No data 
are available for the levels of circulating MMP-2 in genetic thoracic aortopathy (see 
Section 1.7.3: Matrix metalloproteinases (MMP)-2, -3 and -9).  
Table 4.8 and Figure 4.2 shows the levels of circulating MMP-2 in MFS patients and 
controls. As discussed in Section 4.3.4.1: Estimation of normal range, the average 
control value we obtained (430.14 ± 18.85 ng/mL) was slightly above the normal range 
quoted by the manufacturer (R&D Systems) (155 – 323 ng/mL). The data show, that for 
our patient cohort, there is no significant difference between the control group and the 
MFS groups (all MFS patients group and the Surgical and Non-Surgical MFS patients 
groups considered individually) (Table 4.8). Notably, we can observe a trend towards a 
slightly higher MMP-2 level in MFS, but this trend is on average only approximately 
10% higher than controls. Thus, if a difference exists, these data suggest that it is small. 
With a larger sample size, it is possible that this trend could become significant.  
Additionally, the data show that for the most severe MFS group, the Surgical group, the 
average MMP-2 level is higher than both controls and the MFS non-surgical group (by 
approximately 13%), but is still not statistically significantly elevated, again probably 
because of the small sample size (15 patients).  
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MMP-2 (ng/mL) 
 Control ± SEM MFS ± SEM p 
Ctrl vs. MFS 430.14 ± 18.85; n=37 481.01 ± 24.77; n=52 0.11 
Ctrl vs. MFS-NS 430.14 ± 18.85; n=37 449.82 ± 19.54; n=37 0.47 
Ctrl vs. MFS-S 430.14 ± 18.85; n=37 557.94 ± 68.79; n=15 0.09 
 MFS-NS ± SEM MFS-S ± SEM p 
MFS-NS vs. MFS-S 449.82 ± 19.54; n=37 557.94 ± 68.79; n=15 0.15 
Table	  4.8	   Circulating	   MMP-­‐2	   level	   in	   MFS	   patients,	   stratified	   by	   gender,	  
compared	  to	  controls.	   	  
Circulating	  MMP-­‐2	   level	   (ng/mL)	   ±	   SEM.	   p	   values	   calculated	   by	   unpaired	   two	   tailed	  
t-­‐test	  using	  Welch’s	  correction.	  
 
 
Figure	  4.2	   MMP-­‐2	  levels	  (ng/mL)	  in	  Control,	  MFS,	  MFS-­‐NS	  and	  MFS-­‐S	  groups.	   	  
There	   were	   no	   significant	   differences	   between	   groups.	   Circulating	   MMP-­‐2	   level	  
(ng/mL)	   ±	   SEM.	   p	   values	   calculated	   by	   unpaired	   two	   tailed	   t-­‐test	   using	   Welch’s	  
correction.	  
 
A gender difference in the severity of MFS has been observed, where males have been 
shown to develop a more severe form of the disease (Gray et al., 1998). The cause of 
this gender difference is unknown. Consequently, we analysed the MMP-2 data 
stratified by gender. Table 4.9 – 4.11 show that there were no significant differences in 
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MMP-2 levels based on gender, within each patient group. However, a careful 
examination of the data reveals that in all cases, we can observe a trend towards a 
slightly higher MMP-2 level in males, but this trend is on average only approximately 
6% higher than females. Thus, if a difference in MMP-2 levels between genders exists, 
these data suggest that it is small. With a larger sample size, it is possible that this trend 
could become significant.  
Following stratification of patients on the basis of gender, we also examined whether 
any differences exist in circulating MMP-2 levels between controls from each gender 
and MFS patients from each gender. Surprisingly, Table 4.10 and Figure 4. 3 show that 
there was a weakly significant increase in MMP-2 levels in female surgical MFS 
patients compared to control females (Control female: 425.88 ± 23.75; MFS-S female: 
523.51 ± 34.86; p=0.04) and compared to non-surgical MFS patients (MFS-NS female: 
418.59 ± 24.87; MFS-S female: 523.51 ± 34.86; p=0.02). While not conclusive, these 
data provide some support for the possibility that on average MMP-2 levels may be 
slightly elevated in MFS patients compared to controls, if a sufficiently large sample 
size were examined. 
MMP-2 levels (ng/mL) 
Groups  Females ± SEM Males ± SEM p 
All (Controls + MFS) 443.68 ± 16.50; n=42 474.33 ± 27.77; n=47 0.35 
Control 425.90 ± 23.75; n=15 433.00 ± 27.70; n=22 0.19 
MFS 453.60 ± 22.10; n=27 510.70 ± 45.50; n=25 0.27 
MFS-NS 418.60 ± 24.87; n=18 479.40 ± 28.87; n=19 0.47 
MFS-S 523.50 ± 34.86; n=9 609.60 ± 171.20; n=6 0.64 
Table	  4.9	   Comparison	  of	  circulating	  MMP-­‐2	   levels	   in	  males	  and	   females	  among	  
different	  groups.	  
Circulating	  MMP-­‐2	   level	   (ng/mL)	   ±	   SEM.	   p	   values	   calculated	   by	   unpaired	   two	   tailed	  
t-­‐test	  using	  Welch’s	  correction.	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MMP-2 Females levels (ng/mL) 
Groups Control ± SEM MFS ± SEM p 
Ctl vs. MFS  425.88 ± 23.75; n=15 453.56 ± 22.10; n=27 0.40 
Ctl vs. MFS-NS 425.88 ± 23.75; n=15 418.59 ± 24.87; n=18 0.61 
Ctl vs. MFS-S 425.88 ± 23.75; n=15 523.51 ± 34.86; n=9 0.04 
 MFS-NS ± SEM MFS-S ± SEM  
MFS-NS vs. MFS-S 418.59 ± 24.87; n=18 523.51 ± 34.86; n=9 0.02 
Table	  4.10	   Comparison	  of	  MMP-­‐2	  in	  females	  among	  different	  groups.	  
Circulating	  MMP-­‐2	   level	   (ng/mL)	   ±	   SEM.	   p	   values	   calculated	   by	   unpaired	   two	   tailed	  
t-­‐test	  using	  Welch’s	  correction.	  
 
 
Figure	  4.3	   Comparison	  of	  circulating	  MMP-­‐2	  levels	  in	  females	  among	  Control	  and	  
MFS-­‐S	  groups	  (Left);	  MFS-­‐NS	  and	  MFS-­‐S	  groups	  (Right).	  
Circulating	  MMP-­‐2	   level	   (ng/mL)	   ±	   SEM.	   p	   values	   calculated	   by	   unpaired	   two	   tailed	  
t-­‐test	   using	   Welch’s	   correction.	   (Control	   vs.	   MFS-­‐NS:	   *	   p<0.05;	   MFS-­‐NS	   vs.	   MFS-­‐S:	  
*p<0.5)	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MMP-2 Males levels (ng/mL) 
Groups Control ± SEM MFS ± SEM p 
Ctl vs. MFS  433.00 ± 27.70; n=22 510.70 ± 45.50; n=25 0.15 
Ctl vs. MFS-NS 433.00 ± 27.70; n=22 479.40 ± 28.87; n=19 0.90 
Ctl vs. MFS-S 433.00 ± 27.70; n=22 609.60 ± 171.20; n=6 0.36 
 MFS-NS ± SEM MFS-S ± SEM p 
MFS-NS vs. MFS-S 479.40 ± 28.87; n=19 609.60 ± 171.20; n=6 0.49 
Table	  4.11	   Comparison	   of	   circulating	   MMP-­‐2	   levels	   in	   males	   among	   different	  
groups.	  
Circulating	  MMP-­‐2	   level	   (ng/mL)	   ±	   SEM.	   p	   values	   calculated	   by	   unpaired	   two	   tailed	  
t-­‐test	  using	  Welch’s	  correction.	  
 
Circulating MMP-2 levels were further analysed to determine whether there was any 
correlation between MMP-2 and measured clinical parameters, including those that are 
predictors of disease severity. The parameters considered were age, BSA, aortic 
diameter and Z-score (Table 4.12). To our surprise, we found a weak, but significant, 
correlation in the control group between circulating MMP-2 levels and age (r2=0.11; 
p=0.05, Figure 4.4), and between circulating MMP-2 levels and BSA (r2=0.13; p=0.03, 
Figure 4.4). There was no correlation between any other clinical parameters and 
circulating MMP-2 levels (Table 4.12) 
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MMP-2 Correlation Ctrl (r2) Ctrl (p) MFS-NS (r2) MFS-NS (p) 
Age (y) 0.11 0.05 0.01 0.68 
BSA (m2) 0.13 0.03 0.04 0.21 
Aortic diameter (mm) 0.02 0.44 <0.01 0.92 
Z-score 0.03 0.36 <0.01 0.58 
Table	  4.12	   Linear	   regression	  of	  MMP-­‐2	   levels	   vs.	  Age,	   BSA,	  Aortic	   diameter	   and	  
Z-­‐score	  in	  Control	  and	  MFS-­‐NS	  groups.	  
 
 
Figure	  4.4	   Circulating	  MMP-­‐2	  levels	  (ng/mL)	  as	  a	  results	  of	  Age	  (y)	  (Left)	  and	  BSA	  
(m2)	  (Right)	  in	  Control	  group.	  
Plot	  curve	  with	  95%	  confidence	  band.	  (Age:	  r2=0.11;	  *	  p=0.05;	  BSA:	  r2=0.13;	  *	  p<0.05)	  
 
In Males, MMP-2 is significantly associated with BSA in Control samples (p=0.05 
Table 4.13, Figure 4.5). 
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MMP-2 Correlation Males Ctrl (r2) Ctrl (p) MFS-NS (r2) MFS-NS (p) 
Age (y) 0.04 0.40 0.16 0.09 
BSA (m2) 0.20 0.05 0.01 0.68 
Aortic diameter (mm) 0.02 0.53 0.01 0.70 
Z-score 0.01 0.61 0.01 0.71 
Table	  4.13	   Linear	   regression	  of	  MMP-­‐2	   levels	   vs.	  Age,	   BSA,	  Aortic	   diameter	   and	  
Z-­‐score	  in	  males	  among	  Control,	  MFS-­‐NS	  and	  All	  groups.	  
 
 
Figure	  4.5	   Circulating	  MMP-­‐2	   levels	   (ng/mL)	   as	   a	   result	   of	   BSA	   (m2)	   in	   Control	  
Males	  group.	  
Plot	  curve	  with	  95%	  confidence	  band.	  (r2=0.20;	  *	  p=0.05)	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On the other hand, in Females MMP-2 was significantly correlated with age in the 
Control population (p=0.002; Table 4.14, Figure 4.6). 
MMP-2 Correlation Females Ctrl (r2) Ctrl (p) MFS-NS (r2) MFS-NS (p) 
Age 0.52 0.002 0.02 0.572 
BSA 0.04 0.501 0.01 0.760 
Aortic diameter <0.01 0.963 0.06 0.316 
Z-score 0.15 0.194 0.01 0.718 
Table	  4.14	   Linear	   regression	  of	  MMP-­‐2	   levels	   vs.	  Age,	   BSA,	  Aortic	   diameter	   and	  
Z-­‐score	  in	  females	  among	  Control	  and	  MFS-­‐NS	  groups.	  
 
 
Figure	  4.6	   Circulating	   MMP-­‐2	   levels	   (ng/mL)	   as	   a	   result	   of	   Age	   (y)	   in	   Control	  
Females	  group.	  
Plot	  curve	  with	  95%	  confidence	  band.	  (r2=0.52;	  **	  p<0.01)	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4.3.4.4	   MMP-­‐9	  
MMP-9 is a type IV collagenase matrix metalloproteinase that is able to digest collagen 
during extra-cellular matrix remodelling (see Section 1.7.3: Matrix metalloproteinases 
(MMP)-2, -3 and -9). MMP-9 is known to be expressed within the aortic wall 
(Schmoker et al., 2007) and has been shown to become substantially elevated in the 
presence of aortic atherosclerotic disease (Koullias et al., 2004; Taketani et al., 2005; 
Sinha et al., 2006; Botta, 2010), and in genetic aortopathy, where it is substantially 
elevated in both MFS and BAV (Segura et al., 1998; Boyum et al., 2004; Ikonomidis et 
al., 2006; Nataatmadja et al., 2006; Chung, A. W. et al., 2007; Schmoker et al., 2007; 
Ikonomidis et al., 2012; Jackson et al., 2012). MMP-9 levels can also be measured 
within the circulation and in atheromatous aneurysm disease MMP-9 becomes 
substantially elevated (Lindholt et al., 2000; Sangiorgi et al., 2006; Karapanagiotidis et 
al., 2009). No data are available for the levels of circulating MMP-9 in genetic thoracic 
aortopathy (see Section 1.7.3: Matrix metalloproteinases (MMP)-2, -3 and -9). 
Table 4.15 shows the levels of circulating MMP-9 in MFS patients and controls. As 
discussed in Section 4.3.4.1: Estimation of normal range, The average control value we 
obtained (117.14 ± 8.59 ng/mL) was at the upper limit of the normal range quoted by 
the manufacturer (R&D Systems) (13.2 – 105 ng/mL). The data show, that for our 
patient cohort, there is no significant difference between the control group and the MFS 
groups (all MFS patients group and the Surgical and Non-Surgical MFS patients groups 
considered individually) (Table 4.15). Additionally, no difference is seen between any 
of the groups when considered after stratification by gender (Table 4.16 – 4.18).  
Finally, when we examined whether MMP-9 correlated with any clinical parameters we 
found no correlation (Table 4.19). 
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MMP-9 levels (ng/mL) 
Groups Control ± SEM MFS ± SEM p 
Ctrl vs. MFS 117.16 ± 8.59; n=37 117.49 ± 11.70; n=52 0.98 
Ctrl vs. MFS-NS 117.16 ± 8.59; n=37 112.92 ± 13.74; n=37 0.80 
Ctrl vs. MFS-S 117.16 ± 8.59; n=37 128.76 ± 22.81; n=15 0.64 
 MFS-NS ± SEM MFS-S ± SEM p 
MFS-NS vs. MFS-S 112.92 ± 13.74; n=37 128.76 ± 22.81; n=15 0.56 
Table	  4.15	   Comparisons	  of	  MMP-­‐9	  levels	  in	  different	  groups.	  
Circulating	  MMP-­‐9	   level	   (ng/mL)	   ±	   SEM.	   p	   values	   calculated	   by	   unpaired	   two	   tailed	  
t-­‐test	  using	  Welch’s	  correction.	   	  
 
MMP-9 levels (ng/mL) 
Groups Females ± SEM Males ± SEM p 
All 122.56 ± 10.09; n=42 112.68 ± 11.46; n=47 0.52 
Control 128.04 ± 14.90; n=15 109.70 ± 10.26; n=22 0.32 
MFS 119.52 ± 13.49; n=27 115.30 ± 19.80; n=25 0.86 
MFS-NS 106.03 ± 10.86; n=18 119.45 ± 24.99; n=19 0.63 
MFS-S 146.51 ± 33.74; n=9 102.14 ± 25.97; n=6 0.32 
Table	  4.16	   Gender	  difference	  between	  different	  groups	  in	  MMP-­‐9	  levels.	  
Circulating	  MMP-­‐9	   level	   (ng/mL)	   ±	   SEM.	   p	   values	   calculated	   by	   unpaired	   two	   tailed	  
t-­‐test	  using	  Welch’s	  correction.	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MMP-9 Males levels (ng/mL) 
Groups Control ± SEM MFS ± SEM p 
Ctrl 109.70 ± 10.26; n=22 115.30 ± 19.80; n=25 0.80 
Ctl vs. MFS-NS 109.70 ± 10.26; n=22 119.45 ± 24.99; n=19 0.72 
Ctl vs. MFS-S 109.70 ± 10.26; n=22 102.14 ± 25.97; n=6 0.79 
 MFS-NS ± SEM MFS-S ± SEM p 
MFS-NS vs. MFS-S 119.45 ± 24.99; n=19 102.14 ± 25.97; n=6 0.64 
Table	  4.17	   Comparison	  of	  MMP-­‐9	  levels	  in	  males	  among	  Control	  and	  MFS	  groups	  
(including,	  MFS-­‐NS	  and	  MFS-­‐S	  groups).	  
Circulating	  MMP-­‐9	   level	   (ng/mL)	   ±	   SEM.	   p	   values	   calculated	   by	   unpaired	   two	   tailed	  
t-­‐test	  using	  Welch’s	  correction.	   	  
 
MMP-9 Females levels (ng/mL) 
Groups Control ± SEM MFS ± SEM p 
Ctl vs. MFS 128.04 ± 14.90; n=15 119.52 ± 13.49; n=27 0.67 
Ctl vs. MFS-NS 128.04 ± 14.90; n=15 106.03 ± 10.86; n=18 0.24 
Ctl vs. MFS-S 128.04 ± 14.90; n=15 146.51 ± 33.74; n=9 0.63 
 MFS-NS ± SEM MFS-S ± SEM p 
MFS-NS vs. MFS-S 106.03 ± 10.86; n=18 146.51 ± 33.74; n=9 0.28 
Table	  4.18	   Comparison	   of	   MMP-­‐9	   levels	   in	   females	   Control	   and	   MFS	   groups	  
(including,	  MFS-­‐NS	  and	  MFS-­‐S	  groups).	  
Circulating	  MMP-­‐9	   level	   (ng/mL)	   ±	   SEM.	   p	   values	   calculated	   by	   unpaired	   two	   tailed	  
t-­‐test	  using	  Welch’s	  correction.	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MMP-9 Correlation Ctrl (r2) Ctrl (p) MFS-NS (r2) MFS-NS (p) 
Age  <0.01 0.87 <0.01 0.98 
BSA 0.01 0.61 <0.01 0.76 
Aortic diameter 0.01 0.58 0.03 0.29 
Z-score 0.01 0.59 0.01 0.54 
Table	  4.19	   Linear	   regression	  of	  MMP-­‐9	   levels	   vs.	  Age,	   BSA,	  Aortic	   diameter	   and	  
Z-­‐score	  in	  Control	  and	  MFS-­‐NS	  groups.	  
 
4.3.4.5	   TIMP-­‐1	  and	  TIMP-­‐2	  
The expression and activity of MMPs within the vascular wall are regulated at several 
levels, including at transcription, post-translation and effector antagonism via 
endogenous tissue inhibitors (TIMPs) (see Section 1.7.5: Tissue Inhibitor of 
Metalloproteinases (TIMPs)). TIMP-1 and 2 have been implicated in aortic aneurysm 
formation (Barbour et al., 2007). All the TIMPs are able to inhibit all the MMPs to 
some extent, but TIMP-2 most effectively inhibits MMP-2 and TIMP-1 most effectively 
inhibits MMP-9 (Hidalgo et al., 2001). Thus, the ratios MMP-2:TIMP-2 and 
MMP-9:TIMP-1 may be indices of the balance of the proteolytic activity (Chung, A. W. 
et al., 2007). 
As discussed in Section 4.3.4.1: Estimation of normal range, The average control value 
we obtained (TIMP-1: 108.67 ± 5.98 ng/mL; TIMP-2: 90.51 ± 4.52 ng/mL) was in good 
agreement with the normal range quoted by the manufacturer (R&D Systems) (TIMP-1: 
44 – 304 ng/mL; TIMP-2: 19 – 254 ng/mL).  
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For TIMP-1, there was no significant difference seen between control and the various 
MFS patient groups (including after stratification by gender). However, a small, weakly 
significant increase was seen in TIMP-2 in MFS patients compared to controls (Control: 
90.51 ± 4.52; MFS: 102.95 ± 4.39; * p=0.05). Similarly, a weak increase in TIMP-2 
was seen in non-surgical MFS patients compared to controls (Control: 90.51 ± 4.52; 
MFS-NS: 105.51 ± 4.98; p=0.03).  
When clinical parameters were correlated with TIMP-1 levels, a weak but significant 
correlation was observed between TIMP-1 levels and age (r2=0.22; p=0.004) and 
between TIMP-1 levels and aortic diameter (r2=0.13; p=0.040). Notably, since these 
correlations are weak, their contribution to variance in TIMP-1 levels is likely to be 
minor. 
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TIMP-1 Control ± SEM MFS ± SEM p 
Ctrl vs. MFS 108.67 ± 5.98; n=37 119.09 ± 7.04; n=52 0.26 
Ctrl vs. MFS-NS 108.67 ± 5.98; n=37 117.95 ± 8.97; n=37 0.39 
Ctrl vs. MFS-S 108.67 ± 5.98; n=37 121.93 ± 10.70; n=15 0.29 
 MFS-NS MFS-S p 
MFS-NS vs. MFS-S 117.95 ± 8.97; n=37 121.93 ± 10.70; n=15 0.78 
    
TIMP-2 Control ± SEM MFS ± SEM p 
Ctrl vs. MFS 90.51 ± 4.52; n=37 102.95 ± 4.39; n=52 0.05 
Ctrl vs. MFS-NS 90.51 ± 4.52; n=37 105.51 ± 4.98; n=37 0.03 
Ctrl vs. MFS-S 90.51 ± 4.52; n=37 96.64 ± 9.06; n=15 0.55 
 MFS-NS ± SEM MFS-S ± SEM p 
MFS-NS vs. MFS-S 105.51 ± 4.98; n=37 96.64 ± 9.06; n=15 0.40 
Table	  4.20	   Comparisons	  of	  TIMP-­‐1	  and	  TIMP-­‐2	  in	  different	  groups.	  
Circulating	  TIMP-­‐1	  and	  TIMP-­‐2	   levels	  (ng/mL)	  ±	  SEM.	  p	  values	  calculated	  by	  unpaired	  
two	  tailed	  t-­‐test	  using	  Welch’s	  correction.	   	  	  
 
Figure	  4.7	   Comparison	  of	   circulating	   TIMP-­‐2	   levels	   (ng/mL)	   in	   Control	   and	  MFS,	  
MFS-­‐NS	  groups.	  
Circulating	   TIMP-­‐2	   levels	   (ng/mL)	   ±	   SEM.	   p	   values	   calculated	   by	   unpaired	   two	   tailed	  
t-­‐test	   using	   Welch’s	   correction.	   (Control	   vs.	   MFS:	   *	   p<0.05;	   Control	   vs.	   MFS-­‐NS:	  
*	  p=0.05)	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TIMP-1 
Female vs. Male Female ± SEM Male ± SEM p 
All 114.15 ± 6.86; n=42 115.30 ± 6.82; n=47 0.91 
Control 105.82 ± 9.22; n=15 110.62 ± 8.01; n=22 0.70 
MFS 118.78 ± 9.36; n=27 119.43 ± 10.80; n=25 0.96 
MFS-NS 118.65 ± 12.37; n=18 117.28 ± 13.29; n=19 0.94 
MFS-S 119.06 ± 14.27; n=9 126.23 ± 17.49; n=6 0.76 
    
TIMP-2 
Female vs. Male Female ± SEM Male ± SEM p 
All 92.75 ± 4.71; n=42 102.27 ± 4.38; n=47 0.14 
Control 82.27 ± 6.12; n=15 96.12 ± 6.18; n=22 0.12 
MFS 98.58 ± 6.28; n=27 107.68 ± 6.10; n=25 0.30 
MFS-NS 102.11 ± 7.80; n=18 108.73 ± 6.39; n=19 0.52 
MFS-S 91.51 ± 10.80; n=9 104.33 ± 16.59; n=6 0.53 
Table	  4.21	   Gender	   difference	   between	   different	   groups	   in	   TIMP-­‐1	   and	   TIMP-­‐2	  
levels.	  
Circulating	  TIMP-­‐1	  and	  TIMP-­‐2	   levels	  (ng/mL)	  ±	  SEM.	  p	  values	  calculated	  by	  unpaired	  
two	  tailed	  t-­‐test	  using	  Welch’s	  correction.	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TIMP-1 Males levels (ng/mL) 
Groups Control ± SEM MFS ± SEM p 
Ctl vs. MFS 110.62 ± 8.01; n=22 119.43 ± 10.80; n=25 0.52 
Ctl vs. MFS-NS 110.62 ± 8.01; n=22 117.28 ± 13.29; n=19 0.67 
Ctl vs. MFS-S 110.62 ± 8.01; n=22 126.23 ± 17.49; n=6 0.44 
 MFS-NS ± SEM MFS-S ± SEM p 
MFS-NS vs. MFS-S 117.28 ± 13.29; n=19 126.23 ± 17.49; n=6 0.69 
    
Groups Control ± SEM MFS ± SEM p 
Ctrl vs. MFS 96.12 ± 6.18; n=22 107.68 ± 6.10; n=25 0.19 
Ctrl vs. MFS-NS 96.12 ± 6.18; n=22 108.73 ± 6.39; n=19 0.16 
Ctrl vs. MFS-S 96.12 ± 6.18; n=22 104.33 ± 16.59; n=6 0.66 
 MFS-NS ± SEM MFS-S ± SEM p 
MFS-NS vs. MFS-S 108.73 ± 6.39; n=19 104.33 ± 16.59; n=6 0.81 
Table	  4.22	   Comparison	   of	   TIMP-­‐1	   levels	   in	   Males	   among	   Control	   and	   MFS-­‐NS	  
groups.	  
Circulating	  TIMP-­‐1	  and	  TIMP-­‐2	   levels	  (ng/mL)	  ±	  SEM.	  p	  values	  calculated	  by	  unpaired	  
two	  tailed	  t-­‐test	  using	  Welch’s	  correction.	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TIMP-1 Female levels (ng/mL) 
Groups Control ± SEM MFS ± SEM p 
Ctl vs. MFS 105.82 ± 9.22; n=15 118.78 ± 9.36; n=27 0.33 
Ctl vs. MFS-NS 105.82 ± 9.22; n=15 118.65 ± 12.37; n=18 0.41 
Ctl vs. MFS-S 105.82 ± 9.22; n=15 119.06 ± 14.27; n=9 0.45 
 MFS-NS ± SEM MFS-S ± SEM p 
MFS-NS vs. MFS-S 118.65 ± 12.37; n=18 119.06 ± 14.27; n=9 0.98 
    
Groups Control ± SEM MFS ± SEM p 
Ctrl vs. MFS 82.27 ± 6.12; n=15 98.58 ± 6.28; n=27 0.07 
Ctrl vs. MFS-NS 82.27 ± 6.12; n=15 102.11 ± 7.80; n=18 0.05 
Ctrl vs. MFS-S 82.27 ± 6.12; n=15 91.51 ± 10.80; n=9 0.47 
 MFS-NS ± SEM MFS-S ± SEM p 
MFS-NS vs. MFS-S 102.11 ± 7.80; n=18 91.51 ± 10.80; n=9 0.44 
Table	  4.23	   Comparison	   of	   TIMP-­‐1	   and	   TIMP-­‐2	   levels	   in	   Females	   among	   Control	  
and	  MFS-­‐NS	  groups.	  
Circulating	  TIMP-­‐1	  and	  TIMP-­‐2	   levels	  (ng/mL)	  ±	  SEM.	  p	  values	  calculated	  by	  unpaired	  
two	  tailed	  t-­‐test	  using	  Welch’s	  correction.	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TIMP-1 Correlation Ctrl (r2) Ctrl (p) MFS-NS (r2) MFS-NS (p) 
Age (y) 0.22 0.004 <0.01 0.764 
BSA (m2) <0.01 0.925 0.03 0.283 
Aortic diameter (mm) 0.13 0.040 0.02 0.456 
Z-score 0.06 0.173 <0.01 0.986 
     
TIMP-2 Correlation Ctrl (r2) Ctrl (p) MFS-NS (r2) MFS-NS (p) 
Age (y) 0.04 0.27 0.03 0.34 
BSA (m2) 0.02 0.41 0.01 0.53 
Aortic diameter (mm) <0.01 0.75 0.01 0.55 
Z-score <0.01 0.93 0.01 0.52 
Table	  4.24	   Linear	   regression	   of	   TIMP-­‐1	   levels	   vs.	   Age,	   BSA,	   Aortic	   diameter	   and	  
Z-­‐score	  in	  Control	  and	  MFS-­‐NS	  groups.	  
 
 
Figure	  4.8	   Circulating	  TIMP-­‐1	  levels	  (ng/mL)	  as	  a	  result	  of	  Age	  (y)	  (Left)	  and	  Aortic	  
diameter	  (mm)	  (Right)	  in	  Control	  group.	  
Plot	   curve	   with	   95%	   confidence	   band.	   (Ctrl	   Age:	   r2=0.22;	   **	   p<0.01;	   Ctrl	   Aortic	  
diameter:	  r2=0.13;	  *	  p<0.05)	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4.3.4.6	   Correlations	  between	  levels	  of	  circulating	  biomarkers	  
Circulating levels of TGF-β1, MMP-2, MMP-3, MMP-9, TIMP-1 and TIMP-2 were 
further analysed to determine whether there was any correlation between their 
respective levels in various groups: Control, MFS, MFS Non-surgical and MFS 
Surgical were analysed separately.  
Table 4.25 shows circulating MMP-3 levels significantly correlate with TGF-β1 levels 
in the Control group (r2=0.16, p=0.01; Figure 4.9); but MMP-3 does not correlate with 
TGF-β1 levels in the MFS group. Additionally, MMP-3 values correlate with MMP-2 
values in the MFS Non-surgical group (r2=0.24, p=0.002; Figure 4.9), but not in no 
other groups.  
In terms of circulating TGF-β1 levels in Table 4.26, Control TGF-β1 levels strongly 
correlate with TIMP-1 (r2=0.35, p=0.0001; Figure 4.10); while MFS No-surgical 
circulating TGF-β1 figures slightly but significantly associate with MMP-9 levels 
(r2=0.14, p=0.02; Figure 4.10). 
Finally, our data demonstrate that the MMP inhibitors TIMP-1 and TIMP-2 both rise in 
parallel (Table 4.27 – 4.28 and Figures 4.11 – 4.12). Thus, circulating TIMP-1 levels 
consistently and significantly correlate with circulating TIMP-2 levels in every single 
group listed in the table (both controls and MFS).  
Notably, the ratios of MMP-2:TIMP-2 and MMP-9:TIMP-1 have been used to assess 
MMP activity (Chung, A. W. et al., 2007). There was no significant difference in these 
ratios between Controls and MFS groups. 
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 Ctrl  MMP-3 (r2) 
Ctrl  
MMP-3 (p) 
MFS  
MMP-3 (r2) 
MFS  
MMP-3 (p) 
MFS-NS MMP-3 
(r2) 
MFS-NS 
MMP-3 (p) 
MFS-S 
MMP-3 (r2) 
MFS-S 
MMP-3 (p) 
TGF-β1 0.16 0.01 0.06 0.09 0.03 0.26 0.02 0.67 
MMP-2 0.07 0.11 <0.01 0.76 0.24 0.002 0.14 0.16 
MMP-9 0.04 0.25 0.02 0.36 0.02 0.46 0.03 0.57 
TIMP-1 <0.01 0.98 <0.01 0.70 <0.01 0.92 0.02 0.60 
TIMP-2 0.01 0.48 0.02 0.37 0.03 0.30 <0.01 0.79 
Table	  4.25	   Correlations	  between	  circulating	  MMP-­‐3	  levels	  (ng/mL)	  and	  other	  biomarkers.	  
 
Figure	  4.9	   Correlations	  between	  circulating	  MMP-­‐3	  levels	  (ng/mL)	  and	  TGF-­‐β1	  and	  MMP-­‐2	  levels.	  
(Left)	  TGF-­‐β1	  levels	  in	  Control	  group;	  (Middle)	  MFS	  Surgical	  group	  and	  (Right)	  MFS	  No-­‐surgical	  MMP-­‐2	  levels.	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 Ctrl TGF-β1 (r2) 
Ctrl 
TGF-β1 (p) 
MFS 
TGF-β1 (r2) 
MFS 
TGF-β1 (p) 
MFS-NS 
TGF-β1 (r2) 
MFS-NS 
TGF-β1 (p) 
MFS-S 
TGF-β1 (r2) 
MFS-S 
TGF-β1 (p) 
MMP-2 <0.01 0.73 <0.01 0.88 <0.01 0.84 0.03 0.57 
MMP-9 0.06 0.15 <0.01 0.71 0.14 0.02 0.11 0.22 
TIMP-1 0.35 0.0001 0.04 0.15 0.07 0.11 0.03 0.53 
TIMP-2 0.03 0.35 <0.01 0.86 <0.01 0.70 0.04 0.45 
Table	  4.26	   Correlations	  between	  circulating	  TGF-­‐β1	  levels	  (ng/mL)	  and	  other	  biomarkers.	  
 
Figure	  4.10	   Correlations	  between	  circulating	  TGF-­‐β1	  levels	  (ng/mL)	  and	  TIMP-­‐1	  and	  MMP-­‐9	  levels.	  
(Left)	  Circulating	  TGF-­‐β1	  levels	  correlate	  with	  TIMP-­‐1	  levels	  in	  Control	  group	  and	  (Right)	  MMP-­‐9	  levels	  in	  MFS	  No-­‐surgical	  group.	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 Ctrl TIMP-1 (r2) 
Ctrl 
TIMP-1 (p) 
MFS 
TIMP-1 (r2) 
MFS 
TIMP-1 (p) 
MFS-NS 
TIMP-1 (r2) 
MFS-NS 
TIMP-1 (p) 
MFS-S 
TIMP-1 (r2) 
MFS-S 
TIMP-1 (p) 
TIMP-2 0.16 0.01 0.43 < 0.0001 0.44 < 0.0001 0.52 0.0024 
Table	  4.27	   Correlations	  between	  circulating	  TIMP-­‐1	  levels	  (ng/mL)	  and	  TIMP-­‐2	  levels.	  
 
 
Figure	  4.11	   Correlations	  between	  circulating	  TIMP-­‐1	  levels	  (ng/mL)	  and	  TIMP-­‐2	  levels	  in	  both	  Control	  and	  MFS	  groups.	  
(Left)	  Circulating	  TIMP-­‐1	  levels	  correlate	  with	  TIMP-­‐2	  levels	  in	  Control	  group	  and	  (Right)	  Circulating	  TIMP-­‐1	  levels	  correlate	  with	  TIMP-­‐2	  levels	  
in	  MFS	  group.	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 Ctrl TIMP-1 (r2) 
Ctrl 
TIMP-1 (p) 
MFS 
TIMP-1 (r2) 
MFS 
TIMP-1 (p) 
MFS-NS 
TIMP-1 (r2) 
MFS-NS 
TIMP-1 (p) 
MFS-S 
TIMP-1 (r2) 
MFS-S 
TIMP-1 (p) 
TIMP-2 0.16 0.01 0.43 < 0.0001 0.44 < 0.0001 0.52 0.0024 
Table	  4.28	   Correlations	  between	  circulating	  TIMP-­‐1	  levels	  (ng/mL)	  and	  TIMP-­‐2	  levels.	  
 
Figure	  4.12	   Correlations	  between	  circulating	  TIMP-­‐1	  levels	  (ng/mL)	  and	  TIMP-­‐2	  levels	  in	  both	  MFS	  no-­‐surgical	  and	  MFS	  surgical	  groups.	  
(Left)	   Circulating	   TIMP-­‐1	   levels	   correlate	   with	   TIMP-­‐2	   levels	   in	  MFS	   no-­‐surgical	   group	   and	   (Right)	   Circulating	   TIMP-­‐1	   levels	   correlate	   with	  
TIMP-­‐2	  levels	  in	  MFS	  surgical	  group.	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4.4	   Discussion	  
We have examined a series of circulating biomarkers relevant to vascular disease to 
determine whether any of these biomarkers correlated with various aspects of MFS 
disease. Specifically, we sought to determine whether any of these biomarkers may be 
useful for diagnosis, or for the prediction of severity of the disease, which in turn would 
be useful for determining prognosis, particularly with respect to predicting increased 
risk of aortic aneurysm dissection. The biomarkers we examined were TGF-β1, 
MMP-2, -3, -9 and TIMP-1 and -2. 
Overall, of the biomarkers examined in this Chapter, the results of this study found that 
none of these biomarkers possessed encouraging clinical utility. For all of these 
biomarkers studied within this Chapter, either no significant differences, or barely 
significant differences, were observed for a range of parameters. The major limitation of 
this study was the relatively small number of participants, which may have masked 
significant differences between controls and MFS patients for these biomarkers.  
Although no significant differences were seen in MFS patients compared to controls for 
the biomarkers studied in this Chapter, a consistent trend was observed for several 
biomarkers towards higher levels in MFS patients compared to controls. Specifically, 
data for TGF-β1 (trend), MMP-2 (overall trend, plus weakly significant difference in 
female surgical MFS patients compared to controls) and TIMP-2 (weakly significant 
difference) support the possibility that these biomarkers may be slightly elevated in 
MFS compared to controls. Notably, although trends were observed for these 
biomarkers, the differences were always small (~10% increase). Thus, any real 
differences for these biomarkers are unlikely to be of substantial clinical significance 
for diagnostic or prognostic purposes.  
Conversely, MMP-9 and TIMP-1 did not show any trend towards a difference between 
controls and MFS patients. 
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The known gender difference in MFS severity (Brown et al., 1975) led us to stratify our 
patients by gender. We observed a strong gender difference in MMP-3 levels, as 
discussed in Chapter 3. However, a careful examination of the data also suggested a 
trend towards a minor gender difference in MMP-2, where MMP-2 levels trended 
towards being higher in males. 
In the case of all the biomarkers investigated in this Chapter, we evaluated whether 
circulating biomarker levels correlated with the clinical parameters of age, BSA, aortic 
diameter and Z-score. We observed the following correlations: 
1. TGF-β1 levels were found to increase with age in control subjects 
2. MMP-2 levels were found to increase with both age and BSA in the control group, 
with control males correlating best with BSA, while control females correlated best 
with age 
3. TIMP-1 was found to increase with both age and aortic diameter in controls 
 
4.4.1	   TGF-­‐β1	  as	  a	  biomarker	  of	  MFS	  
Our data show that there is no difference in the level of circulating TGF-β1 in MFS 
patients compared to controls. However, a consistent, small, non-significant trend 
towards higher levels was observed across all MFS patient groups, compared to 
controls, but this trend was small, and, even if real, may be of limited clinical 
significance. It is possible that this trend may become significant if a larger number of 
patients had been recruited.  
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There are several reports in the literature concerning changes in TGF-β1 in patients with 
MFS compared to controls. A very recent study, published while this thesis was being 
written, also failed to find a difference in circulating TGF-β1 levels (Ogawa et al., 
2013). Indeed, Ogawa’s data very closely agreeing with ours (Table 4.29). On the other 
hand, two studies have observed an elevation in circulating TGF-β1 levels in both 
humans with MFS (Matt et al., 2008; Franken et al., 2013) and a mouse model of MFS 
(Ng et al., 2004; Matt et al., 2009)(Table 4.29).  
 Normal (ng/mL) Pathological (ng/mL) Disease Reference 
TGF-β1  1.17 ± 0.33 1.31 ± 0.40 MFS (Ogawa et al., 
2013) 
TGF-β1  1.17 ± 0.33 1.24 ± 0.37 Untreated MFS (Ogawa et al., 2013) 
TGF-β1  1.17 ± 0.33 1.46 ± 0.45 Treated MFS (Ogawa et al., 2013) 
TGF-β1 2.50 ± 0.40 15.00 ± 1.70 MFS (Matt et al., 2009) 
TGF-β1 0.05 ± 0.01 0.19 ± 0.01 MFS (Franken et al., 2013) 
TGF-β1 1.24 ± 0.10 1.37 ± 1.09 MFS This thesis 
TGF-β1 1.24 ± 0.10 1.22 ± 0.85 MFS-NS This thesis 
TGF-β1 1.24 ± 0.10 1.76 ± 0.30 MFS-S This thesis 
Table	  4.29	   Comparison	  of	  data	  from	  various	  studies	  
 
A possible explanation for the differences observed in the study by Matt (Matt et al., 
2008) may reside in the preparation of the samples analysed. As discussed in the 
methods section (see Sections 2.3: Collection and storage of blood), it is necessary to 
remove platelets from the plasma prior to storage and analysis, to prevent TGF-β release 
from cytoplasmic granules in the platelets. Notably, the methods described in the Matt 
et al. (2008, 2009) make it clear that this was not done for their study. Furthermore, the 
control values obtained by Matt et al. (2008, 2009) were over six fold higher than those 
obtained by both us and the Ogawa group (Ogawa et al., 2013). Taken together, these 
factors suggest that the accuracy of the measurements made by Matt et al. (2008, 2009) 
are questionable.  
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The easily observed high levels of circulating TGF-β in the mouse model of MFS, also 
observed by Matt (Matt et al., 2009) may reflect differences between the mouse model 
and humans, particularly since the mouse model may be considered an accelerated form 
of aneurysm development. In such a relatively severe form of MFS disease seen in the 
mouse model, pathological signalling may be more pronounced, where this signalling 
occurs against a pure genetic background, compared to humans. These differences in 
pathogenesis may partially explain the clear and obvious increase in circulating TGF-β 
levels that were observed in the mouse compared to our data in humans. 
While this thesis was being written, a paper was published by Franken et al. (2013) that 
found that TGF-β1 levels were significantly elevated, with a rise of approximately four 
fold (Table 4.28). However, their values are quite different to ours and those of the 
Ogawa group (Table 4.28), with controls being 20-fold lower and the MFS level being 
5-fold lower. The reasons for these differences in control values are unknown, but we 
note that a different ELISA assay (Bio-Rad) was used, whose normal range is reported 
by the manufacturer to be approximately half of ours.  
On the other hand, the data obtained by Franken et al. (2013) showed that the 
circulating level of TGF-β1 increased four-fold in MFS patients, and the level in MFS 
patients also correlated with aortic diameter and prospective event curves. The latter 
correlations would argue that the data obtained by Franken et al. (2013), using a 
different, and possibly more sensitive, ELISA assay, is a more accurate picture of the 
dynamics of the release of TGF-β1 into the circulation in MFS patients. In future work, 
we plan to more closely evaluate the use of the Bio-Rad ELISA assay for TGF-β1. 
Notably, using our own ELISA assay from R&D Systems, we did see a trend towards a 
rise in TGF-β1 in MFS patients, but if real that trend was small (~10%). 
An interesting but minor observation that emerged from our data was a weak 
association between circulating TGF-β1 levels and age, with TGF-β1 levels rising with 
age. Two recent papers that examined changes in TGF-β activity with increasing age 
have failed to observe an increase in TGF-β levels during aging. However, both papers 
noted an increased sensitivity to TGF-β signalling at the cellular level as the cellular 
tissue aged (van der Kraan et al., 2012; Yu et al., 2013). An additional factor that may 
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contribute to the increased level of circulating TGF-β1 as a function of age may be 
alterations in the ECM, particularly the increased fibrosis that often accompanies aging. 
This could in turn result in decreased availability of sites for sequestration of TGF-β1.  
Finally, the overall evidence for an abnormality in TGF-β signalling being an important 
element in MFS pathogenesis is now well established (Pardali et al., 2012). Our 
observation of a small, non-significant trend towards slightly higher circulating levels of 
TGF-β1 (~10%) in MFS patients is consistent with that proposed pathogenesis. 
Similarly, the very recent paper by Franken (Franken et al., 2013), in which a 
significant 4-fold rise in TGF-β1 was observed in MFS patients is also consistent with 
the importance of TGF-β1 signalling in the pathogenesis of MFS.  
 
4.4.2	   MMP-­‐2	  and	  MMP-­‐9	  
MMP-2 and MMP-9 are both gelatinases and are closely related. In both cases, no 
correlation was seen with MFS, although a possible trend towards slightly elevated 
circulating MMP-2 was observed, supported by a weakly significant elevation in 
MMP-2 in non-surgical females compared to control females. No trend was observed 
for MMP-9. 
The probable rise in circulating MMP-2 levels in MFS patients is consistent with 
previous data, since MMP-2 has been shown to be increased in the aortic tissue of 
patients in two forms of genetic aortopathy, MFS and BAV (LeMaire et al., 2005). On 
the other hand, MMP-2 has been reported to increase slightly in the tissue of 
atheromatous disease, but has been report to both increase slightly and decrease slightly 
in the circulation in patients atherosclerosis by various groups (Ikonomidis et al., 2006; 
Karapanagiotidis et al., 2009). The circulating levels of MMP-2 in genetic aortopathy 
have not been measured. The small rise in MMP-2 observed in this study is likely to be 
of minimal clinical diagnostic significance.  
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MMP-9 is known to rise dramatically in atheromatous aortic aneurysm disease, and to 
be a major participant in its pathophysiology (Ikonomidis et al., 2006; Karapanagiotidis 
et al., 2009). Additionally, previous groups have reported that MMP-9 is elevated 
within the aortic tissue of patients with MFS and BAV (Ikonomidis et al., 2006), but not 
to the same extent as in atheromatous disease. On the other hand, others have reported 
no change in MMP-9 in genetic aortopathy tissue (LeMaire et al., 2005). The papers 
that reported a rise in MMP-9 in genetic aortopathy tissue measured MMP-9 using a 
wide range of methodologies, including RT-PCR analysis of mRNA levels, 
immunohistological analysis and tissue ELISA (LeMaire et al., 2005). Our study 
observed no change in levels of circulating MMP-9 in MFS, even as a non-significant 
trend, consistent with the likelihood that MMP-9 levels are not dramatically increased in 
genetic aortopathy tissue.  
Furthermore, LeMaire and colleagues (2005) proposed the hypothesis that MMP-9 and 
MMP-2 levels in diseased aortic wall tissue appear to be inversely correlated with each 
other, such that when significant inflammation is present in the aortic wall (for example, 
associated with atherosclerotic aneurysmal disease) MMP-9 is high, while MMP-2 is 
close to normal. Conversely, in genetic aortopathy (in this case BAV), where minimal 
inflammation is present in the aortic wall, MMP-2 is likely to be elevated, while 
MMP-9 is close to normal. These data are at least partially consistent with our 
observations, since we observed no change in circulating MMP-9 levels in MFS, but a 
trend towards a slight rise in circulating MMP-2 (weakly significant for MFS surgical 
females compared to controls). 
A weakly significant correlation between circulating MMP-2 and both age and BSA 
was observed. The mechanism underlying this correlation is unclear, although in the 
case of age, the increased stiffness of the aorta with age may reflect increased wall 
stress, which may, in turn, result in increased MMP-2 activity. In the case of BSA, a 
trend towards higher levels of MMP-2 in males compared to females was observed, and, 
if true, would be consistent with the observed correlation between higher MMP-2 levels 
and BSA, since, on average, males have a higher BSA than females.  
 
Chapter	  4	  –	  Additional	  Biomarkers	  
Yaxin	  Lu	   	   	   August	  2013	  
163	  
4.4.3	   TIMP-­‐1	  and	  TIMP-­‐2	  
Our data show that circulating levels of TIMP-1 and TIMP-2 also do not change 
significantly in MFS compared to controls. However, our data do suggest a trend 
towards a slight increase in TIMP-1, although this change is small and does not reach 
significance. LeMaire and colleagues (2005) measured TIMP-1 and TIMP-2 levels in 
the wall of aortic aneurysms associated with BAV and found no change in their levels.  
 
4.4.4	   Correlations	  between	  levels	  of	  biomarker	  expression	  
Although few associations between levels of circulating biomarkers and MFS have been 
demonstrated (except for MMP-3, described in Chapter 3), our data have demonstrated 
a number of interesting correlations between individual biomarker levels. The following 
correlations were observed: 
A strong correlation was observed between TGF-β1 and MMP-3, but only in the control 
group. The level of MMP-3 was lower in patients who had higher TGF-β1 levels. As 
discussed in Chapter 3, MMP-3 levels were lower in MFS patients, compared to 
controls, raising the possibility that elevated TGF-β1 levels may involved in negatively 
regulating the level of MMP-3. To our knowledge, this possibility has not been 
previously published in the literature and is an intriguing area for future research. 
A paradoxical correlation was observed between MMP-2 and MMP-3 in MFS 
non-surgical patients. Elevated levels of MMP-2 correlated with elevated levels of 
MMP-3. This result is paradoxical in the sense that, based on our data in Chapter 3, 
MMP-3 levels are expected to fall in MFS patients, where MMP-2 are more likely to 
rise (see Section 4.3.4.3: MMP-2). We are unaware of an explanation for this 
correlation. 
A strong correlation was observed between circulating TGF-β1 levels and TIMP-1 
levels in control subjects. TIMP-1 levels were elevated in subjects who had higher 
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TGF-β1 levels. A possible explanation for this observation is that TGF-β1 is believed to 
increase the expression of MMPs (Cheon et al., 2002) and TIMP expression usually 
increases in parallel with MMP expression, to maintain tight regulation of MMP 
activity (Webb et al., 1997). 
A weak correlation was observed between circulating TGF-β1 levels and MMP-9 levels 
in MFS non-surgical patients. MMP-9 levels were elevated in patients who had higher 
TGF-β1 levels. A possible explanation for this observation is that TGF-β1 is believed to 
increase the expression of MMPs (Cheon et al., 2002).  
Finally, circulating levels of TIMP-1 correlated strongly with TIMP-2 levels in all 
groups (controls and MFS). This result is consistent with the hypothesis that TIMP-1 
and TIMP-2 are regulated at least partly by the same signalling processes. 
 
4.5	   Conclusions	  
Our data have shown that the levels of circulating TGF-β1, MMP-2, MMP-9, TIMP-1 
and TIMP-2 were not significantly different between controls and MFS patients. On the 
other hand, a number of weak but significant correlations were seen between 
biomarkers, and with some demographic measurements, suggesting the possibility that 
when measured in combination, these biomarkers may have some clinical utility. Thus, 
based on our data, these biomarkers, when used in isolation, are unlikely to be effective 
biomarkers for the diagnosis of thoracic aortopathy. Additionally, these biomarkers may 
have some therapeutic use when serial measurements are taken to monitor response to 
therapy. Testing of this latter possibility was beyond the scope of this thesis.  
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Chapter	  5	  
ACE	  polymorphism	  
 
5.1	   ACE	  polymorphism	  
The ACE polymorphism was first discovered by Rigat et al., who concluded that it 
accounted for approximately half of the total variance in serum ACE levels (Rigat et al., 
1990). Since then, it has been the subject of much excitement and controversy.  
The angiotensin-converting enzyme (ACE) is part of the renin-angiotensin system 
(RAS) (see Figure 1.29: Overview of the RAS system), which is a major cardiovascular 
regulatory system (Kennon et al., 1999). It has been suggested to be crucial in the 
development of both abdominal aortic aneurysms (AAAs) and TAAs. (Lu et al., 2008) 
Genetic variability in the RAS might, thus, plays a role in the development of TAAs, 
and determination of the genotype may allow individualized assessment of patients at 
risk of acute aortic syndromes. Recent studies have shown that the 
angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism represents 
a marker of increased susceptibility to AAAs (Yeung et al., 2002) (Fatini et al., 2005) 
(Lucarini et al., 2009). 
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Two studies have investigated the association of the I/D polymorphism of the ACE 
gene with thoracic aortic aneurysm (TAA) in patients with either non-Marfan’s 
syndrome-related diseases (Lesauskaite et al., 2011), or an aortic valve abnormality 
(Foffa et al., 2012), revealing that the D allele of the ACE gene conferred a risk of 
TAA. Consequently, this study aimed to determine whether the ACE I/D polymorphism 
genotype exhibited a correlation with the disease phenotype in patients with MFS, with 
the expectation that the DD phenotype could result in a more severe phenotype. 
5.2	   Materials	  and	  Methods	   	  
5.2.1	   Subjects	  
The controls and MFS patients that were genotyped were described in Chapter 3 (see 
Section 3.2.1: Subjects). Briefly, 37 controls and 52 MFS patients were genotyped. 
 
5.2.2	   Detection	  of	  the	  ACE	  polymorphism	  
Genomic DNA was extracted from the buffy coat of peripheral blood monocytes, that 
had been purified by Ficoll gradient centrifugation, using the QIAGEN QIAamp DNA 
mini kit. The purity of the genomic DNA was assessed spectrophotometrically using a 
Nanodrop UV/Vis spectrometer. DNA was considered to be of sufficient purity if the 
260/280 nm ratio was 1.7-2.0. 
The extracted DNA was genotyped via the triple primer method, which has been found 
to be the most accurate procedure in genotyping the ACE I/D polymorphism (Rigat et 
al., 1990; Ueda et al., 1996). The 3 primers used were:  
ACE 1: 5'-CAT CCT TTC TCC CAT TTC TC-3' 
ACE 2: 5'-TGG GAT TAC GG CGT GAT ACA G-3 
ACE 3: 5'-ATT TCA GAG CTG GAA TAA AAT T-3' 
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ACE 1 is a forward primer that anneals downstream of the insertion sequence; ACE 2 is 
a forward primer that anneals at the junction between the insertion sequence and the 
upstream sequence, while ACE 3 is a reverse primer that binds upstream of the insertion 
sequence (Figure 5.1). When only the insert is present (i.e. the genotype is II) ACE 1, 2 
and 3 can bind, thus producing a 65 bp and 302 bp product. When the insert is not 
present (i.e. the genotype if DD) then the ACE2 forward primer can not bind, and only 
the 84 bp product of ACE 1/3 is produced. If the patient is heterozygous (ID genotype) 
then all 3 bands can be produced. This is shown schematically in Figure 5.1. Standard 
PCR reaction was performed and involved 35 cycles of extension (Rigat et al., 1990). 
 
Figure	  5.1	   Detection	  of	  the	  ACE	  polymorphism	  using	  the	  triple	  primer	  method.	   	  
P1	  and	  P2	  are	  forward	  primers,	  P3	  is	  the	  reverse	  primer.	  If	  the	  insert	  is	  not	  present,	  P2	  
cannot	  bind	  and	  this	  yields	  a	  product	  of	  84	  bp.	  If	  the	  insert	  is	  present,	  both	  P1	  and	  P2	  
bind	  in	  the	  forward	  direction,	  yielding	  products	  of	  65	  bp	  (plus	  302	  bp’s;	  not	  depicted	  
here)	  (Rigat	  et	  al.,	  1990).	  
 
Figure	  5.2	   Partial	  sequence	  of	  the	  ACE	  gene	  (total	  1856	  bases	  long).	   	  
The	  insert	   is	  underlined	  (for	  our	  studies),	  and	  the	  respective	  primers	  used	  have	  been	  
colour	  coded:	  ACE1	  forward	  primer,	  ACE2	  forward	  primer,	  ACE3	  reverse	  primer	  is	  the	  
complimentary	  sequence	  of	  this	  sequence.	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5.2.3	   DNA	  polymerise	  gel	  
The size of the PCR fragments generated were determined via 6% polyacrylamide gel 
electrophoresis, followed by staining with GelRed (Figure 5.3). An example of a typical 
gel is shown in Figure 5.4. 
1) Set up gel plates for pouring. 
2) Prepare a 30% acrylamide gel (separating gel ) by mixed the following reagents: 
Reagent Volume 
29:1 acrylamide/bisacrylamide 2 mL 
10×TBE buffer 1 mL 
dH2O 6 mL 
3) Add 100 µL 10% APS and 10 µL TEMED to polymerise the acrylamide.  
4) POUR IMMEDIATELY. 
5) Allow gel to polymerise completely (about 30 min).  
6) Prepare samples for loading: add 1 µL 5×sample buffer to 4 µL PCR sample. 
7) Load 2 µL Hyperladder V and 5 µL of prepared samples into the wells of the gel 
using a sterile pipette tip. 
8) Run gel at 60 V for about 60 min (or until the orange dye front is close to the 
bottom of the gel). 
9) Disassemble gel plates and stain in TBE buffer with Gel Red for about 1 – 2 min. 
10) Rinse gel in dH2O and view under UV light. Photograph. 
11) The gel is visualised by placing on a Syngene G:Box Chemi HR16 Bioimaging 
system emitting UV light at a wavelength of 302 nm. When photographing, place a 
fluorescent ruler next to the gel so that measurements can be accurately made from 
the photograph. 
12) GeneSys software on the gel documentation computer can be used to estimate the 
molecular weight of the fragments. 
Figure	  5.3	   Protocol	  for	  PAGE	  detection	  of	  PCR	  fragment.	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Figure	  5.4	   A	  photographed	  gel	  sample	  of	  ACE	  polymorphism	  genotype.	   	  
The	   insertion	  (I)	  allele	   is	  demonstrated	  by	  the	  65	  bp	  and	  302	  bp	  bands.	  The	  deletion	  
(D)	  allele	  is	  represented	  by	  the	  84	  bp	  band.	  
 
5.2.4	   Statistical	  Analysis	  
The GraphPad Prism Version 6 (GraphPad Software, Inc. USA) was used to analyse the 
data and graph the data obtained. Data were expressed as averages with standard errors 
of the mean. Statistical significance was determined using unpaired two tailed t-test 
with Welch’s correlation. Results were considered to be significant if p<0.05. 
Differences in noncontinuous variables were tested by chi-square (χ2) analysis (and 
Fisher’s exact test with a two tailed p value), and the odds ratios (ORs) and 95% 
confidence intervals (CIs) were determined. 
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5.3	   Results	  
5.3.1	   Allelic	   and	   genotypic	   distributions	   in	   MFS	   patients	  
compared	  to	  controls	  
The distributions of the I and D alleles and the ACE genotypes are given in Table 5.1 
and Figure 5.5. The distributions of the II, ID and DD alleles and the ACE genotypes 
are given in Table 5.3 and Figure 5.6. There was no significant difference observed 
between the allele distributions when the control allele distribution was compared to the 
MFS allele distribution (χ2=0.32, 1 df, p=0.57) (Table 5.2). The odds ratio for this result 
was 0.84 with the 95% confidence interval being 0.46-1.54.  
No differences were observed in the allelic distributions when the MFS patients were 
stratified by disease severity (MFS-surgical, more severe; MFS-non-surgical, less 
severe). For MFS-non-surgical versus MFS-surgical, χ2=0.25 (1 df, p=0.62) (Table 5.2), 
with an odds ratio of 0.80 and 95% confidence interval of 0.34-1.88.  
Groups I (n) I (%) D (n) D (%) 
Control 31 41.9 43 58.1 
MFS 48 46.2 56 53.9 
MFS-NS 33 44.6 41 55.4 
MFS-S 15 50.0 15 50.0 
Table	  5.1	   Distribution	   of	   allelic	   frequencies	   in	   MFS	   patients	   compared	   to	  
controls.	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Figure	  5.5	   Distribution	   of	   allelic	   frequencies	   in	   MFS	   patients	   compared	   to	  
controls.	  
 
Groups χ2 Degrees of freedom p Odds ratio 
95% 
confidence interval 
Ctl vs MFS 0.32 1 0.57 0.84 0.46 to 1.54 
MFS-NS vs MFS-S 0.25 1 0.62 0.80 0.34 to 1.88 
Ctl vs MFS-NS 0.11 1 0.74 0.90 0.47 to 1.72 
Ctl vs MFS-S 0.57 1 0.45 0.72 0.31 to 1.69 
Table	  5.2	   Significance	  of	  allelic	  frequencies	  in	  MFS	  compared	  to	  controls	  
 
Similarly, no significant difference was observed in the genotypic distributions between 
the controls and the MFS patients (χ2=0.38, 2 df, p=0.83) (Table 5.4). When the MFS 
patients were stratified by disease severity, there was also no difference in the genotypic 
distribution (Table 5.4).  
 
Genotypic frequencies in both MFS patients and controls were in Hardy-Weinberg 
equilibrium, making selection bias less likely. 
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 II (n) II (%) ID (n) ID (%) DD (n) DD (%) 
Control 6 16.2 19 51.4 12 32.4 
MFS-NS 7 18.9 19 51.4 11 29.7 
MFS-S 4 26.7 7 46.6 4 26.7 
MFS 11 21.2 26 50 15 28.8 
Table	  5.3	   Distribution	  of	  genotypic	  frequencies	  in	  MFS	  compared	  to	  controls.	  
 
 
Figure	  5.6	   Distribution	  of	  genotypic	  frequencies	  in	  MFS	  compared	  to	  controls.	  
 
Groups χ2 Degrees of freedom p 
Ctl vs MFS 0.38 2 0.83 
MFS-NS vs MFS-S 0.38 2 0.83 
Ctl vs MFS-NS 0.12 2 0.94 
Ctl vs MFS-S 0.77 2 0.68 
Table	  5.4	   Significance	  of	  genotypic	  frequencies	  in	  MFS	  compared	  to	  controls.	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5.3.2	   Correlation	  of	  genotype	  with	  potential	  biomarkers	  of	  MFS	  
To determine whether the genotype of the subjects in this study influenced the level of 
circulating biomarkers investigated in Chapter 3 and 4, we compared the levels of these 
biomarkers as a function of genotype.  
 
5.3.2.1	   Comparison	  of	  circulating	  biomarker	  levels	  between	  control	  and	  MFS	  
patients	  as	  a	  function	  of	  genotype	  
Table 5.5 A, B, C compares the circulating levels of six biomarkers in MFS patients 
versus controls, stratified by genotype (II, ID and DD). Only two significant differences 
were observed.  
There was a significant difference between MFS patients and controls in the level of 
circulating MMP-3 in the ID group, but no difference in the II or DD groups. This result 
was expected, since we observed a significant difference in MMP-3 levels between 
controls and MFS patients overall, before stratification by genotype (see Section 
3.3.4.3: Circulating MMP-3 is reduced in MFS patients). The ID groups are the largest 
groups (Control: n=19; MFS: n=26; Table 5.5 B) compared to the DD and II groups that 
are approximately half the size of the ID groups. Thus, the numbers in the DD and II 
groups were probably too small to reach significance. 
Our data also show a significant difference between MMP-9 levels for the DD genotype 
between MFS patients and controls (p=0.01; Table 5.5 C). Interestingly, the level of 
MMP-9 was lower in MFS patients than in controls.  
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A 
Biomarkers Control (II) ± SEM MFS (II) ± SEM p 
TGF-β1 1.38 ± 0.35; n=6 1.24 ± 0.18; n=11 0.72 
MMP-3 9.26 ± 1.58; n=6 6.39 ± 1.09; n=11 0.17 
MMP-2 440.80 ± 16.69; n=6 502.10 ± 32.23; n=11 0.11 
MMP-9 85.72 ± 21.96; n=6 177.00 ± 46.12; n=11 0.10 
TIMP-1 121.60 ± 10.40; n=6 105.90 ± 12.02; n=11 0.34 
TIMP-2 83.25 ± 11.27; n=6 96.09 ± 5.88; n=11 0.34 
B 
Biomarkers Control (ID) ± SEM MFS (ID) ± SEM p 
TGF-β1 1.17 ± 0.13; n=19 1.46 ± 0.19; n=25 0.22 
MMP-3 9.88 ± 1.13; n=19 6.84 ± 0.94; n=25 0.04 
MMP-2 455.50 ± 23.50; n=19 514.90 ± 45.87; n=25 0.26 
MMP-9 105.10 ± 9.46; n=19 102.30 ± 9.47; n=25 0.83 
TIMP-1 108.10 ± 7.60; n=19 120.80 ± 9.15; n=25 0.29 
TIMP-2 93.65 ± 7.24; n=19 111.70 ± 6.91; n=25 0.08 
C 
Biomarkers Control (DD) ± SEM MFS (DD) ± SEM p 
TGF-β1 1.268 ± 0.1875; n=12 1.34 ± 0.14; n=16 0.76 
MMP-3 9.212 ± 1.869; n=12 6.06 ± 1.05; n=16 0.16 
MMP-2 384.6 ± 42.49; n=12 413.60 ± 24.52; n=16 0.56 
MMP-9 151.9 ± 15.07; n=12 100.40 ± 10.42; n=16 0.01 
TIMP-1 103.2 ± 13.29; n=12 125.5 ± 16.16; n=16 0.30 
TIMP-2 89.16 ± 6.123; n=12 93.95 ± 7.884; n=16 0.64 
Table	  5.5	   Comparison	  of	  circulating	  biomarker	   levels	  between	  control	  and	  MFS	  
patients	  as	  a	  function	  of	  genotype	  
(A)	  II	  genotype;	  (B)	  ID	  genotype	  and	  (C)	  DD	  genotype	  
  
Chapter	  5	  –	  ACE	  polymorphism	  
Yaxin	  Lu	   	   	   August	  2013	  
175	  
 
5.3.2.2	   Comparison	  of	  circulating	  biomarker	  levels	  within	  patient	  groups	  as	  
a	  function	  of	  genotype	  
We observed two significant differences in the levels of circulating biomarkers when 
patients within each group were stratified by genotype (Table 5.6).  
The circulating level of MMP-9 was observed to be approximately 30% higher in DD 
genotype control subjects, compared to control II subjects (p=0.03) and control ID 
subjects (p=0.02; Table 5.6). However, this difference in circulating MMP-9 levels was 
not observed in the MFS patients, when stratified by genotype. 
The circulating level of MMP-2 was observed to be approximately 20% lower in DD 
genotype MFS patients, compared to MFS II patients (p=0.04). However, no difference 
was observed between the MFS DD patients and MFS ID patients (p=0.06). Similarly, 
no significant difference in circulating MMP-2 levels was observed in the control 
subjects, when stratified by genotype. 
 
5.3.2.3	   Comparison	  of	  aortic	  diameter	  and	  Z-­‐score	  within	  patient	  groups	  as	  a	  
function	  of	  genotype	  
Aortic diameter and Z-score correlate with disease severity. We found there was no 
significant difference in the average aortic diameter or Z-score when patients were 
stratified by genotype (Table 5.7).  
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Biomarkers II vs. ID p II vs. DD p ID vs. DD p 
TGF-β1 Ctrl 1.38 ± 0.35; n=6 1.17 ± 0.13; n=19 0.58 
1.38 ± 0.35; n=6 
1.27 ± 0.19; n=12 0.78 
1.17 ± 0.13; n=19 
1.27 ± 0.19; n=12 0.66 
TGF-β1 MFS 1.24 ± 0.18; n=11 1.46 ± 0.19; n=25 0.42 
1.24 ± 0.18; n=11 
1.34 ± 0.14; n=16 0.66 
1.46 ± 0.19; n=25 
1.34 ± 0.14; n=16 0.64 
MMP-3 Ctrl 9.26 ± 1.58; n=6 9.88 ± 1.13; n=19 0.75 
9.26 ± 1.58; n=6 
9.21 ± 1.87; n=12 0.99 
9.88 ± 1.13; n=19 
9.21 ± 1.87; n=12 0.76 
MMP-3 MFS 6.39 ± 1.09; n=11 6.84 ± 0.94; n=25 0.76 
6.39 ± 1.09; n=11 
6.06 ± 1.05; n=16 0.83 
6.84 ± 0.94; n=25 
6.06 ± 1.05; n=16 0.58 
MMP-2 Ctrl 440.8 ± 16.69; n=6 455.5 ± 23.50; n=19 0.61 
440.8 ± 16.69; n=6 
384.6 ± 42.49; n=12 0.24 
455.5 ± 23.50; n=19 
384.6 ± 42.49; n=12 0.16 
MMP-2 MFS 502.1 ± 32.23; n=11 514.9 ± 45.87; n=25 0.82 
502.1 ± 32.23; n=11 
413.6 ± 24.52; n=16 0.04 
514.9 ± 45.87; n=25 
413.6 ± 24.52; n=16 0.06 
MMP-9 Ctrl 85.72 ± 21.96; n=6 105.1 ± 9.459; n=19 0.44 
85.72 ± 21.96; n=6 
151.9 ± 15.07; n=12 0.03 
105.1 ± 9.459; n=19 
151.9 ± 15.07; n=12 0.02 
MMP-9 MFS 177.0 ± 46.12; n=11 102.3 ± 9.469; n=25 0.14 
177.0 ± 46.12; n=11 
100.4 ± 10.42; n=16 0.13 
102.3 ± 9.469; n=25 
100.4 ± 10.42; n=16 0.90 
TIMP-1 Ctrl 121.6 ± 10.40; n=6 108.1 ± 7.600; n=19 0.32 
121.6 ± 10.40; n=6 
103.2 ± 13.29; n=12 0.29 
108.1 ± 7.600; n=19 
103.2 ± 13.29; n=12 0.75 
TIMP-1 MFS 105.9 ± 12.02; n=11 120.8 ± 9.147; n=25 0.34 
105.9 ± 12.02; n=11 
125.5 ± 16.16; n=16 0.34 
120.8 ± 9.147; n=25 
125.5 ± 16.16; n=16 0.80 
TIMP-2 Ctrl 83.25 ± 11.27; n=6 93.65 ± 7.235; n=19 0.46 
83.25 ± 11.27; n=6 
89.16 ± 6.123; n=12 0.66 
9365 ± 7.235; n=19 
8916 ± 6.123; n=12 0.64 
TIMP-2 MFS 96.09 ± 5.882; n=11 111.7 ± 6.908; n=25 0.09 
96.09 ± 5.882; n=11 
93.95 ± 7.884; n=16 0.83 
111.7 ± 6.908; n=25 
93.95 ± 7.884; n=16 0.10 
Table	  5.6	   Comparison	  of	  circulating	  biomarker	  levels	  within	  patient	  groups	  as	  a	  function	  of	  genotype.	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Groups 
Aortic diameter (mm) ±SEM 
p 
Z-Score ±SEM 
p 
II ID DD II ID DD 
All 37.67 ± 2.05; n=12 37.03 ± 0.96; n=35 37.78 ± 1.45; n=23 0.89 2.07 ± 0.59; n=12 1.65 ± 0.33; n=35 1.78 ± 0.41; n=23 0.98 
MFS-NS 42.57 ± 1.36; n=7 40.89 ± 0.99; n=18 42.42 ± 1.43; n=12 0.48 3.36 ± 0.52; n=7 2.93 ± 0.41; n=18 3.08 ± 0.43; n=12 0.83 
Controls 30.80 ± 1.88; n=5 32.94 ± 0.95; n=17 32.73 ± 1.51; n=11 0.62 0.26 ± 0.58; n=5 0.29 ± 0.25; n=17 0.37 ± 0.39; n=11 0.98 
Table	  5.7	   Comparison	  of	  aortic	  diameters	  (mm)	  and	  Z-­‐score	  after	  stratification	  by	  genotype	  in	  various	  patient	  groups.	   	  
Statistic	  significance	  was	  calculated	  using	  one-­‐way	  ANOVA	  with	  Tukey’s	  correction.	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5.4	   Discussion	  
5.4.1	   Summary	  of	  results	  
Our data show that there is no difference in the allelic or genotypic frequency of the 
ACE insertion/deletion polymorphism in MFS patients compared to control subjects. 
Additionally, there is no difference in these frequencies when MFS patients are 
stratified by severity (surgical versus non-surgical patients).  
When the levels of circulating biomarkers were stratified by genotype, some weakly 
significant comparisons were observed. Not unexpectedly, a difference was observed in 
the level of MMP-3 between controls and MFS patients for subjects with the ID 
genotype. The absence of a difference in MMP-3 levels in the II and DD groups 
probably reflects the much smaller sample sizes for these genotypes.  
Additionally, the level of MMP-9 was observed to be lower in DD MFS patients 
compared to DD controls. The MMP-9 difference that was observed was only weakly 
significant and the number of patients in the DD groups were small (n=16). Thus, the 
clinical relevance of this difference is of uncertain significance. 
Circulating levels of MMP-9 in control patients were found to be significantly higher in 
controls with a DD genotype compared to both II and ID controls. However, a similar 
difference was not seen in MMP-9 levels in MFS patients when stratified by genotype. 
Finally, the level of MMP-2 was observed to be lower in DD MFS patients compared to 
II MFS patients. The MMP-2 difference that was observed was only weakly significant 
and the number of patients in both the II (n=11) and the DD (n=16) MFS groups were 
small. Thus, the clinical relevance of this difference is of uncertain significance. 
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5.4.2	   Comparison	   of	   allelic	   and	   genotypic	   frequencies	   with	  
published	  data	  
Our control frequency distributions are in excellent agreement with published data 
(Table 5.8). A previous study in our laboratory that examined the relationship between 
athletic performance and genotypes within the Australian Olympic rowing team shows 
that the control subjects exhibited almost identical allelic and genotypic frequencies to 
the ones obtained in this study (Gayagay et al., 1998). Similarly, a very large French 
study also exhibited the same frequencies (Schachter et al., 1994). Thus, although our 
control cohort was small, it appears to be in excellent agreement with other much larger 
studies in similar populations and constitutes an appropriate control cohort to compare 
frequencies with the MFS group.  
Groups n 
ACE allele ACE genotype 
I D II ID DD 
Olympic Rowers 64 0.57 0.43 0.30 0.55 0.16 
Olympic Controls 118 0.43 0.57 0.18 0.51 0.32 
French Controls 553 0.45 0.56 0.18 0.53 0.28 
Present study Controls 37 0.42 0.58 0.16 0.51 0.32 
Present study MFS 52 0.46 0.54 0.21 0.50 0.29 
Table	  5.8	   Comparison	  of	  allelic	  and	  genotypic	  frequencies	  with	  published	  data.	  
 
Two studies have investigated the association of the I/D polymorphism of the ACE 
gene with thoracic aortic aneurysm (TAA) in patients with either non-Marfan’s 
syndrome-related diseases (Lesauskaite et al., 2011), or an aortic valve abnormality 
(Foffa et al., 2012), revealing that the D allele of the ACE gene conferred a risk of 
TAA. 
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The study by Foffa et al. (2012) examined 216 patients with thoracic aortic aneurysm, 
of which 105 had bicuspid aortic valves (BAV) and 111 had tricuspid aortic valves 
(TAV). All patients were thought to have cystic medial necrosis and all patients 
exhibited some degree of dilatation of their ascending aortas. 30-50% of the patients 
also reported risk factors for atherosclerosis (mean age 58 years, smoking, 
dyslipidaemia and hypertension), raising the question as to the aetiology of the 
aneurysms in the TAV group. The BAV group can be more clearly defined as an 
congenital ascending aortic aneurysm (see Section 1.4.4: Pathogenesis of thoracic 
aortic aneurysms in BAV). MFS patients and traumatic aneurysms were excluded. The 
allelic frequency in the control group was similar to our own (D allele=0.57 compared 
to our study D=0.58) but the genotype distribution for the control subjects in Foffa’s 
study was skewed towards the DD genotype (DD genotype=0.36 compared to our study 
DD=0.32). The D allele was noted to be significantly more frequent in both the BAV 
(0.64) and TAV (0.64) groups when compared to controls (0.57). The differences in 
allelic frequencies were reflected in changes in the genotype distribution, with an 
increase in ID, but little change in DD, in the aneurysm group. Additionally, there was a 
statistically significant increase in the average aortic diameter associated with the DD 
genotype, both overall and for BAV and TAV-associated aneurysms.  
In contrast to the results of Foffa et al. (2012), our study of MFS showed no significant 
difference in the allelic frequency or genotype distribution between controls and MFS 
patients. Additionally, our study saw no correlation between aortic diameter/Z-score 
and genotype. The reasons for the differences observed in our study compared to Foffa 
et al. (2012) are speculative, but include the following. Firstly, although BAV thoracic 
aneurysm is a genetic disease, thought to involve abnormal TGF-β signalling, the 
precise genetic aetiology remains unclear, but is believed to involve multiple genetic 
mutations (Ikonomidis et al., 2013). Thus, it may well be that ACE gene polymorphism 
plays a significant role in the aetiology of BAV, as the data of Foffa et al. show. On the 
other hand, the primary mutation in MFS is known to occur in the FBN, consequently, 
any contribution that a polymorphism within the ACE gene may make to the aetiology 
of MFS may be small, consistent with our data. Secondly, the number of patients 
studied by Foffa et al. was approximately 5 times more than our own study, facilitating 
discovery of significant genetic associations by Foffa et al. (Foffa et al., 2012).  
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The study of Lesauskaite et al. (2011) examined 107 patients with aneurysm of the 
ascending thoracic aorta. Patients with MFS or aortitis were excluded. 29% of patients 
had a bicuspid aortic valve (BAV). The control group consisted of 773 patients. The 
frequency of the D allele was 0.48 in controls and 0.55 in aneurysm patients. 
Additionally the genotype distribution was altered in the aneurysm group towards the 
DD genotype compared to controls (Lesauskaite et al., 2011). A problem with this study 
was that the allelic and genotype distributions differed substantially from the 
distributions found by us and others in a Caucasian population (see Table 5.8). The D 
allele and the DD genotype were underrepresented in the large control population, while 
the frequencies of the frequencies of the aneurysm group were similar to the published 
control frequencies. Both the patient and control groups were derived from an Eastern 
European population, which may explain the lower representation of the D allele in the 
control group. An ethnic difference in genotype frequencies has been previously noted 
(Sagnella et al., 1999). However, the overall conclusion that the D allele is over 
represented in ascending thoracic aortic aneurysm concurs with the study by Foffa et al. 
(2012). Notably, in both these studies patients with MFS were excluded, making our 
study of the association between the ACE I/D polymorphism and MFS the only one to 
date.  
Our interest in considering the ACE I/D polymorphism was to explore an explanation 
for differences in the phenotype seen in MFS patients with the same mutation in FBN, 
in some cases within the same family. Thus, we were interested in investigating ACE as 
a potential modifying gene. Our comparison of MFS patients on the basis of disease 
severity found no differences in genotypic or allelic frequencies. Although our study 
was small, our data suggest that it is unlikely that the ACE I/D polymorphism is acting 
as a significant modifying gene in MFS. 
 
5.4.3	   Elevated	  circulating	  levels	  of	  MMP-­‐9	  in	  the	  DD	  genotype	  
Surprisingly, when circulating levels of MMP-9 in control patients were compared as a 
function of genotype, MMP-9 levels were found to be significantly higher in controls 
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with a DD genotype compared to both II and ID controls. However, a similar difference 
was not seen in MMP-9 levels in MFS patients when stratified by genotype. The higher 
level of MMP-9 in DD control subjects is consistent with the observation that patients 
with the DD phenotype develop more severe atherosclerotic AAA (Yeung et al., 2002; 
Fatini et al., 2005; Lucarini et al., 2009). The major MMP involved in ECM 
remodelling in atherosclerotic AAA is considered to be MMP-9 (Ikonomidis et al., 
2013), thus the higher basal level of MMP-9 in DD control subjects that we have 
observed in our data is likely to result in a more severe level of ECM degradation in 
patients with the DD phenotype should they develop an atherosclerotic AAA. 
On the other hand, some studies have suggested that MMP-9 is less important in the 
pathogenesis congenital thoracic aortopathy (Ikonomidis et al., 2013), which may 
partially explain the lack of a difference observed in MMP-9 levels in our MFS patient 
cohort, as a function of genotype.  
5.5	   Conclusions	  
This study aimed to determine whether the ACE I/D polymorphism genotype correlated 
with the disease phenotype in patients with MFS, with the expectation that the DD 
phenotype could result in a more severe phenotype. Our study was hampered by the 
small numbers of controls and patients, but our data are consistent with the hypothesis 
that, if there is any effect on phenotype by the ACE I/D polymorphism, then it is a very 
small one. Thus, the ACE polymorphism is unlikely to be a significant modifying gene 
in MFS and other genetic aortopathies. 
An interesting observation that did emerge from our data is that the level of circulating 
MMP-9 appears to be higher in normal control subjects with a DD genotype compared 
to ID or II. This observation may have significance for explaining the association 
between the DD genotype and atherosclerotic vascular disease (Fatini et al., 2005), 
including in the pathogenesis of AAA (Fatini et al., 2005).
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Chapter	  6	  
Overall	  Conclusion	  
 
6.1	   Pathogenesis	  of	  Marfan	  syndrome	  
Marfan syndrome (MFS) is an autosomal dominant inherited connective tissue disorder 
with an incidence of approximately 1 in 5000 worldwide. It can vary in severity from 
mild to severe and may finally cause the death of affected individuals as a result of 
dissection of the thoracic aortic aneurysm (TAA). The possible pathogenesis remains 
uncertain, but essentially all patients have a mutation in the fibrillin 1 gene, either 
inherited or as a sporadic mutation.  
Fibrillin is a glycoprotein, which is vital for the formation of elastic and non-elastic 
fibres found in extracellular connective tissue. It provides a scaffold for deposition of 
elastin and fibrillin-associated proteins and also incorporated into insoluble microfibrils, 
which are particularly abundant in the aorta, ligaments and lens ciliary zonules (all 
affected in MFS). 
Additionally, fibrillin sequesters TGF-β. Microfibrils have roles not only in maintaining 
the structural integrity of tissues, but also in the regulation of cytokines through the 
sequestration of molecules such as TGF-β and the bone morphogenetic proteins in the 
matrix. Normally, extracellular microfibrils bind the LLC of TGF-β. This complex 
binding sequesters TGF-β and hence, suppresses free active TGF-β until its required 
release. Once released, free active TGF-β can interact with its cell surface receptors to 
induce a signalling cascade of intracellular protein phosphorylation, beginning with 
receptor associated Smads. The Smad complex follows the classic pathway of 
translocation to the nucleus, allowing for downstream activation of gene transcription. 
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In the presence of defective microfibrils (e.g. MFS), failure to sequester the LLC results 
in promiscuous activation of TGF-β (lightening bolt). Free, active TGF-β is then able to 
interact with its cell surface receptors leading to the activation of the alternate p38 
mitogen activated kinase (MAPK) pathway (Ramirez et al., 2010). In view of these 
results, the theory that the TGF-β signal translation pathway activation may be one of 
the major pathways of MFS pathogenesis, through MMP activation, which promotes 
ECM proteolysis, is plausible (Lebreiro et al., 2010). 
 
	   6.2	   Mechanism	  of	  thoracic	  aortic	  aneurysm	  formation	  
It was initially thought that extracellular microfibrils containing mutant fibrillin directly 
impaired mechanical strength of the aortic wall in MFS, but the microfibrils are not 
load-bearing in the vertebrate aorta. Instead, it has been hypothesised that microfibrils 
are able to transmit haemodynamic load information to the vascular smooth muscle 
cells (VSMC) in the aortic media. Importantly, the VSMC can respond to changes in 
loading conditions (e.g. stretch) by increasing secretion of cytokines and growth factors, 
including TGF-β, in a process of mechano-chemical signal transduction . Intrinsic tone 
in the VSMC, determined by actin-myosin interactions, would determine an operating 
set-point for ideal balance between haemodynamic load and stimulus to aortic 
remodelling. It is known that TGF-β, acting through myofibroblast cell-surface 
receptors, coupled to both Smad and MAPK35 systems, can stimulate both extracellular 
proteolysis (e.g. via metalloproteinases) and increased synthesis of extracellular matrix 
ground substance, leading to the vascular remodelling observed as cystic medial 
necrosis. It is likely that a common pathological pathway underlies the development of 
TAAD and that this pathway can be activated at several points and includes a number of 
modulating factors. This latter point explains why congenital aneurysm can arise from 
mutations in many genes (most common is FBN, causing MFS), but mutations can also 
occur in other parts of the mechano-chemical signal transduction mechanism. 
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6.3	   Biomarker	  discovery	  
Genetic thoracic aortic aneurysm and dissection kills people in various age groups, 
especially in young generations. One in six patients with a genetic aortopathy is dead by 
50. Those at risk are often unaware, until either death or dissection occurs, or an 
incidental diagnosis is made on cardiac imaging. Aortic aneurysm and dissection are 
often inherited. Diagnosis of people at risk is critical but difficult, as there may be no 
clinical signs or obvious aortic enlargement in young patients. All too often, however, 
diagnosis is not straightforward. Therefore, there is a need for improved diagnostic 
accuracy, better risk-stratification and more effective therapeutic intervention for 
individuals and their families. Matrix metalloproteinases contribute to aneurysm 
formation and animal studies suggest their potential utility as biomarkers of thoracic 
aortic disease (Matt et al., 2009). In addition, the TGF-β1 signalling pathways play a 
vital role in the progression of aortic aneurysm formation (Ramirez et al., 2010). 
 
6.3.1	   MMP-­‐3	  
MMP-3 has been implicated in thoracic aortic aneurysm formation (Barbour et al., 
2007). It is a stromelysin that can degrade intact collagen (Raffetto et al., 2008) and is 
secreted from vascular smooth muscle cells (Barbour et al., 2007; Raffetto et al., 2008). 
A moderate elevation in MMP-3 within the circulation has been observed in patients 
suffering from atherosclerotic aneurysms (Karapanagiotidis et al., 2009), and MMP-3 is 
believed to decrease within the aortic tissue of patients suffering from thoracic 
aneurysm associated with a bicuspid aortic valve (Ikonomidis et al., 2012; Jackson et 
al., 2012). 
Our data have shown that the levels of circulating MMP-3 are significantly higher in 
males compared to females. Paradoxically, the levels of circulating MMP-3 fall in MFS 
patients, presumably as a compensatory mechanism to limit pathological extra-cellular 
matrix remodelling. These data are new and novel findings, and may explain, in part, 
the more severe disease that is seen in males compared to females in MFS. Finally, 
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while the average MMP-3 levels in MFS and controls are significantly different, the 
large scatter of levels between individuals makes the use of this test of limited value for 
diagnosis. However, serial determinations of MMP-3 levels in individuals may be of 
use for monitoring response to therapy, for example, pharmacological interventions. 
 
6.3.2	   TGF-­‐β1	  
A current hypothesis is that the common mechanism behind genetic aortopathy 
formation involves abnormal TGF-β signalling (El-Hamamsy et al., 2009). 
Furthermore, substantial evidence exists that the final pathway for aortic wall damage is 
through excessive protease activity, causing the characteristic histological features of 
cystic medial necrosis, namely, loss of extra-cellular matrix, especially collagen and 
elastin, and a reduction in medial cell numbers, possibly via the induction of apoptosis 
(Nataatmadja et al., 2006). In the search for circulating biomarkers capable of 
predicting disease progression and severity, prospective candidates would include 
TGF-β. 
Our data show that there is no difference in the level of circulating TGF-β1 in MFS 
patients compared to controls. However, a consistent, small, non-significant trend 
towards higher levels was observed across all MFS patient groups, compared to 
controls, but this trend was small, and, even if real, may be of limited clinical 
significance. It is possible that this trend may become significant if a larger number of 
patients had been recruited.  
There are several reports in the literature concerning changes in TGF-β1 in patients with 
MFS compared to controls. Two very recent studies, published while this thesis was 
being written, have found contradictory data on this point. One study also failed to find 
a difference in circulating TGF-β1 levels (Ogawa et al., 2013), while another study 
found a four-fold increase in TGF-β1 in MFS patients (Franken et al., 2013), using a 
different commercial ELISA assay. Clearly, additional future work is required to 
resolve this issue. 
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6.3.3	   MMP-­‐2	  and	  MMP-­‐9	  
MMPs mediate extra-cellular matrix (ECM) destruction, leading to weakening of the 
aortic wall and aneurysm formation (Barbour et al., 2007). The MMPs are a family of 
27 extracellular proteases that are capable of degrading all constituents of the aortic 
ECM. The expression and activity of MMPs within the vascular wall are regulated at 
several levels, including at transcription, post-translation and effector antagonism via 
endogenous tissue inhibitors (TIMPs). Perturbation of these regulatory mechanisms will 
influence aortic wall remodelling, leading to aneurysm formation.  
Although no significant differences were seen in MFS patients compared to controls for 
the biomarkers MMP-2, MMP-9, TIMP-1 and TIMP-2, a consistent trend was observed 
for several biomarkers towards higher levels in MFS patients compared to controls. 
Specifically, data for MMP-2 (overall trend, plus weakly significant difference in 
female surgical MFS patients compared to controls) and TIMP-2 (weakly significant 
difference) support the possibility that these two biomarkers may be slightly elevated in 
MFS compared to controls. Notably, although trends were observed for these 
biomarkers, the differences were always small (~10% increase). Thus, any real 
differences for these biomarkers are unlikely to be of substantial clinical significance 
for diagnostic or prognostic purposes. 
The probable rise in circulating MMP-2 levels in MFS patients is consistent with 
previous data, since MMP-2 has been shown to be increased in the aortic tissue of 
patients in two forms of genetic aortopathy, MFS and BAV (LeMaire et al., 2005). On 
the other hand, MMP-2 has been reported to increase slightly in the tissue of 
atheromatous disease, but has been report to both increase slightly and decrease slightly 
in the circulation in patients atherosclerosis by various groups (Ikonomidis et al., 2006; 
Karapanagiotidis et al., 2009).  
MMP-9 is known to rise dramatically in atheromatous aortic aneurysm disease, and to 
be a major participant in its pathophysiology (Ikonomidis et al., 2006; Karapanagiotidis 
et al., 2009). Additionally, previous groups have reported that MMP-9 is elevated 
within the aortic tissue of patients with MFS and BAV (Ikonomidis et al., 2006), but not 
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to the same extent as in atheromatous disease. On the other hand, others have reported 
no change in MMP-9 in genetic aortopathy tissue (LeMaire et al., 2005). Our study 
observed no change in levels of circulating MMP-9 in MFS, even as a non-significant 
trend, consistent with the likelihood that MMP-9 levels are not dramatically increased in 
genetic aortopathy tissue.  
 
6.3.4	   TIMP-­‐1	  and	  TIMP-­‐2	  
All the TIMPs are able to inhibit all the MMPs to some extent, but TIMP-2 most 
effectively inhibits MMP-2 and TIMP-1 most effectively inhibits MMP-9 (Hidalgo et 
al., 2001). Thus, the ratios MMP 2:TIMP 2 and MMP 9:TIMP 1 may be indices of the 
balance of the proteolytic activity (Chung, A. W. et al., 2007). 
Our data show that circulating levels of TIMP-1 and TIMP-2 also do not change 
significantly in MFS compared to controls. However, circulating levels of TIMP-1 
correlated strongly with TIMP-2 levels in all groups (controls and MFS). This result is 
consistent with the hypothesis that TIMP-1 and TIMP-2 are unregulated at least partly 
by the same signalling processes. 
 
6.4	   ACE	  polymorphism	  
This study aimed to determine whether the ACE I/D polymorphism genotype correlated 
with the disease phenotype in patients with MFS, with the expectation that the DD 
phenotype could result in a more severe phenotype. Our study was hampered by the 
small numbers of controls and patients, but our data are consistent with the hypothesis 
that, if there is any effect on phenotype by the ACE I/D polymorphism, then it is a very 
small one.  
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We found no difference in the allelic or genotypic frequency of the ACE 
insertion/deletion polymorphism in MFS patients compared to control subjects. 
Additionally, there is no difference in these frequencies when MFS patients are 
stratified by severity (surgical versus non-surgical patients).  
When the levels of circulating biomarkers were stratified by genotype, some weakly 
significant comparisons were observed. Not unexpectedly, a difference was observed in 
the level of MMP-3 between controls and MFS patients for subjects with the ID 
genotype. The absence of a difference in MMP-3 levels in the II and DD groups 
probably reflects the much smaller sample sizes for these genotypes.  
Thus, the ACE polymorphism is unlikely to be a significant modifying gene in MFS 
and other genetic aortopathies. 
 
6.5	   Future	  direction	  
The primary limitation of this study is the sample size, which is relatively small, thus, 
these studies should be considered pilot studies. It may be possible in future to recruit 
additional subjects to a larger study via collaborations with other groups. Specifically, 
our pilot data have identified MMP-3, and possibly TGF-β1, as biomarkers of MFS that 
could be useful for stratification of disease severity, particularly if combined with a 
panel of other biomarkers (as yet undiscovered). Additionally, these biomarkers may be 
useful for monitoring response to drug therapy. 
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